Guidance Framework for Testing the Sterile Insect Technique as a Vector Control Tool against Aedes-Borne Diseases
Contributors

IkeOluwapo Ajayi, Romeo Bellini, Pascal Boireau, Steven Bradbury, Salome A. Bukachi, Lee Ching Ng, Fang Jing, Pattamaporn Kittayapong, Pablo Liedo, Kenneth Linthicum, John Mumford, Manju Rahi, Matthew Thomas, Yesim Tozan, Alia Zayed

Affiliations

IkeOluwapo O. Ajayi, Department of Epidemiology and Medical Statistics, Faculty of Public Health, University of Ibadan, Ibadan, Nigeria
Romeo Bellini, Centro Agricoltura Ambiente “G. Nicoli” IAEA Collaborating Centre, Via Sant’Agata 835, 40014 Crevalcore, Italy
Pascal Boireau, ANSES, Animal Health Laboratory, Maisons Alfort and High Council for Biotechnology, Paris, France
Steven Bradbury, Department of Entomology, Iowa State University, Ames, Iowa, 50011, USA
Salome A. Bukachi, Institute of Anthropology, Gender and African Studies, University of Nairobi, P.O. Box 30197-00100, Nairobi, Kenya
Lee Ching Ng, Environmental Health Institute, National Environment Agency, Singapore
Fang Jing, Institute for Health Sciences, Kunming Medical University, 1168# Chun Rong Xi Lu, Yuhua Jiedao, Cheng Gong Xinqu, Kunming City, 650500, Yunnan Province, P.R. China
Pattamaporn Kittayapong, Center of Excellence for Vectors and Vector-Borne Diseases, Faculty of Science, Mahidol University at Salaya, Nakhon Pathom 73170, Thailand
Pablo Liedo, Departamento de Entomología, El Colegio de la Frontera Sur, Tapachula, Chiapas 30700, Mexico
Kenneth Linthicum, USDA-ARS Center for Medical, Agricultural and Veterinary Entomology, Gainesville, FL 32608, USA
John Mumford, Imperial College London, Centre for Environmental Policy, Silwood Park Campus, Ascot, Berkshire, UK
Manju Rahi, Scientist-F, Division of Epidemiology and Communicable Diseases, Indian Council of Medical Research, New Delhi, India
Matthew Thomas, Department of Entomology, Center for Infectious Disease Dynamics, Pennsylvania State University, University Park, PA 16802, USA
Yesim Tozan, New York University, College of Global Public Health, New York, NY 10012, USA
Alia Zayed, Cairo University/U.S. Naval Medical Research Unit No. 3, Cairo Detachment, Cairo, Egypt
**Reviewers**

**Rafael Argiles Herrero**, Livestock and Human Health Pests, Insect Pest Control Section, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture (NAFA) | Department of Nuclear Application | International Atomic Energy Agency | Vienna International Centre, PO Box 100, 1400 Vienna, Austria

**Rui Cardoso Pereira**, Insect Pest Control Section, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture (NAFA) | Department of Nuclear Application | International Atomic Energy Agency | Vienna International Centre, PO Box 100, 1400 Vienna, Austria

**Lauren Carrington**, Vector Ecology and Management, Department of Control of Neglected Tropical Diseases (CDS/NTD), World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland

**Walther R. Enkerlin Hoeflich**, Plant Pests, Insect Pest Control Section, Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture (NAFA) | Department of Nuclear Application | International Atomic Energy Agency | Vienna International Centre, PO Box 100, 1400 Vienna, Austria

**Elkhan Gasimov**, Malaria, NTDs and other Vector-borne Diseases Division of Health Emergencies & Communicable Diseases, World Health Organization Regional Office for Europe, UN City, Marmorvej 51, 2100 Copenhagen, Denmark

**Tessa B. Knox**, Malaria and other vector-borne and parasitic diseases, World Health Organization, Port Vila, Vanuatu

**Raman Velayudhan**, Vector Ecology and Management, Department of Control of Neglected Tropical Diseases (CDS/NTD), World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland

**Secretariat**

**Jérémy Bouyer**, Human Disease Vectors | Insect Pest Control Laboratory | Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture (NAFA) | Department of Nuclear Application | International Atomic Energy Agency | Vienna International Centre, PO Box 100, 1400 Vienna, Austria

**Anna Drexler**, Western Pacific/Regional Office/WHO Health Emergencies/Country health Emergency Preparedness (WP/RGO/WHE/CPI), Manila, Philippines


**Patricia Godoy-Kain**, Division for Latin America and Caribbean Technical Cooperation
Department, International Atomic Energy Agency, Vienna International Centre, Wagramer Strasse 5, PO Box 100, 1400 Vienna, Austria

**Editor**

**Eva Ciabattoni**
Acknowledgements

The Secretariat thanks the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) based at the World Health Organization and its director, Dr John Reeder, as well the Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture and its director, Mr Qu Liang, and the Department of Technical Cooperation for Latin America and Caribbean of IAEA and its Section Head, Mr Raúl Ramirez Garcia, for having allowed the development of this work. The authors also express their sincere gratitude to Makiko Kitamura, Communication Officer in TDR for the help in the design and layout of the final document, and to all collaborators from both agencies’ operational units and programmes for their feedback, support and advice. This document was developed through an extensive consultation process, including an advisory committee covering different disciplines. Declarations of interest were provided by all experts as required by WHO and no conflicts of interest were found.
# Table of Contents

Abstract .................................................................................................................................................. 10

Foreword .................................................................................................................................................. 12

Chapter 01 Framework for the implementation of the sterile insect technique (SIT) for *Aedes* control ........................................................................................................................................... 17
  1.1 Introduction ........................................................................................................................................ 18
  1.2 Key framework components ............................................................................................................. 21
    1.2.1 Making the decision to embark on an SIT programme ............................................................... 22
    1.2.2 Testing and implementing SIT ...................................................................................................... 23

Chapter 02. Framework for health and environmental risks assessment ........................................... 31
  2.1 Introduction ........................................................................................................................................ 32
  2.2 Theoretical planning and risk assessment process ............................................................................. 34
    2.2.1 Planning ......................................................................................................................................... 35
    2.2.2 Problem formulation ...................................................................................................................... 35
    2.2.3 Analysis of hazard and exposure ................................................................................................... 35
    2.2.4 Risk characterization ..................................................................................................................... 35
  2.3 Risk planning for SIT against *Aedes* mosquitoes ............................................................................ 36
  2.4 Risk assessment for *Aedes* SIT ........................................................................................................ 38
    2.4.1 Problem formulation ...................................................................................................................... 38
    2.4.2 Risk analysis for *Aedes* SIT ....................................................................................................... 40
    2.4.3 Risk characterization for *Aedes* SIT in a likelihood-consequence matrix .................................... 41
  2.5 Risk communication for *Aedes* SIT .............................................................................................. 43
  2.6 Risk management for *Aedes* SIT .................................................................................................... 44
  2.7 Risk assessment responsibilities and governance ............................................................................. 46
  2.8 Risk analysis checklist ..................................................................................................................... 47

Chapter 03. Permits and authorization pathways .................................................................................. 49
  3.1 Introduction ........................................................................................................................................ 50
  3.2 Different levels of authorization pathway ....................................................................................... 51
    3.2.1 Four phases of development before license ................................................................................. 51
    3.2.2 Development of the technology: Scale-up and additional authorizations ................................... 53
  3.3 SIT applied to mosquitoes and existing authorizations/regulations (past 10 years) ...................... 56
    3.3.1 Montenegro: Importation of irradiated sterile mosquitoes .......................................................... 56
    3.3.2 Germany: Importation of irradiated sterile mosquitoes ............................................................... 57
    3.3.3 France: Experiments on the island of La Réunion ......................................................................... 57
3.3.4 Italy: Trial with sterile mosquitoes ................................................................. 58
3.3.5 Other trials ........................................................................................................ 58
3.4 The next steps in permits and authorization pathways for Aedes SIT .................. 62

Chapter 04. Mass production and release of sterile male Aedes ............................ 65
4.1 Background ........................................................................................................ 66
4.2 Strain selection and colonization ...................................................................... 67
4.3 Mass production ............................................................................................... 68
4.4 Sterilization ....................................................................................................... 70
4.5 Transport and release ....................................................................................... 71
4.6 Quality control ................................................................................................. 72
4.7 Guidelines and SOPs ......................................................................................... 73
4.8 Ongoing SIT projects ....................................................................................... 74

Chapter 05. Evaluation of entomological efficacy .................................................... 77
5.1 Introduction ....................................................................................................... 79
5.2 Outline of phase I studies .................................................................................. 81
  5.2.1 Survival and longevity .................................................................................. 82
  5.2.2 Mating competition and impact on female fecundity .................................. 82
  5.2.3 Flight ability .............................................................................................. 83
5.3 Outline of phase II studies ................................................................................ 83
  5.3.1 Semi-field evaluations .............................................................................. 83
  5.3.2 Small-scale pilot field trials ....................................................................... 84
5.4 Outline of phase III studies ............................................................................. 85
5.5 Outline of phase IV studies ............................................................................. 85
5.6 General considerations and guiding principles ............................................... 86
  5.6.1 Defining objectives ................................................................................... 86
  5.6.2 Selection of study site ................................................................................ 86
  5.6.3 Baseline interventions as comparators ...................................................... 87
  5.6.4 Outcome (endpoints and effect size) .......................................................... 87
  5.6.5 Trial design .............................................................................................. 88
  5.6.6 Understanding of confounders ................................................................... 90
  5.6.7 Quality control ......................................................................................... 90

Chapter 06. Epidemiological efficacy and effectiveness trials to evaluate SIT
against Aedes-borne diseases ............................................................................... 93
6.1 Introduction ...................................................................................................... 95
6.2. Step 1: Develop the PICO question ................................................................. 96
6.3. Step 2: Design of the study ........................................................................... 97
   6.3.1. Randomized controlled trials and cluster-randomized controlled trials ....... 98
   6.3.2. Stepped wedge cluster-randomized trial ......................................................... 98
   6.3.3. Rolling-carpet and wave principle methods ...................................................... 98
6.4. Step 3: Determine the sample size ................................................................. 102
6.5. Step 4: Site selection for intervention and control ........................................ 103
6.6. Step 5: Baseline parameters ......................................................................... 105
   6.6.1 Epidemiological endpoints .............................................................................. 105
   6.6.2 Contamination effect ....................................................................................... 105
6.7. Step 6: Blinding ............................................................................................... 106
6.8. Step 7: Implementation of the intervention and partnerships to be established for field testing .... 107
6.9. Step 8: Measuring the outcome and effectiveness of the technology ............ 108
   6.9.1. The epidemiological outcome indicators ......................................................... 108

Chapter 07. Ethics and community/stakeholder engagement ................................113
7.1 Introduction ........................................................................................................ 115
7.2. Ethical issues .................................................................................................... 116
7.3. Communities and stakeholder engagement or participation .......................... 120
   7.3.1. Definition of community and/or stakeholder participation ............................ 122
   7.3.2. The purpose of community and/or stakeholder participation ....................... 122
   7.3.3. How to foster community and/or stakeholder participation ......................... 123

Chapter 08. Cost-effectiveness assessment ......................................................... 127
8.1. The use of cost-effectiveness analysis for priority-setting in health ................. 129
8.2. The use of cost-effectiveness analysis in economic evaluation of SIT ............ 130
8.3. The estimation of cost-effectiveness ................................................................. 132
8.4. Determining the costs ..................................................................................... 134
8.5. Computing incremental cost-effectiveness ratios ............................................. 138

Chapter 09. Programme monitoring and evaluation ............................................ 143
9.1 General concept ............................................................................................... 144
9.2. Specificities of monitoring and evaluation ..................................................... 145
9.3. Requirements for a functioning M&E system .................................................. 146
   9.3.1. Organization in charge of M&E ..................................................................... 146
   9.3.2. Operational steps for M&E of a vector control programme .......................... 146
   9.3.3. Collection and dissemination of data ............................................................... 147
9.4. M&E of outcomes and expected impact of the success of SIT ....................... 148
   9.4.1. Definition of the different indicators and framework of a M&E programme .... 149
Abstract

This document is intended to be a comprehensive guide for programme managers tasked with recommending a “go/no-go” decision on testing, full deployment and scale-up of the sterile insect technique (SIT) in regions of the world affected by diseases transmitted by Aedes mosquitoes. However, the authors hope that the material presented herein will be used more widely—by scientists, decision makers, review groups and others.

The SIT has a long history of successfully combatting many pest species without negatively impacting the environment or health. This guidance document will inform stakeholders and all persons involved with SIT testing on vectors of human diseases about how to plan, develop, test and evaluate the impacts of the technology against Aedes mosquitoes, the main vectors of dengue, yellow fever, chikungunya and Zika. The nine chapters of this document cover the processes for decision support—including risk assessment and regulatory aspects, technical aspects (e.g., insect mass rearing), entomological and epidemiological indicators, as well as community involvement, cost-effectiveness and programme monitoring and evaluation.

The scope of this document covers programme initiation through pilot evaluation, while touching on aspects of scale-up and full implementation. The technical and operational details of SIT implementation are beyond the scope of this guidance, but readers are referred to other sources for this information.

An overview of SIT test planning is provided in Chapter 1. Chapter 2 describes the requirements for assessment of environmental and health risks related to the technology. Chapter 3 informs about regulatory frameworks, which are determined by individual countries and, in some cases, regional or local authorities within countries. Project plans, performance expectations and protection goals should be discussed with key stakeholders in individual countries, including with regulatory authorities, to determine the scope of any risk assessment and risk management activities.

Protection-goal-related risk assessment and risk management for mosquito SIT are likely to include technical risks, such as radiation; entomological and epidemiological risks, such as niche replacement by other vector species, new or different disease transmission by alternative vectors, loss of immunity in the human population; and social risks, such as a complacent attitude towards vector control by communities. SIT facilities and operations also pose conventional environmental and health risks related to buildings, processing activities, waste, transport and worker safety.

The SIT requires mass production of sterile insects of high quality (Chapter 4). The technological package for mass rearing, sterilization, release and quality control of sterile Aedes mosquitoes has been developed. Standard operating procedures or guidelines are available for colonization, colony

---

1 A list of abbreviations and their definitions is provided at the end of this document.
management, mass rearing and irradiation for sterilization. Guidelines for transportation and release, as well as for quality control, are under development. Evaluation of entomological efficacy and epidemiological impacts is key to understanding the impact of SIT (Chapters 5 and 6). A phased conditional approach is proposed to guide the SIT testing programme through a series of evaluation steps of increasing complexity, with “go/no-go” decisions based on robust, established evaluation methods made at each phase. Illustrative “go/no-go” criteria are presented for the key performance indicators.

Chapter 7 highlights issues of ethics and community and/or stakeholder participation in the process of testing SIT interventions to control Aedes-borne diseases. The two issues are mutually interlinked, but with different purpose and objectives. When doing any research that involves human subjects, researchers are obligated to follow the highest possible ethical principles and standards stipulated in international research ethics guidelines, of which informing communities and stakeholders and involving them at the early stages of any research or intervention that will affect their health, life and wellbeing is an essential component. Meanwhile, the understanding, support and collaboration of communities and stakeholders for the research and the intervention are absolutely crucial for the success of any research activity, including SIT testing activities, and for the sustained effect of those interventions. Therefore, the SIT testing team must take both issues into account at the very beginning of any SIT testing project and plan and act accordingly. SIT testing teams also need to be aware that the diverse communities where SIT testing will be conducted are embedded within different socioeconomic, political, cultural and environmental contexts and ecosystems; hence, they need to fulfill their ethical responsibilities and plan and adapt their community participation strategies and actions based on locally prevailing conditions.

The decision to implement SIT is also linked to the cost-effectiveness of the technology, which is explicated in Chapter 8. And in Chapter 9, the general concept of monitoring and evaluation (M&E) is discussed in light of the general framework for testing SIT. The relationship between monitoring and evaluation and the requirements for a functioning M&E system are highlighted. Results should be assessed using an input-process-output-outcome-impact framework. Well-designed outputs achieve short-term effects (outcomes), which in turn will lead to the long-term effects (impact). Examples of M&E indicators useful for assessing long-term impact are given for inclusion during the planning and implementation stages. Entomological and epidemiological evaluation components also are provided.

The objectives of the guidance document on testing the sterile insect technique are to provide the necessary and sufficient information for decision-making in testing and for evaluating the outcomes and epidemiological and entomological impacts of this new vector control approach against Aedes mosquitoes, vectors of major arboviruses and Aedes-borne diseases.
Causing more than one million deaths per year, with few new drugs or strategies to combat these emerging infectious pathogens, vector-borne diseases (VBDs) such as malaria, dengue, Zika, chikungunya, yellow fever and others account for 17% of the total morbidity from infectious diseases. The incidence of arboviral diseases transmitted by Aedes mosquitoes has grown dramatically in recent decades, with about one third of the world population now at risk from Aedes-borne epidemics (Map 1), 99% of which are caused by just two species, Aedes aegypti and Aedes albopictus. This increase is due to global changes that include unplanned urbanization, increased travel and climate change, coupled with a lack of efficient vector control methods. This accelerating increase prompted WHO to state the urgent need for alternative vector control methods in its Global vector control response (GVCR) 2017–2030, which was approved at the World Health Assembly in 2017 by more than 190 Member States (WHO 2017).

The general objective of vector control is the reduction of vector populations, which in turn will bring about a reduction in mortality or morbidity associated with vector-borne diseases. By acting on four key vector capacity parameters (vector density, vector longevity, number of bites and rate of infective vectors), vector control aims to prevent or reduce the intensity of transmission of pathogens at a community or regional level and to protect against infective arthropod bites at an individual level. Control strategies can apply different methods or techniques depending on the vectors and the epidemiological and socio-economic contexts.
One of these alternative technologies is the sterile insect technique, "a method of pest control using area-wide inundative releases of sterile insects to reduce reproduction in a field population of the same species" (FAO 2007). Released sterile males mate with wild females, which will then not produce offspring. The SIT thus has the potential to strongly decrease the density of a target insect's natural population, sometimes to the point of eradication. This technique has been successfully implemented in agriculture against numerous insects (Dyck et al. 2006) and is presently under development against mosquitoes (Lees et al. 2015). In this guidance document, we focus on the release of irradiated sterile male insects that are exempted worldwide from product regulations due to their long safety record of conventional use in a number of applications (EFSA 2013) and are not classified as genetically modified organisms (GMOs) and/or living modified organisms (LMOs) according to the Cartagena Protocol on Biosafety to the Convention on Biological Biodiversity (Secretariat of the Convention on Biological Diversity 2000). According to Protocol definitions, irradiation is not considered as one of the modern biotechnologies used for the purpose of genetically modifying the DNA of the organisms (in this case, mosquitoes).

An alternative method for sterilizing target populations is Wolbachia-induced cytoplasmic incompatibility, a natural phenomenon whereby mating between males carrying the Wolbachia bacterium and wild-type females results in embryonic lethality (McMeniman et al. 2009; Sinkins 2004). The release of Wolbachia-carrying males to suppress insect populations is termed the incompatible insect technique (IIT) and can be used in combination with irradiation-induced sterility (Yen and Barr 1971). However, the use of Wolbachia-infected mosquitoes having not yet received the full approval of legislative bodies in many countries, this technology is not included in this document.

Recent systematic reviews of the effectiveness of vector control methods against Ae. aegypti and Ae. albopictus in the context of dengue control have concluded that there is a paucity of reliable evidence (WHO 2019): Few rigorous studies are available on the impact of vector control on the vector population and on dengue incidence, hence there is a need for standardized and comparative studies (Erlanger et al. 2008; Bowman et al. 2016). The methods for which the most evidence of their effectiveness is available are source reduction—but only as one element of an integrated strategy (WHO 2012)—and house screening. In addition, there is experience in the European Region with the use of insecticides (larviciding and targeted residual spraying) to suppress or eliminate local Aedes populations (Schaffner et al. 2014). Emergency space spraying of insecticides is still considered to be a useful tool in emergency situations (outbreaks or epidemics) for Aedes-borne viruses, even though evidence on its effectiveness is lacking. Several other options such as mosquito traps (Degener et al. 2014; Perich et al. 2003; Kittayapong et al. 2008; Rapley et al. 2009), autodissemination of juvenile hormones like pyriproxyfen (Devine et al. 2009), insecticide-treated materials (Wilson et al. 2014) and topical repellents are also available for

\(^2\) https://bch.cbd.int/protocol/text/
controlling the vectors of diseases. In specific settings, these methods could be considered as complementary to the main interventions.

The SIT against mosquitoes is still under development. It is not a stand-alone technique, but rather meant to complement (not replace) existing vector control measures within area-wide integrated control strategies for mosquito control. Vector control agencies should continue to carry out and promote source reduction activities additional to SIT and remain vigilant about mosquito breeding sites. A unique aspect of SIT is its inverse density-dependent efficacy, whereby the ratio of sterile to wild males increases exponentially as the target population is reduced. This sets SIT apart from most conventional control techniques and makes it a useful tool in modern integrated strategies (Feldmann et al. 2001).

For public health vector control, the sterile insect technique applied to *Aedes* mosquitoes is designed to control both the *Aedes* mosquitoes and *Aedes*-borne diseases, including dengue, chikungunya and Zika. Several Member States expressed the need for guidance on how to plan, implement and assess SIT-*Aedes* field testing. To that end, a joint collaboration was established between the Department of Nuclear Sciences and Applications (NA), the Department of Technical Cooperation (TC) of the International Atomic Energy Agency (IAEA), and the UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR) of the World Health Organization (WHO), in partnership with the WHO Department of Control of Neglected Tropical Diseases (NTD), with the goal of providing guidance to Member States on the use of the sterile insect technique as a component of integrated vector control programmes for disease prevention.

An expert working group (WG) appointed by the collaborating agencies has developed and finalized this guidance framework to support and planning for and assessment of field testing and operational use of the sterile insect technology for *Aedes* control. This effort was facilitated by two in-person meetings of the WG in February 2019 in Tapachula, Mexico, and July 2019 in Vienna, Austria. This document presents the results of the work between this WG and the Secretariats of the participating UN Agencies (IAEA and WHO).
Chapter 01

Framework for the implementation of the sterile insect technique (SIT) for Aedes control
1.1 Introduction

Transformative changes such as an increased global trade, international travel, urbanization and climate change facilitate the proliferation and spread of *Aedes* mosquitoes, vectors of human pathogens that are consequently also on the rise. For example, dengue virus now causes nearly 400 million infections annually (Bhatt et al. 2013), yellow fever is experiencing a resurgence in Africa and the Americas (Massad et al. 2018; Chan et al. 2016) and chikungunya and Zika have emerged in recent years to cause outbreaks on multiple continents. The resurgence of such *Aedes*-borne disease outbreaks underscores the limitations of conventional vector control programmes, which are heavily focused on insecticide application and the elimination of larval breeding sites. Challenges include the development of insecticide resistance, the presence of cryptic breeding sites, insufficient infrastructure or government support and high cost. Thus, there is a pressing need for innovative, sustainable and cost-effective control strategies targeting *Aedes* mosquitoes, particularly *Ae. aegypti* and *Ae. albopictus*, the two major vectors of arboviruses that together are responsible for more than 99% of arbovirus transmission within human populations.

A promising method for *Aedes* control is the sterile insect technique, which involves the mass rearing and inundative release of sterile male insects into target populations. Because mating between sterile males and wild-type (field) females does not produce viable offspring, sustained releases of sterile males, if properly conducted, will suppress vector populations, and hence reduce the risk of *Aedes*-borne disease transmission (Figures 1.1 and 1.2).
Overview of the sterile insect technique.

**Present**
- Wild-type male
- Wild-type female

About 300 eggs:
- **Future**
  - Sterilized male
  - Wild-type female

Eggs do not hatch which results in reduction in population.

**Figure 1.1.** Overview of the sterile insect technique.

**Figure 1.2.** *Aedes* population reduction using the sterile insect technique.
SIT methods using ionizing radiation to sterilize male insects have been deployed to control and even eradicate agricultural pests, such as the New World screwworm in the Americas (Wyss 2000), medflies in Mexico (Enkerlin et al. 2015) and tsetse flies on the island of Unguja, Zanzibar (Vreysen et al. 2000).

Despite its effectiveness against agricultural pests, SIT has not yet been widely used operationally to target Aedes species, vectors of several diseases. A major challenge is that SIT is not currently a turnkey solution, thus strategies and protocols may need to be customized for different epidemiological settings, social contexts, legislative systems, geographical distributions and ecologies. Testing and deployment also should dovetail with existing public health priorities and vector control methods. For example, because SIT targets future generations of vectors, the technology aims mostly at decreasing or eliminating endemic disease transmission and preventing future outbreaks, although it can be used as a supplementary tool during long-standing epidemics. Therefore, when infected females are circulating, SIT must be integrated with control tools designed for the immediate removal of adult mosquitoes.

Any successful implementation of SIT for Aedes control will therefore require systematic, well-thought-out plans and processes to address these wide-ranging and important issues. In this chapter, we discuss some of the key principles and considerations required for the success of SIT programmes and present a comprehensive guidance framework for the testing and use of SIT for Aedes control (Figure 1.3). This framework is intended to serve as a reference for countries exploring alternative methods for Aedes control and to assist health authorities with making informed decisions about the feasibility of SIT for their unique contexts. The chapters that follow will discuss various components of the framework in greater detail.
1.2 Key framework components

The planning and implementation of an SIT programme requires implementing the full suite of framework components, as these interlink with, depend on and underpin one another (Figure 1.4). A poor implementation of any of the components can cause derailments or delays. To avoid this, the entire life cycle of the SIT programme should be carefully laid out and examined during the planning stages, so that required activities can be identified and timelines can be aligned.

Figure 1.4. Interconnectivity and interdependency of SIT framework components.

To achieve their goals, SIT programmes should be well structured, with clearly defined roles, responsibilities and timelines for the various groups, agencies or organizations involved. At the same time, the success of the programme will depend upon communication and cooperation across the various groups, so that progress can be made in an integrated manner. To assist managers in developing an SIT programme, we provide a checklist of the framework’s components (Annex 1), which can be used to list required actions, assign lead agencies and estimate timelines.
1.2.1 Making the decision to embark on an SIT programme

a. Assessing priorities, costs, and benefits

Given limited resources and multiple public health issues to address, health authorities must prioritize which issues to take on, using which interventions. For example, planners may need to divide resources between malaria and dengue control programmes or choose between implementing an SIT programme and stepping up existing vector control measures.

Therefore, when considering SIT, countries should undertake a systematic decision-making process early on. This process takes into consideration factors such as disease burden and risk, public perception of the disease, suitability of the SIT compared with other interventions, whether or not SIT aligns with existing national health strategies and whether or not long-term financial, political and other commitments can be made to sustain the programme.

SIT programmes often require a substantial initial investment and may only yield results in the medium or long term. Therefore, planners should undertake a thorough and transparent evaluation of the costs and benefits associated with an SIT programme and compare them with the costs and benefits associated with alternative control interventions. Chapter 8 will review the process of performing a cost-effectiveness analysis and elaborate on how such analyses can serve as important decision-support tools.

b. Risk analysis

Like any other approaches, SIT approaches can yield secondary ecological, social or economic repercussions; hence, comprehensive risk assessments must be conducted against the backdrop of local disease epidemiology, social issues, legislation, and processes to identify any such potential impacts. Risk management activities, such as monitoring and mitigation measures, can then be planned and incorporated into the design of the programme.

For example, a secondary social impact might be the development of complacency in the wake of a successful SIT programme (NEA 2019). As with any control method, complacency could result in the public relaxing their personal source reduction efforts or policy makers allocating resources elsewhere, despite the need to sustain control efforts. To manage this risk, health authorities could design advocacy strategies and public messaging to emphasize the importance of continued vigilance and action.

To gather a broader range of perspectives on risk and to identify risks that need to be managed, focus group discussions can be held to engage diverse stakeholders, including members of the public, academic experts, medical professionals, government agencies.
and non-governmental organizations. Risk assessment and stakeholder engagement are closely intertwined, thus findings from risk assessment should be promptly and transparently communicated to stakeholders.

While an initial assessment typically is needed to satisfy national regulatory requirements and obtain approval for SIT, risk assessment should be an ongoing, iterative process with regular reviews to incorporate new information and knowledge. Chapter 2 will highlight the importance of risk assessment and management and provide guidance on principles and methodologies.

c. Obtaining long-term commitment and resources

Like most public health interventions, SIT programmes are long-term propositions, requiring sustained releases of sterilized insects and continuous monitoring. To protect the programme and ensure continuity, it is important for planners to obtain a long-term governmental commitment to trial and implement SIT as part of a national or regional integrated vector management strategy. This commitment should also include the financial resources and workforce required for implementation.

As SIT programmes comprise many dynamic components, securing the commitment and support of key stakeholders—including political leaders, grassroots leaders, implementing agencies and private sector partners—will be crucial for the SIT programme to run smoothly. Stakeholders’ and implementers’ roles and responsibilities for activities from mass rearing, releases, monitoring and surveillance to community engagement—should be defined from the start.

1.2.2 Testing and implementing SIT

a. Setting objectives and targets

The decision to trial and implement an SIT programme should be accompanied by the identification of the target vector, geographical region and local human population (cf. PICO in Chapter 6), as well as a clear definition of the programme’s short- and long-term objectives. Short-term objectives typically include immediate activities that need to be carried out before field trials can begin, such as the selection of an appropriate sterile male strain and evaluation of its mating competitiveness. Long-term objectives may include entomological and epidemiological endpoints developed in partnership with public health programs, such as sustained suppression of the vector population and reduction of the number of cases of disease in the target population, respectively.

Objectives and implementation targets can be determined through a situational analysis of the epidemiological, entomological and environmental factors affecting disease transmission. This analysis requires comprehensive surveillance programs (discussed in more detail in Chapters 5 and 6) to characterize the distribution of the disease and its vectors, as well as to identify high-risk areas and outbreak epicentres.
For example, because *Ae. aegypti* and *Ae. albopictus* co-exist in many regions, a detailed understanding of their spatial and temporal distributions, as well as their relative roles in disease transmission, will help planners prioritize targets. Vector and case surveillance also can yield data on the entomological thresholds that should be reached to prevent outbreaks (Ong et al. 2019); this information can be used as a guide for setting SIT programme objectives in terms of reductions in mosquito populations.

**b. Regulation, permits and authorization pathways**

SIT programmes typically are subject to regulation throughout their development and implementation and to regulatory processes at the institutional, state, national and international levels. Due to their multifaceted nature, SIT programmes are likely to require a range of approvals and permits, such as authorizations to ship, import and release mosquitoes and certifications of biosafety compliance and occupational safety. Chapter 3 will elaborate on the regulatory considerations faced by SIT approaches.

To avoid delays at later stages, it is critical for planners to conduct a comprehensive examination of the SIT programme life cycle in the initial phases of the project to identify, understand and budget for regulatory requirements. This is especially important as legislation, regulations and standards may differ from country to country and because SIT approaches may be subject to different requirements. SIT programme managers should communicate openly and regularly with regulators to enhance the latter’s familiarity with SIT methodology and its associated mass rearing and field procedures.

**c. Modalities of implementation**

SIT implementation requires the production of large numbers of high-quality sterile male *Aedes* mosquitoes, followed by releases in the field. Optimal procedures for mass rearing and sterilization, effective systems for field delivery and robust mechanisms for quality control are therefore critical to the success of an SIT programme. Chapter 4 will provide further guidance on these modalities of implementation.

During the planning phases, sufficient staff, budget and laboratory space should be allocated to mass rearing, with provisions for scaling up to support expanded SIT trials or deployment in the future. Scalability is an important factor that should be considered when initially deciding what techniques, technologies and procedures to incorporate into the workflow. To ensure scalability, planners may wish to consider evaluating or developing automated technologies to perform menial functions such as tray tilting, counting of larvae and pupae, and gender-sorting of pupae.

Once produced, sterile males must be released in the field in adequate but not excessive numbers and at the appropriate times, frequencies and locations. Release strategies should be developed and fine-tuned based on what is known about the behaviour of the target vector, as well as on a situational...
Guidance framework for testing the sterile insect technique as a vector control tool against Aedes-borne diseases

analysis of disease risk and mosquito populations in the target area.

For example, in areas with seasonal variations in disease transmission or mosquito numbers, releases could commence before the high season. In areas with less seasonality, tiered releases could be implemented, beginning with a high-density release to crash the population, followed by lower density releases thereafter to sustain suppression. Automated release systems such as drones can also be evaluated and implemented to boost release volume and improve horizontal and vertical dispersal. Integration of SIT with other control measures to initially reduce the target population should also be considered to optimize the cost-effectiveness of the programme.

The production of high-quality sterile males and the implementation of high-quality releases are critical to the success of SIT programmes. Regular quality control checks should be implemented at various stages to ensure that all workflow components are performing optimally. Examples of parameters to be monitored include rates of female contamination after gender-sorting, longevity and mating competitiveness of sterile males, and mortality upon transport and release in the field.

d. Ethics and community engagement

Ethical acceptability of SIT programs to their host communities is based on providing adequate and sufficient information on the goals, benefits and risks of SIT and responding to public concerns about the technology. Community engagement should be a key priority throughout the SIT testing and implementation process, with the aim of sharing information and consulting with stakeholders and gaining their approval and cooperation. Chapter 7 will discuss ethical issues surrounding SIT trials and provide guidelines for effective community engagement.

Strong community support is crucial for the success of novel public health interventions such as SIT. Engagement with various stakeholders—including residents of study sites, the public, medical and scientific communities, policy makers, government agencies and non-governmental organizations—should be initiated as early as possible, before beginning laboratory feasibility studies. Allocating time for stakeholders to familiarize themselves with the technology and raise concerns avoids misunderstandings that could derail the SIT programme at later stages. It also allows social expertise feedback to be incorporated into the design and implementation of laboratory and field studies at an early stage, thereby increasing their likelihood of success.

We further recommend a consultative approach that respects and takes into account the concerns and opinions of stakeholders, especially those of residents who will be directly in contact with the SIT trials. Activities such as dialogue sessions with residents and community leaders can help garner a spectrum of views and concerns, which can be integrated into implementation strategies. Public feedback mechanisms, such as hotlines or online reporting systems, should also be established to enable the community to pose queries and voice concerns.
Good situational awareness is a pillar of effective community engagement, as keeping tabs on the vector situation in an area and being attuned to the local community can help identify concerns from the public as they arise, so that they can be swiftly addressed. For example, a coincidental rise in the population of non-target mosquito species could lead to doubts in the community about the efficacy of the SIT programme. In this case, data on the population dynamics of non-target mosquito species, together with detection of their breeding sites, could provide the evidence needed to dissociate these experiences from the SIT programme.

**e. Evaluation of epidemiological and entomological efficacy**

The efficacy of the SIT approach against VBDs must be evaluated using both entomological and epidemiological endpoints (Chapters 5 and 6).

Referring to a reduction in the risk of disease transmission due to changes in vector population characteristics, entomological endpoints are an important outcome measure at all phases of testing and implementation. Because direct measures of transmission intensity (such as the entomological inoculation rate, sometimes defined as the number of infectious bites per person per unit of time) are difficult to measure, surrogate measures that monitor vector population parameters are often used instead, especially in the early phases of an SIT programme when sample sizes are small. These proxy measures may include egg hatch rates and ovitrap or gravitrap indices, as well as biting rates.

Referring to a reduction in the incidence of human infection or clinical disease, epidemiological endpoints typically only become informative once the SIT programme advances to larger, more advanced field trials. Study design will depend on the goal of the SIT programme and the disease being targeted, with possibilities including cluster-randomized trials, case-control analysis, longitudinal studies or seroprevalence surveys to gauge long-term impact.

**f. Surveillance and monitoring**

Comprehensive and robust surveillance systems (Chapter 9) for monitoring the progress of the programme, as well as entomological, epidemiological and environmental indicators, are required throughout the planning, testing, deployment and evaluation phases of SIT programmes. Up-to-date surveillance data enable prompt situational analyses, which in turn allow planners to track seasonal variations in cases or mosquito populations, detect high-risk areas to target and to improve release strategies, trial design and community engagement activities.

Entomological surveillance allows vector population dynamics and spatial distribution to be monitored and is often carried out via a network of ovitraps, which collect eggs, and gravitraps or other adult traps, which target adult female mosquitoes. Care must be taken to standardize handling procedures and protocols across the network, so that data obtained are
Guidance framework for testing the sterile insect technique as a vector control tool against Aedes-borne diseases

robust and comparable across different time points and geographical areas.

Epidemiological surveillance entails a notification system for the mandatory and timely reporting of arboviral disease cases, together with laboratory support to confirm cases using standardized, quality-controlled testing procedures. A passive surveillance system can be supplemented with active surveillance or other forms of monitoring, such as serological surveys to estimate the dynamics of infection rates and disease burdens and/or to detect changes in the patterns of circulating virus serotypes—not only to assess the results of SIT testing, but also to eventually provide early warning of outbreaks. For example, in Singapore, switches in the predominant dengue virus serotype have been associated with epidemics caused by the newly circulating serotype (Lee et al. 2010).

Incorporating environmental monitoring into the surveillance system will further strengthen situational analysis. Climatic variables such as temperature, rainfall and humidity affect mosquito populations and the incubation periods of Aedes-borne pathogens (also called extrinsic incubation), thus have the potential to impact disease transmission (Colón-González et al. 2013; Bouzid et al. 2014). Weekly climate monitoring, which is sometimes carried out in collaboration with the local meteorological service, therefore can complement entomological and epidemiological data to follow disease dynamics and eventually predict outbreaks.

g. Phased conditional approach implementation

We recommend that SIT programs be tested and deployed using a phased conditional approach (Figure 1.5) (Wilson et al. 2015) with demonstration of safety and efficacy as requirements for transitioning to the next phase. Phased implementation is analogous to the development roadmap for vaccines and drugs and has been proposed for the testing and deployment of genetically modified mosquitoes (WHO 2014) and new vector control technologies (Wilson et al. 2015).
Chapter 01 | Framework for the implementation of the sterile insect technique (SIT) for Aedes control

Phase I should focus on laboratory studies to demonstrate the feasibility of the technology, with a view towards SIT’s future efficacy and safety in the field. This may involve assessments of the chosen strain’s biological characteristics, such as hatch rates, mating competitiveness, longevity, dose response curves, flight ability, insecticide resistance and response to lab colonization, as well as characterization of the target population.

Once feasibility has been demonstrated at the laboratory level, the programme may proceed to a phase II semi-field and small-scale field trial in an ecologically confined area to assess whether the SIT strain retains the desired biological characteristics in the field. This phase could include the study and calibration of release parameters, such as horizontal and vertical dispersal and release numbers and frequencies. Phase II trials also assess the competitiveness of the released sterile males in the field and the impact of releases on local mosquito populations.

Following a successful phase II, phase III involves scaled-up trial releases covering progressively larger areas, with the aim of demonstrating entomological and epidemiological efficacy. Trial design and release strategies will depend on the chosen objective, which may include targeting high-
risk areas, responding to seasonal variation in mosquito populations or achieving sustained suppression in the target area. Early results of phase III trials typically will include the impact of the release on mosquito populations. Data on the impact of the release on cases of human disease can start being collected in this phase, but data collection will need to continue over a longer term. In the case of testing programmes designed for disease risk reduction in areas with little or no disease, only entomological endpoints may be collected for phase III.

While still developmental, phase III effectively constitutes a pre-operational deployment of the SIT approach. Already by phase III, SIT programmes should have ensured adequate capacity for producing the required numbers of sterile males and designed a robust and comprehensive surveillance and monitoring system.

Depending on the outcome of phase III, planners may decide to operationalize the SIT approach in phase IV, marking a transition from development to deployment as a public health intervention. Deployment should be accompanied by long-term, continuous assessment of the SIT approach’s impact on entomological and epidemiological indicators, as well as monitoring to evaluate how the programme is running and to detect any potential secondary impacts on human health and the environment. The efficiency and cost-effectiveness of both the SIT approach and the integrated vector management programme of which it is a part should be routinely assessed to determine if adjustments need to be made. Assessment of the SIT approach will require feedback mechanisms and close communication between the management, field and mass-rearing teams, following an adaptive management scheme. An independent panel to review testing programme progress and validate the interpretation of the results is desirable at all stages and necessary in phase IV.

Progress from one phase to the next will require fulfilment of pre-defined criteria covering safety, efficacy, regulatory approvals, ethical approvals and social acceptance. A “go” vs “no go” decision, based on the results achieved and relevant criteria, will be taken before moving from one phase to the next until phase IV. If a “no-go” decision is made by any of the responsible parties, the technology or procedure in question will need to be improved or refined until the criteria are satisfied and a “go” decision is reached. Lead government ministries take this decision; to do so, they assess the results jointly with SIT programme managers, regulatory authorities and independent external reviewers, all of whom together factor in risk assessment and cost-benefit analyses of the technology. The final decision to progress to each subsequent phase, and especially to deployment in phase IV, requires several levels of government oversight and evaluation.
Chapter 02

Framework for health and environmental risks assessment
Due to SIT’s long history as a tool for controlling insect pests, many aspects of the technology are relatively well-known. It is an area-wide, species-specific pest control tool, whose potential risks to non-target species and ecosystems typically are significantly less than those associated with less targeted technologies, such as aerial applications of conventional, broad spectrum adulticides. However, performing risk assessment as part of SIT planning is important to acknowledge the risks and mitigate them, obtain the relevant authorizations, garner public support and ensure effective and efficient programme management.

Risk analysis is one of at least four interrelated risk processes: risk assessment, risk management, risk communication and risk policy. However, a general framework for risk assessment will include all processes. Plausible risk concerns must be identified by risk assessors and SIT programme managers, together with relevant stakeholders, and consequently inform risk planning and the formulation of risk management options. Risk analysis is also an integral part of vector control programme design and planning. Considering risk at an early phase allows programme design to reduce the likelihood or impact of any harms before the programme is deployed.

2.1 Introduction

Risk analysis focuses on changes that lead to harm. Harm is an expression of a negative value associated with a change and not simply of change itself. Very small negative values may or may not be important to individuals or society, while a high likelihood of an outcome occurring beyond a defined threshold value of harm may be unacceptable. An important question for risk assessment/management is what constitutes an acceptable outcome? Risk assessment can provide qualitative or quantitative estimates of the probability of an outcome, including its magnitude and distribution in human communities and ecosystems, to help programme managers, stakeholders and regulators in making informed decisions that reflect social values.

Risk-assessment planning is a crucial step before the full risk assessment process (US EPA 1998; NRC 2009). The goals and objectives of the risk assessment are established in the planning step; this includes not only identifying risks but also risk management options, and defining the level of uncertainty that is acceptable for risk management decisions. After establishing the objectives and scope of the assessment, the risk assessment starts with the problem formulation phase, which documents the characteristics of the technology, its operational use, the human population and ecosystem potentially at risk and the acceptable endpoints. This process takes into account the regulatory and societal objectives and values identified during planning. A conceptual model can be designed to describe the technology and the risks associated with its application, the communities and ecosystems in which it will be used, and how the technology may
directly or indirectly interact with humans and the risk-assessment-endpoint-relevant ecological entities. The analysis plan, which is created subsequent to problem formulation, describes the approaches that will be used to estimate risks and evaluate uncertainty. During the analysis phase, exposure to the operational events and exposure-related effects are characterized. The final step is the risk characterization phase, which yields a risk description along with an analysis (qualitative or quantitative) of the uncertainties associated with the likelihood and impact of the identified risks. The results of the risk assessment are then communicated. If any harm and uncertainty in the risk estimate do not exceed the level defined as acceptable during the planning stage, the risk management decision would be to approve the SIT programme within the regulatory framework. If they exceed the defined level, the risks must be mitigated or otherwise addressed before approval is given.

Figure 2.1. Risk assessment process (adapted from US EPA 1998).
2.2 Theoretical planning and risk assessment process

Risk assessment is an iterative process that is likely to include the steps shown in Figure 2.1 (Mumford 2018b). Box 2.1 shows the steps in conventional risk assessment in vector control programmes. The SIT programme managers are required to provide information relevant for this process to the national and/or regional regulatory authorities for review in accordance with their specifications for an SIT programme. The relevant regulator and/or the SIT programme manager also may ask independent groups to provide information. Consultation with stakeholders usually is required as early as possible in the risk assessment process.

Box 2.1. Conventional risk assessment in vector control programmes

Vector control has been carried out in many countries for many years, with broad public backing and participation, and strong regulatory and political support. SIT is a novel area-wide control approach for vectors in many countries and both the public and the relevant regulators will consider its adoption in the context of current conventional vector control programmes. There is a relatively simple approach to risk analysis in conventional area-wide mosquito control aimed at vector population suppression, which has had broad acceptance in many countries and includes the following steps:

Planning
• Catalogue problem mosquito species in the geographical area of responsibility;
• Describe the nature of the problem (vector, nuisance);
• Describe management criteria for each listed action;

Risk Assessment
• Map areas and time frames of mosquito concern and proposed application of insecticide;
• Delineate any areas of special protection;
• Summarize toxicity of insecticide to non-target organisms, including humans, and approaches to predict community or ecosystem harm;
• Summarize data sources and models to estimate exposure to the control actions (generally insecticides and habitat management);
• Establish a conceptual model of hazards to harm and an analysis plan for potential remedial actions;

Risk Management
• List approved control methods for each mosquito stage;
• Describe management plans for identifiable accidents or incidents (spills, application errors, etc).
**2.2.1 Planning**

The *proposed conditions of use*, which are the events that are expected to occur prior to, during and after an SIT release action, are described during the planning phase. During this planning process, SIT programme managers consult with a diverse range of experts, stakeholders and regulators to identify *risk concerns*, plausible pathways to potential harm, levels of acceptable risk and uncertainty in risk estimates. The *limits of concern* and the level of harm that are likely to be negligible or acceptable for regulators are defined during this phase. The planning process can also be handled by an external body of consultants, to avoid any conflict of interest.

**2.2.2 Problem formulation**

The SIT managers, consultants and/or regulatory authorities carry out a review of literature, technical experience and social engagement to identify *pathways to harm* (hazard-pathway-outcome chains). *Risk concerns* are considered at the planning step and a determination is made about how risk assessment endpoints, including those that cannot be empirically quantified (such as the public’s perceptions or fears), can be measured. A *conceptual model* that establishes hazard source to outcome pathways is developed to assess the processes affecting the likelihood and consequences of any harm.

Relevant *comparators* can be used to demonstrate how harm may or may not arise.

The problem formulation phase results in an *analysis plan*, which estimates the time and amount of effort needed for the programme managers and independent groups (inasmuch as they have been involved) to complete the risk assessment. To determine the placement of potential outcomes in risk matrices, workshops and consultations with experts, regulators and other stakeholders can be held throughout the risk analysis process to gather input or feedback on issues such as risk concerns, pathways, endpoints, uncertainty, acceptability and hazard-pathway-outcome chains.

**2.2.3 Analysis of hazard and exposure**

Analysis is dependent on an accurate plan for the activities, so that the scale and exposure of any identified hazards can be estimated. Conceptual and quantitative models can be used to support analyses of the effects of exposure or events. Analysis may rely on estimates derived from expert opinion, but care should be taken to document the assumptions and justification for those opinions.

**2.2.4 Risk characterization**

Qualitative, semi-quantitative or quantitative descriptions of the likelihood and consequences of risk (and associated levels of uncertainty) illustrate the distribution of outcomes that would be expected from a causal event, given the assumptions and evidence used in the analysis.
Van den Brink et al. (2016) provide some recommendations and specifications for performing ecological risk assessments in landscape-scale scenarios with multiple pathways to harm and multiple endpoints. Specifications for ecological risk assessments include:

- Creating a digital map of the site that includes land use, topography and locations that are potentially sensitive to any pathways to harm;
- Mapping regions in the landscape that have similar land uses and management goals;
- Establishing a priori the cultural values and protection goals that will determine the success of the assessment and decision-making process;
- Determining interactions among species and ecological processes and functions that would be affected by any plausible pathways to harm;
- Constructing a conceptual model that reflects the plausible pathways to harm, the habitats, the expected effects and impacts on the system under investigation;
- Using the conceptual model to organize information that will inform cause-effect modelling of the plausible pathways to harm;
- Transforming the cause-effect model, as data permit, into a quantitative model that considers both deterministic and probabilistic aspects of the ecosystem.

The decision to approve vector control actions rests with the relevant national or regional regulator, who would decide whether a programme poses any unacceptable risks based on evidence provided by the programme manager and any appropriate independent sources. If the level of risk for a proposed technology when used as intended does not exceed a level of concern, then it may be approved (subject to other factors also being successfully addressed). If the risk does exceed a level of concern, management conditions may be required to reduce the level of risk to an acceptable level. It should be noted that the risk conclusion is about the acceptability of risk without consideration of any of the potential benefits of the technology, which are part of an implementation decision (cf. Chapter 8).

2.3 Risk planning for SIT against Aedes mosquitoes

During the planning stage, the relevant authorities should organize the SIT risk assessment and request the necessary information from the programme managers. The scope of what must be included in human health and ecological risk assessments is defined at the planning stage. According to Gormley et al. (2011), agreement on the scope of the risk assessment can be influenced by these factors:

- Purpose of a health and environmental risk assessment;
- Legislative and regulatory requirements;
- Boundaries of responsibility for the SIT programme and related roles;
- Environmental impact of the SIT programme;
- International, national, regional and local environmental aspects.

**Risk concerns** may arise upon consultation with internal and external stakeholders and/or from general categories or specific concerns indicated in national or regional regulations. Planning typically will include regulators and stakeholders relevant to the risk management decisions.

**Specific protection goals** will be defined, which are desired characteristics of human health or ecological values that the public wants to protect and that are relevant to the management being undertaken. Possible management goals include maintenance or improvement of individual and community health status (e.g., reduced disease transmission) and ecological integrity (cf., for example, US EPA 1998). Protection goals are defined in the planning stage and form the basis of risk assessment endpoints, which may be much more specifically stated. These protection goals will also be embedded in risk hypotheses and conceptual models defined during the problem formulation.

In the case of the SIT against vectors affecting not only human health and well-being but also animal health, there is a biodiversity concern, since the vectors may also occupy a niche with some value as part of natural or introduced ecological systems. Consequently, broad protection goals are needed for the health and environment to reflect all roles of the vector and yield endpoints related to these wider goals. For example, within the sphere of human health, objectives might include ensuring that the mosquito biting rate does not increase or that another vector species does not replace the SIT target species.

The identification of a protection goal or specific risk concern does not in itself indicate that there is an unacceptable risk; that is an issue to be addressed in later stages of the risk analysis.

At an IAEA-supported workshop on *Aedes* SIT, held in Singapore (Mumford 2018a), risk concerns related to protection goals were identified in three broad areas linked to health and the environment: human health, nuisance to humans and biodiversity.

The human health goal could be further broken down into more specific risk concerns, including:

- SIT production facility workers affected by health problems such as allergic reactions or irradiation in the production environment;
- Disease transmission not reduced after the release;
- Mutations in under-irradiated males that modify the vectorial capacity and behaviour of the mosquito vectors;
- Niche replacement by a more competent vector species;
- Complacency leading to reduced complementary vector control efforts.

The nuisance goal was related to more specific risk concerns about the biting nuisance from any female mosquitoes released...
via SIT and the perceived nuisance from non-biting, sterile males.

The biodiversity goal was related to more specific risk concerns around niche replacement affecting ecological balance and the loss of all or part of an endemic or naturalized vector species with an ecological role.

Health and environmental concerns related to the request to authorize a small-scale SIT pilot against *Ae. albopictus* on Reunion Island (HCSP 2018) were considered in a national risk assessment and yielded the following risks:

- Epidemiological risks;
- Risks linked to the technology and processes;
- Risks for the workers;
- Risks for the local population;
- Ecological risks;
- Risks associated to the change of scale of the SIT operations.

Nienstedt et al. (2012) proposed an ecosystem service approach to protection goals that integrates cultural and social values and is defined by these six dimensions:

- Ecological entity: individual to ecosystem;
- Attribute: behaviour, survival, growth, abundance, biomass, process, biodiversity;
- Magnitude: negligible to large;
- Temporal scale: days to years;
- Spatial scale: local to landscape;
- Degree of certainty: low to high.

Thus, a protection goal may be more specifically defined in terms of a particular health situation, ecological level, the specific attributes of organisms in that level and the scales of protection. The levels of protection can be specified, along with the degree of certainty that could be achieved.

### 2.4 Risk assessment for Aedes SIT

#### 2.4.1 Problem formulation

Following risk planning, the first step in the risk assessment process is problem formulation (Figure 2.1 and Gormley et al. 2011), as it defines the planned use of the technology, the plausible hazards, the pathways to harm, the assessment endpoints and the limits to concerns. Potential effects on health and important environmental indicators are elucidated and actions are defined. Plausible pathways to harm are identified and described in this phase, with explicit risk hypotheses linking a causal event, such as the reduction in a vector population, to a potential harm of concern, such as the
replacement in the ecological niche by another vector species. Methods for measuring key indicators, such as target and non-target vector densities, are selected and decisions taken on priorities and risk outcomes, especially which outcomes would be acceptable.

Problem formulation, adapted from EFSA (2013) for SIT, should cover the following aspects:

- Description of the SIT planned rearing and release programme, including its scale in space and time and its intended outcome (prevention, reduction or suppression);
- Characteristics of irradiated released mosquitoes and production and application systems that can cause direct or indirect negative effects on human and animal health and the environment;
- Characteristics from the environment of the released area that need to be protected from harm according to environmental protection goals and identification of risk assessment endpoints;
- Identification of environmental exposure pathways and plausible links to assessment endpoints;
- Description of the methods to estimate how exposure and effects data will be collected and analysed, and how risk and uncertainty in risk estimates will be qualitatively or quantitatively characterized;
- Definition of assessment endpoints proportionate to protection goals;
- Definition of measurement endpoints for both hazard and exposure;
- Methods for evaluating assessment and measurement endpoints in relation to protection goals;
- Reference comparators for potentially harmful ecological effects;
- Limits of concern for relevant ecological effects that would not constitute harm;
- Uncertainties and their source (natural variability, knowledge, measurement).

To provide a clear route for regulatory decision-making, national and local regulatory requirements must be included and considered in any problem formulation. In addition, stakeholder input provided in the planning stage should be incorporated in problem formulation to ensure that the risk assessment is responsive to social values.

Some aspects of the abovementioned problem formulation are detailed herein. For a risk assessment to establish an objective estimate of the likelihood and impact of a potential harm, there must be a plausible pathway by which the planned events lead to that harm. This requires a conceptual model of a hazard-pathway-harm chain in which the probability and extent of harm can be measured or estimated. The cause-effect model includes five interconnected nodes: hazard source, environment, hazard effect on the environment, effects of exposure to the hazard, and impacts or outcomes. The source is the cause of the potentially negative response. In a SIT programme, the hazard source might include, for example, the unintended escape of mosquitoes from a production facility.

An assessment endpoint is an indicator of a protection goal. It describes how a harm may arise from exposure to an effect related to SIT operations. For example, an assessment endpoint related to a biodiversity protection goal could address non-target
predator organism abundance that may be affected by a decline in Aedes abundance as prey. A measure of exposure in that case could be the density of Aedes present over a season, measured by oviposition traps, larval site sampling or adult catches, while the measurement endpoint for the effects would be the density of the non-target predator species before, during and after the releases.

As noted above, SIT exposure information, including the location and type of introduction (i.e., the timing and frequency of the release and also the mechanism, such as drones or ground), together with estimates of the number of mosquitoes released and their persistence and distribution in the environment, is needed to inform SIT exposure-response relationships. Changes in population size and in the dynamics and effective breeding size of the vector over time as a result of the release are then related to endpoints, including, for example, reduction in human and animal disease, changes in biodiversity, and non-target species effects. The SIT exposure-response relationships can be assessed by combining data collected in limited field trials with deterministic or probabilistic models.

The limit of concern is a subjective value expressing what would constitute an acceptable level for a particular risk. Limits or levels of concern may be derived from discussions with relevant stakeholders or expressed in national regulations or policies. For example, the ratio of pesticide concentration causing 50% mortality to a non-target species population divided by the estimated upper end of the range of the pesticide’s exposure level in the environment must exceed a certain (specified) value to conclude that the likelihood of an adverse effect is acceptably low. Limits of concern may also be derived from thresholds in epidemiological models (e.g., an R0 value for sustainable disease transmission) or reflect a commonly agreed level of harm, such as a biting rate below which nuisance is considered negligible.

Comparators are used to compare the potential health and environmental risks arising from a planned SIT programme with a baseline estimate of risk. This could be at the level of the characteristics of an individual irradiated mosquito compared with a wild mosquito, irradiated mosquito populations compared with wild populations or an SIT vector control operation compared to conventional control measures. The nature of the risk concern informs the selection of an appropriate comparator. Concerns related to individual behaviour, such as assortative mating or biting, would have an individual comparator. Concerns about population resurgence would have a population comparator. Finally, concerns about human immunity levels following several seasons of SIT control would be compared with such levels after a similar period of conventional control.

2.4.2 Risk analysis for Aedes SIT

Where a pathway to harm has been identified, the exposure to its causal events (such as sterile insect release) should be estimated
in space and time. For example, what is the number, per area and time, of female mosquitoes that might be released in an SIT programme and how would that affect the biting rate and disease transmission? The analysis of the different categories of risks identified, as well as their pathways to harm, endpoints and limits of concern, will be then used to characterize these risks and decide upon the acceptability of the risks and mitigation measures.

### 2.4.3 Risk characterization for Aedes SIT in a likelihood–consequence matrix

Risk matrices illustrate the likelihood and consequences of risks (Table 2.1). They can be used to illustrate outcomes related to protection goals and inform regulators’ decision making on the acceptability of risks. Each potential harm is assigned a value (and optionally an uncertainty range) for likelihood and consequence. The case shown in the table below uses subjective definitions for the likelihood and consequences scores, but scoring can also be more rigorously defined (cf., for example, OGTR 2013). Further operational risks can be characterized in activities such as insect rearing, irradiation, transport, release and monitoring; some examples are shown in Box 2.2.

<table>
<thead>
<tr>
<th>Likelihood levels</th>
<th>Consequence levels</th>
<th>1 Very low</th>
<th>2 low</th>
<th>3 Moderate</th>
<th>4 High</th>
<th>5 Very high</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Very unlikely</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 Unlikely</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 Moderate likely</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 Likely</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 Very likely</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Table 2.1.** A matrix of health/environmental risks assessed in an IAEA-supported workshop in Singapore in June 2018 for Ae. aegypti SIT. The range in values [likelihood/consequence value ranges] are shown after each harm listed (Mumford 2018a), so the range [2/2–4] would indicate a consensus for likelihood at level 2 and the range of consequences from levels 2–4.
Box 2.2. Operational risk characterization in SIT programmes

Insect rearing
- Construction of a rearing facility will require permission from the local environmental planners and will involve the usual environmental concerns related to materials, scale, drainage, traffic etc.
- Operation of the facility will require planning for effluent, nuisance, traffic, radiation safety, insect allergens and feedstock security.

Transport
- Transport of sterile insects to the release points will require consideration of vehicle environmental effects and road (or other) safety measures for personnel.

Release
- Release of sterile insects will involve consideration of road (or other) safety measures and environmental impact.
- Release of sterile mosquitoes is likely to involve personnel moving through populated areas, thus consideration must be given to ensure the safety of bystanders and the security of the release staff.

Monitoring
- Monitoring in release areas is likely to involve monitoring personnel entering properties to conduct mosquito sampling.
- Staff security must be considered.
- Sampling methods may have an environmental or health impact, for example, if they involve collections to assess insecticide knockdown.
2.5 Risk communication for Aedes SIT

Risk communication depends on an accurate description of the planned SIT activities and how these relate to any risk concerns that may have been raised by the various stakeholders. Measures to mitigate those risks should be described, along with an explanation of how and why they will be effective. The protection goals likely to be associated with Aedes SIT should also be addressed in communication about risks and risk management.

According to the HCSP (2018), the risk related to the communication activities was considered one of the most critical risks for the acceptability of the SIT programme to the human population, and several recommendations were proposed to mitigate this risk. The development of a communication plan was strongly advocated with the following objectives and principles:

- The communication plan must be in place before any trials, to inform the entire population concerned, not only the population of the chosen field sites for testing;
- The communication plan must be developed jointly by the SIT managers and the stakeholders, taking into account all the concerns of the civil society;
- The objectives of the plan are to inform the population on the technology—in particular, to promote the benefits and inform about risks and how they are to be mitigated—in order to gain the acceptance of the populace.

The development of the communication plan must include monitoring and evaluation of the communication activities.
2.6 Risk management for Aedes SIT

SIT programme managers should specify standard operational activities and consider options for mitigating any unacceptable risks that have been identified. In consultation with regulators and other stakeholders, SIT programme managers must identify management actions and standards of performance that would bring risks within acceptable levels. For the above example, sorting and screening measures to limit the number of female mosquitoes in a release would be included in the operational plan.

Risk management includes both the general and specific measures taken to reduce known risks. Box 2.3 below illustrates some general risk management measures.

Box 2.3. General risk mitigation measures adapted from the IAEA Singapore workshop for SIT and SIT/IIT (Mumford 2018a).

**Measures for mitigating the risks for health and environment**
- Limit release numbers, (in space and time)
- Optimize rearing quality (known performance, composition)
- Predictive modelling to design operations that minimize risk to an acceptable level
- Close monitoring of laboratory and field operations
- Monitoring of external conditions (disease, mosquito abundance) that might affect release
- Standard health and safety operating procedures for laboratory workers

**Measures for mitigating operational risks**
- Standardize operating procedures, ensure quality control and consistency
- Ensure staff are well trained in their roles
- Plan ahead for material needs and ensure backup supplies
- Appropriate design for facility purpose and maintenance
- Record-keeping
- Plan systematically for the whole operation to ensure efficient rearing, transport, release, monitoring
- Keep facilities clean and secure
- Learn from experience and other projects
Although risk assessment and risk management for all vector control operations, including SIT, are recommended globally; in the first *Aedes* SIT trials prior to 2018, no additional risk management measures were required from the relevant authorities, mainly because the technology was deemed to be agricultural and had been included in available biocontrol methods for decades without any adverse effects having been reported in the scientific literature (Mumford 2018b). Small-scale local releases of irradiated sterile males of *Ae. albopictus* were permitted in Italy, Germany (permission granted at local government level; Norbert Becker, pers. comm.), Montenegro (released irradiated male mosquitoes were specified as reared from locally collected eggs; EPA Montenegro and the Ministry of Agriculture stated that these releases were not subject to permit requirements for releases into the environment; Igor Pajović, pers. comm.), Albania (Enkelejda Dikolli, pers. comm) and Greece (Antonios Michaelakis, pers. comm.), as well as in Spain (Ignacio Pla Mora, pers. comm.) and Mauritius (Ambicadutt Bheecarry, pers. comm.), with no further risk assessment (based on the absence of adverse effects reported from this technology). Local releases of irradiated sterile males of *Ae. aegypti* were also permitted in Mexico in 2018—again with no further risk assessment (based on the absence of adverse effects reported from this technology) (Pablo Liedo, pers. comm.). These decisions in Mexico were based on the SIT programme managers’ long experience with other sterilized insects; in each case, the relevant local, regional or national health or environmental authorities were notified of the nature and scale of intended rearing and releases.

By contrast, in France and for La Réunion Island, *Ae. albopictus* SIT releases were referred for comment and approval to authorities (AFB 2018; HCSP 2018), who noted the absence of a clearly defined regulatory framework for SIT against disease vectors in France specifically and in Europe more broadly. Previously, EPPO (2015) had also noted the lack of a clearly defined regulatory framework for biocontrol.

Generally, despite some concerns being identified, pilot SIT releases were approved, with several risk mitigation measures required to bring risks to an acceptable level. As an example, some of the risk management steps required to address the concerns raised by the proposed SIT mosquito release trials on the island of La Reunion (HCSP 2018) are reported below:

- Baseline entomological and epidemiological monitoring and monitoring of potential ecological effects after release;
- Development of standard operating procedures for technical processes, with review and revision as needed;
- Worker protection via application of good laboratory practices and standard operating procedures;
- Well-defined trial releases, on a relatively small scale in relatively isolated areas;
- Precautions to prevent escapes during transport;
- Development of a communication plan for acceptability of the trials to the local population.
2.7 Risk assessment responsibilities and governance

National authorities are responsible for the specification of SIT risk assessment requirements within their jurisdictions, in line with the regulations for their country (cf. Chapter 3). However, experience has shown that there may be alternative or conflicting roles for different national agencies in some countries, and in some cases, no clear regulatory pathway for this technology. Clarifying a pathway for regulatory oversight is an essential early step for any Aedes SIT project in a country.

The International Risk Governance Council\(^3\) provides some general guidance on risk governance (IRGC 2017) and highlights the following areas of challenges:

- Consistent and appropriate methodologies to assess similar risks across different cases;
- Distribution of risks, benefits and trade-offs;
- Consequences and interconnections of risks and opportunities;
- Efficiency of regulation/management;
- Inclusion of stakeholders and their perceptions;
- Public trust.

Given the range of locations where control actions may be considered and the different regulatory systems involved, global harmonization of the regulations is challenging. While national regulatory requirements preponderate; wherever possible, projects should make use of appropriate precedents in other countries and for related species to help ensure consistent approaches to risk. In many cases, national regulations prescribing environmental risk assessments preclude consideration of benefits alongside harm, with benefit and efficacy at times only considered at a later pre-deployment decision stage. This may also apply to the scope of assessments and the extent to which secondary interactions are considered. Inclusion of stakeholders is necessary at the planning stage and getting value from their views requires proper resources and facilitation. Public trust is derived from the successful interaction of those developing SIT and those responsible for formal approval and community acceptance.

\(^3\) [http://www.irgc.org/](http://www.irgc.org/)
2.8 Risk analysis checklist

1. Determine the appropriate body (or bodies) to oversee and/or undertake the risk analysis. This body (or these bodies) may be the regulatory authority or external consultant with regulatory oversight.

2. Ensure that risk management procedures are in place and adaptable to the increasing scales of insect rearing, transportation, release events and monitoring required for executing phases I through IV of Aedes SIT testing.

3. Ensure that stakeholder and community input are included in the planning stage. This is likely to be a series of meetings as the SIT programme progresses from experimental/preliminary releases to area-wide suppression, with concomitant risk assessments.

4. Share the public health goals of SIT, including feasibility of alternatives; describe how SIT works and where/when the approach is best suited; describe how sterile male mosquitoes are produced and the proposed location of the production; describe how the sterile mosquitoes will be released and the likely locations; identify protection goals for human health and the environment.

5. Perform the risk assessment, i.e., problem formulation, characterization of SIT release and potential human health and ecological effects, and risk characterization. Given the nature and history of SIT in agricultural and livestock pest management programmes without adverse human health or ecological effects, the risk characterization will likely be qualitative and deterministic.

6. Develop a risk communication plan: How will the conclusions of the risk assessment be shared with SIT developers/implementers and the public? Are there any restrictions on how, when and where SIT releases can be made? Will release periods and locations be announced publicly? How will the results of the SIT release be shared with the public?

7. Monitor and mitigate the risks by developing a monitoring and evaluation plan.
Chapter 03

Permits and authorization pathways
The role of governments in creating or cultivating a policy and regulatory environment to oversee sterile mosquito techniques management is essential for ensuring a predictable permitting process and maintaining the public trust. Mosquito production, release, monitoring of outcomes, stakeholder engagement and underlying human health and environmental risk analyses can all be subject to regulatory oversight and support.

When seeking an authority's approval of permits for field releases, transparency is essential. Objectives should be clearly explained with a precise economical model.

The primary focus of this chapter will be the authorizations for SIT technology that must be given by the local or national decision maker(s). Since an authorization may be necessary for each step of the technology, a description of the process is essential. Below, we describe the stages of development from production to irradiated mosquito release and highlight areas for regulation at the local or national levels.
3.2 Different levels of authorization pathway

3.2.1 Four phases of development before license

The concept of phased testing (Wilson et al. 2015) previously described in Figure 1.5 is important to underline how local authorizations can be managed. Irradiated sterile insects are not considered to be transgenic insects and are exempted from specific regulation because of their long safety records (Lutrat et al. 2019).

a. Phases I and II (defined in Chapter 1)

These phases may not require any specific authorization except that of the funder or the research organization supporting the development, as long as the phase II semi-field releases are done into a closed and controlled environment. However, some countries do deliver approvals—including for the production and experimentation with mosquitoes—for phase I and II. In case of semi-field releases into open spaces, the same authorization as for phase III may be needed, according to the country. Depending on the institutions involved, an ethics committee may be called upon, especially for the use of an irradiated source and the release in phase II. Field trials with containment may require a permit from a local authority.

b. Phases III and IV (defined in Chapter 1)

Phases III and IV should demonstrate the efficacy and effectiveness of the new prevention tool, and thus, its epidemiological impact on a population exposed to vector transmission of a pathogen. Particularly important in terms of the regulatory framework, phases III and IV must be supported by regional and national authorities, respectively, depending on their scale and the number of insects handled.

To document the efficacy of SIT for mosquitoes, it is essential to perform a robust evaluation and demonstrate evidence of a decline in pathogen transmission. This is usually the goal of phase III trials. These tests measure the efficacy of a vector control tool based on epidemiological indicators. Efficacy and environmental safety are the key parameters for issuance of a license after completion of phases III and IV.

Concerning the license for release of mosquitoes, each country may already have possibilities for adapting an existing regulation or for delegating relevant tasks to the appropriate authority (e.g., US experience in Box 3.1). A local or national authority can mobilize a dedicated agency for supervision of trial evaluation.
Permits and authorization pathways

Chapter 03

Box 3.1. Regulation by US federal agencies

Some countries, such as the USA, have regulated the release of irradiated, sterile insects associated with agricultural, forestry and livestock production through the United States Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS). An argument can be made that irradiated, sterile insects could be deemed biological control agents, which, as pesticides, are exempt from regulation by the United States Environmental Protection Agency (US EPA), as long as the EPA determines that regulation by another federal agency (e.g., APHIS) is adequate.

However, previous experience shows that since the application of this technology is very new in vector control, there are no overall rules: In some cases, specific regulations were used; in others, no specific regulations were applied. As an example of the latter case, previous field trials in Asia, the EU (including overseas territories) and the USA for phases III and IV neither were subject to nor gave rise to specific regulations. A review of the processes employed to authorize these trials demonstrates that these processes can be modified when applying for national or local permits.

Overall, it appears that although the authorization for release must be requested, it may not be necessary to build a specific regulatory structure to implement phases III and IV for the release of sterile irradiated mosquitoes as was done with “traditional/agricultural” SIT for several arthropods for long-term use in the field. Nevertheless, authorization should be based on these key elements:

- Clear definition of the objective(s) to be achieved from releasing sterile irradiated mosquitoes;
- Clear definition of the required authorization (per location);
- Clear description of insects’ production (quality control, standard operating procedures, permits);
- Risk assessment by phase for the workers, the human populations of the field releases and the environment;
- Transparency throughout all the development steps;
- Mitigation measures in case of adverse effects;
- Citizen engagement and input;
- Post-release surveillance (note: an epidemiological survey is not compulsory for authorization).
3.2.2 Development of the technology: Scale-up and additional authorizations

The SIT requires a factory for irradiation (and the associated irradiation process), transportation of mosquitoes and a release system (Figure 3.1). As SIT implementation progresses and its scale increases, each of these steps is subject to increased oversight based on country’s existing or adapted regulations.

**Story of SIT in the Space**

**Factory**  
**Irradiation**  
**Dissemination**

**Figure 3.1.** Scale-up of SIT applied to mosquitoes. Mass production for deliberate release requires a factory capable of producing millions of mosquitoes weekly. If irradiation is not performed in situ, transportation and storage of mosquitoes must be organized until releases via automated systems. Active post-release surveillance also must be set up with the acceptance of local citizens. (Photo credit: P. Boireau and F. Fouque)

**a. The factory step**

A production permit is required to evaluate risks to workers and the environment and to ensure that the appropriate information is conveyed to citizens. Typically, regulations already exist for mass non-domestic animal rearing. Some countries may have an existing classification for arthropod production for species that are non-domestic animals and not deemed to be pests. In most parts of the world, many species of arthropod are considered to be domestic due to their use in production (e.g., the silkworm, *Bombyx mori*; domestic varieties of the bee, *Apis spp*.; and domestic varieties of fruit flies, *Drosophila spp.*), local culinary customs or other specific uses (e.g., *Locusta migratoria migratoria*, *Acheta domesticus*, *Tenebrio molitor*).
Mosquitoes, however, are considered to be pests. Thus, in several countries, they are regulated by the authorities in charge of the environment, public health worker safety and/or agriculture, who manage permits for mass production in a factory, which typically includes restricted access control. The definitions of possible nuisance and emergency plans must be elaborated within this framework. For example, the accidental escape of female mosquitoes must be covered in an emergency plan to mitigate risks to human health and the environment.

In Europe, these factories are classified and authorized according to the quantity of insects produced per day (1.5 kg/day, 150 kg/day or more). Such a classification makes it possible to define the overall risk of nuisances (intensity of transport for raw material, odours, noise level etc.). With regard to mosquito production, it is expected that most factories will not produce more than 1.5 kg per day of the arthropods.

Depending on local regulations, permits may be given before and after building (e.g., in China, for authorization of a factory posing risks to the environment) (Pascal Boireau, pers. comm.). In most countries, the authorization to implement such a factory is issued after a formal inspection of the premises and the procedures used to ensure environmental protection.

**b. The irradiation procedure**

Existing regulations in countries should support this activity. Local irradiation is always preferred, whenever possible, since it avoids transportation constraints like the transport of fertile material. The country’s radiation authority ensures the proper use of radiation, prevents harmful effects of radiation on human health and promotes protection of the environment. It is emphasized that the benefits of employing radiation must outweigh the associated detriments. The use of radiation should be optimized, such that the ionizing radiation exposure is as low as practically achievable, taking into account technological knowledge and social and economic factors.

**c. The transportation of irradiated mosquitoes**

Containment of mosquitoes should be maintained during transport, with traceability. For example, in the USA, the movement of insects, mites and ticks that affect humans or cause human diseases requires permits from the Center for Disease Control and prevention (CDC). It is to be expected that the transport of mosquitoes will be regulated locally, before and after irradiation.

**d. The release of irradiated male mosquitoes**

Various systems can be used for mosquito release; as an example, drones can be used for efficient release, but all systems are subject to local regulations (Box 3.2).
Box 3.2. Regulation of civil drones in Europe

The European Commission’s proposal for an Implementing Act defined the regulations around operating Unmanned Aircraft Systems (UAS) in Europe and the registration of drone operators and certified drones. The Implementing Act is accompanied by a Delegated Act, which defines the technical requirements for drones. It was adopted by the European Commission on 12 March 2019 and specifies three categories with a gradient of constraints. Spreading mosquitoes with drones should fulfill the specific requirements of the requested category. Operating drones over populated urban areas requires higher levels of safety precautions and specific authorizations.

e. Post-release surveillance

Post-release surveillance typically is necessary for continuing authorization of an SIT programme. As SIT is a self-limiting technology—given the short lifespan of the sterile males released (most probably less than 10 days)—surveillance is only applied during the active phase of release and as long as SIT mosquitoes are found in the release site. The participation of citizens is particularly important and should be promoted by the relevant authority to sustain success in the field. Sentinels sites can be selected and followed to measure programme impact on disease incidence and prevalence (cf. Chapter 6).
3.3 SIT applied to mosquitoes and existing authorizations/regulations (past 10 years)

To provide a representative view across countries of the current experience regarding regulatory pathways, it was found that the relevant national authority typically belongs to one of three ministries: agriculture, environment and/or health. Sometimes agencies are included for their expertise and ability to give recommendations to the certifying authority. Local authorities represent the government in a defined geographic area. In the various examples described below, mostly university or research institute teams supported the request for release authorizations. Private companies or academic consortia were also involved in the development of mosquitoes with a "sterile" phenotype.

3.3.1 Montenegro: Importation of irradiated sterile mosquitoes

Authorization to import *Ae. albopictus* was requested from the Directorate for Environment (under the Ministry of Sustainable Development and Tourism) with expert input from the Agency for Nature and Environment Protection (EPA Montenegro) and the Ministry of Agriculture and Rural Development. EPA Montenegro indicated there was no prior authorization for *Ae. albopictus* importation according to the law on nature protection. *Ae. albopictus* does not appear on a list of not-protected wild animals, plants and fungi that can be used for commercial purposes (Official Gazette of Montenegro, No. 62/10), nor is this species protected by a decision about the protection of designated plant and animal species (Official Gazette of Montenegro, No. 54/16). The Ministry of Agriculture (Directorate for Food Safety, Veterinary and Phytosanitary Affairs) replied that the release of sterile mosquitoes from the species *Ae. albopictus* in the specific area described in the request was not subjected to a permit, since the released mosquitoes were reared from eggs collected in Montenegro and thus there was no possibility of introducing new genomes from other *Ae. albopictus* lines.
3.3.2 Germany: Importation of irradiated sterile mosquitoes

The authorization to release sterile mosquitoes of the species *Ae. albopictus* describes the location of release, density of mosquitoes per hectare and designated scientific leader and was delivered by the local authorities. The permit was compulsory for release and listed additional requirements: no impact on the existing ecosystem; the release species is alien; invasive species should decrease after the release (effectiveness); no risks were identified, since male mosquitoes do not bite. (Concerns about transport were not developed in this authorization.) After the experiment ends, a report must be completed and submitted to the regulatory body.

3.3.3 France: Experiments on the island of La Réunion

Local production of sterile mosquitoes was initiated in 2009 on the island of La Réunion, but no permit has been given for field release, because it was considered to be in phase I development until recently. In 2017, following a round table between the directorates of different ministries and the High Council for Biotechnology (HCB), the request for sterile insect release was formulated again. The two ministries responsible for health and environment sought expertise from two agencies—the High Council for Public Health (HCSP) and the French Biodiversity Agency (AFB)—on the following items:

- Assessment of the risks associated with this technique for the workers and the local population;
- The participatory and information procedures to be put in place to facilitate acceptance of sterile mosquito releases by the local human population;
- The precautionary measures to be taken to supervise the releases of sterile mosquitoes.

The two agencies replied in June 2018 and the Prefecture of La Réunion issued a formal decision to authorize the release of irradiated sterile males, according to phase II of the testing process and under relevant regulations, through Arrêté No. 2019-2213.4

One of the main conclusions of the HCSP response to the item on the participatory and information procedures to be put in place to facilitate acceptance of sterile mosquito releases by the local human population was that “Any public health programme must be presented in a way that is accessible to all communities for its acceptance. This information is essential, even if the methods used do not require active direct individual participation or acceptance of invasive treatments. This is even more true for programmes that require significant community participation to succeed, and for programmes

---

3.3.4 Italy: Trial with sterile mosquitoes

The best-documented recent demonstrations of SIT against mosquitoes were made via pilot tests on Ae. albopictus in Italy between 2004 and 2009 and yielded encouraging results (Bellini et al. 2013). No specific authorization was required for this field trial. Data on the application of the SIT strategy were collected primarily through entomological surveillance.

3.3.5 Other trials

Table 3.1 summarizes examples of mosquito trials conducted in other countries. No specific rule emerges from these various field trials. Several ministries were involved, but the relevant Ministry of Health was rarely mobilized for most of the examples shown in Table 3.1.

Table 3.2 provides examples of SIT projects on non-mosquito species over the last 15 years.
Table 3.1: Examples of field trials (HCB report, CNEV Scientific Committee Working Group, pp. 196212 with updated data) (cf. also Table 4.1).

<table>
<thead>
<tr>
<th>Years</th>
<th>Species</th>
<th>Location</th>
<th>Phase</th>
<th>Institution / Programme</th>
<th>Reference / Source</th>
<th>Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>1959-62</td>
<td>Anopheles quadri-maculatus</td>
<td>Florida, USA</td>
<td>I</td>
<td></td>
<td>Dame and Ford 1964</td>
<td>N/A</td>
</tr>
<tr>
<td>1970</td>
<td>Anopheles albimanus</td>
<td>El Salvador</td>
<td>I</td>
<td></td>
<td>Lofgren et al. 1974, 99% efficacy</td>
<td>Pilot field trial</td>
</tr>
<tr>
<td>1973-75</td>
<td>Culex pipiens quinque-fasciatus</td>
<td></td>
<td>I</td>
<td>Indian Council of Medical Research and WHO/USPHS</td>
<td>Pal and Lachance 1974</td>
<td>N/A</td>
</tr>
<tr>
<td>1973-75</td>
<td>Ae. aegyti / Anopheles stephensi</td>
<td>India (Liston)</td>
<td>I</td>
<td>Indian Council of Medical Research and WHO/USPHS</td>
<td>Pal and Lachance 1974</td>
<td>N/A</td>
</tr>
<tr>
<td>1970</td>
<td>Ae. aegyti</td>
<td>Kenya</td>
<td>I</td>
<td></td>
<td>Lorimer et al. 1976</td>
<td>N/A</td>
</tr>
<tr>
<td>1977-1983</td>
<td>Culex tarsalis</td>
<td>California, USA</td>
<td>I</td>
<td></td>
<td>Zalom et al. 1981</td>
<td>N/A</td>
</tr>
<tr>
<td>2018</td>
<td>Ae. albopictus</td>
<td>Montenegro</td>
<td>II</td>
<td>University of Montenegro, Faculty of Biotechnology</td>
<td>Importation of sterile Ae. Albopictus males</td>
<td>Not necessary</td>
</tr>
<tr>
<td>2015-2017</td>
<td>Ae. albopictus</td>
<td>China, Guangzhou (Guangdong)</td>
<td>II</td>
<td>Zhongshan School of Medicine, Sun Yat-sen University of Medical Sciences</td>
<td>Zheng et al. 2019 Release on two small islands</td>
<td>Yes (for the IIT component)</td>
</tr>
<tr>
<td>2005-2009</td>
<td>Ae. albopictus</td>
<td>Italy</td>
<td>III</td>
<td>Centro Agricultura Ambiente “G. Nicoli”</td>
<td>Bellini et al. 2013b</td>
<td>Yes (local authority)</td>
</tr>
<tr>
<td>2012</td>
<td>Anopheles arabiensis</td>
<td>Sudan</td>
<td>III</td>
<td>Tropical Medicine Research Institute</td>
<td>IAEA Technical Cooperation project SUD004/EU grant COFUND (Ageep et al. 2014)</td>
<td>N/A</td>
</tr>
<tr>
<td>Year</td>
<td>Species</td>
<td>Location</td>
<td>Phase</td>
<td>Institution / Programme</td>
<td>Reference / Source</td>
<td>Authorization</td>
</tr>
<tr>
<td>------</td>
<td>---------</td>
<td>----------</td>
<td>-------</td>
<td>--------------------------</td>
<td>--------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>1959-62</td>
<td><em>Anopheles quadrimaculatus</em></td>
<td>Florida, USA</td>
<td>I</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>1970</td>
<td><em>Anopheles albimanus</em></td>
<td>El Salvador</td>
<td>I</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>1973-75</td>
<td><em>Culex pipiens quinquefasciatus</em></td>
<td>India (Liston)</td>
<td>I</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>1973-75</td>
<td><em>Ae. aegypti / Anopheles stephensi</em></td>
<td>Kenya</td>
<td>I</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>1977-</td>
<td><em>Ae. aegypti</em></td>
<td>California, USA</td>
<td>I</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>1983</td>
<td><em>Ae. albopictus</em></td>
<td>China, Guangzhou</td>
<td>I</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>2005-</td>
<td><em>Ae. aegypti</em></td>
<td>Germany</td>
<td>II</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>2009</td>
<td><em>An. arabiensis</em></td>
<td>Sudan</td>
<td>II</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>2012</td>
<td><em>Ae. albopictus</em></td>
<td>Mauritius</td>
<td>II</td>
<td></td>
<td></td>
<td>N/A</td>
</tr>
<tr>
<td>2014</td>
<td><em>Ae. albopictus</em></td>
<td>Mauritius</td>
<td>III</td>
<td>Ministry of Health and Quality of Life / Vector Biology and Control Division</td>
<td>IAEA Technical Cooperation project MARS019 (no published data)</td>
<td>Yes</td>
</tr>
<tr>
<td>2015</td>
<td><em>Ae. albopictus</em></td>
<td>Germany</td>
<td>III</td>
<td>German Mosquito Control Association (KABS)</td>
<td>Research project with IAEA RER5022 (FAO/IAEA 2017)</td>
<td>Yes</td>
</tr>
<tr>
<td>2015</td>
<td><em>Ae. aegypti</em></td>
<td>Cuba</td>
<td>-</td>
<td>Pedro Kouri Tropical Medicine Institute</td>
<td>Research project with IAEA RLA5074 (FAO/IAEA 2017)</td>
<td>N/A</td>
</tr>
<tr>
<td>2017-2018</td>
<td><em>An. arabiensis</em></td>
<td>South Africa</td>
<td>-</td>
<td>National Institute for Communicable Diseases</td>
<td>Research project with IAEA SAF5014 (FAO/IAEA 2017)</td>
<td>N/A</td>
</tr>
<tr>
<td>2018</td>
<td><em>Ae. aegypti</em></td>
<td>Brazil</td>
<td>-</td>
<td>Biofábrica Moscamed Brasil</td>
<td>Research project with IAEA RLA5074 (FAO/IAEA 2017)</td>
<td>N/A</td>
</tr>
<tr>
<td>2018</td>
<td><em>Ae. aegypti</em></td>
<td>Mexico</td>
<td>-</td>
<td>CRISP - Instituto Nacional de Salud Pública</td>
<td>Research project with IAEA MX5031 (FAO/IAEA 2017)</td>
<td>N/A</td>
</tr>
<tr>
<td>2018</td>
<td><em>Ae. albopictus</em></td>
<td>Spain (Valencia)</td>
<td>-</td>
<td>Grupo Tragsa</td>
<td>Research project with IAEA RER5022 (FAO/IAEA 2017)</td>
<td>Yes (Local)</td>
</tr>
</tbody>
</table>

5 http://www.deutschlandfunk.de/sterile-maennchen-und-klebrige-fallen-wie-deutschland-die.724.de.html?dram:article_id=364179
http://www.srf.ch/sendungen/wissenschaftsmagazin/sterile-maennchen-gegen-die-tigermuecke
### Table 3.2. SIT programmes on species other than mosquitoes: examples of SIT projects on non-mosquito species over the last 15 years (supported by IAEA and FAO) (HCB/CNEV report and additional data).

<table>
<thead>
<tr>
<th>Years</th>
<th>Country</th>
<th>Species</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Chile</td>
<td>Mediterranean fruit fly, Ceratitis capitata</td>
<td>Eradication from northern Chile</td>
</tr>
<tr>
<td>2006</td>
<td>Thailand</td>
<td>Oriental fruit fly, Bactrocera dorsalis and B. correcta</td>
<td>Successful pilot suppression projects</td>
</tr>
<tr>
<td>2007</td>
<td>Israel</td>
<td>Mediterranean fruit fly, C. capitata</td>
<td>Area-wide suppression in Arava valley</td>
</tr>
<tr>
<td>2008</td>
<td>Argentina</td>
<td>Mediterranean fruit fly, C. capitata</td>
<td>Eradication from southern provinces</td>
</tr>
<tr>
<td>2009</td>
<td>Peru</td>
<td>Mediterranean fruit fly, C. capitata</td>
<td>Eradication from southern provinces</td>
</tr>
<tr>
<td>2010</td>
<td>Mexico</td>
<td>Cactus moth, Cactoblastis cactorum</td>
<td>Eradication of an outbreak in Yucatan</td>
</tr>
<tr>
<td>2011</td>
<td>South Africa</td>
<td>False codling moth, Thaumatotibia leucotreta</td>
<td>Area-wide suppression in Western Cape province, expanding to Eastern Cape</td>
</tr>
<tr>
<td>2012</td>
<td>Spain</td>
<td>Mediterranean fruit fly, C. capitata</td>
<td>Area-wide suppression in Valencia province</td>
</tr>
<tr>
<td>2013</td>
<td>Guatemala</td>
<td>Mediterranean fruit fly, C. capitata</td>
<td>Eradication from Western Guatemala</td>
</tr>
<tr>
<td>2014</td>
<td>Morocco</td>
<td>Mediterranean fruit fly C. capitata</td>
<td>Successful pilot suppression project, triggering an area-wide programme</td>
</tr>
<tr>
<td>2015</td>
<td>Croatia</td>
<td>Mediterranean fruit fly, C. capitata</td>
<td>Area-wide suppression in Neretva Valley</td>
</tr>
<tr>
<td>Ongoing</td>
<td>Senegal</td>
<td>Tsetse fly, G. palpalis gambiensis</td>
<td>Eradication from the Niayes well advanced</td>
</tr>
<tr>
<td>Ongoing</td>
<td>Dominican Republic</td>
<td>Mediterranean fruit fly, C. capitata</td>
<td>Eradication of a large outbreak in eastern region</td>
</tr>
<tr>
<td>Ongoing</td>
<td>Ethiopia</td>
<td>Tsetse flies Glossina pallidipes and Glossina fuscipes</td>
<td>Suppression in the Deme Valley in Southern Rift Valley</td>
</tr>
</tbody>
</table>
3.4 The next steps in permits and authorization pathways for Aedes SIT

Garnering permits and authorization to release SIT mosquitoes currently is on a country-by-country basis and subject to different regulatory authorities. Consequently, not only are the different regulatory authorities looking at different issues, but the authorizations also are based on very different perspectives. Criteria for the approval of releases of high scientific quality are shown in Box 3.3.

Box 3.3. Criteria for High Scientific Quality Release Approval (extract from Reeves et al. 2012, modified for irradiated mosquitoes)

- Complete scientific details of the proposed field trial can be made available during pre-approval public consultations and notifications (phasing approval).
- A complete list of all potential hazards considered by regulators is published along with their determined risk classification.
- A substantial body of relevant interdisciplinary research is cited from multiple independent groups with no serious gaps in areas of importance for assessing potential impact on human health and environment.
- Documents concentrate on the issues that are truly significant and specific to the case under consideration, rather than on amassing needless details.
- Data cited in regulatory documents are published, ideally in peer-reviewed journals and are in reports validated according standard operating procedures.
- No scientific points of fundamental importance for human health and environmental protection are left apart at any stage of the process.
- Any prior data obtained from field trials in other countries, cited in support of permit approval, are widely recognized as having been collected in an ethical manner and with input from citizens. Any existing international protocols should have been followed.
- Percentage of females released must be clarified, because it is of importance as it is a key
component with consequences for all citizens where the trial will be done.

- Information in documents provided by the regulator is clear, understandable and accurate with respect to all points of fundamental importance for human health and environmental protection.
- Efficacy in reducing the density of target mosquitoes up to elimination: A threshold should be defined and maintained according to standard operating procedures.
- Effectiveness in reducing vector borne pathogens through animal sentinel survey and blood donor survey.
- Go/no-go and risk benefit analysis.

The governments which are currently creating policies and regulatory environment to oversee sterile mosquito techniques management may participate in an international committee to discuss the different pathways for permits, and eventually propose standard procedures and steps for all the elements required to reach a policy decision.

Transparency in the decision-making process will ensure widely accepted technology, the overall mitigation of risks and public acceptance. Mosquito production, irradiation and release already have good bases, however the risk assessment of impact on health and the environment, and the monitoring of outcomes, are subject to very different regulatory oversight and support. The need for a global approach on this subject will be one of the challenges on the way to full deployment of this technology, if proven efficient.
Mass production and release of sterile male Aedes
The success of the SIT strategy depends on the mass production in dedicated facilities of large numbers of high-quality sterile males of the target species. For SIT, a high-quality male means that the male is capable of flying, surviving and dispersing in the environment; mixing with the wild population; competing with its wild counterparts in courting, mating with and inseminating wild females, thus reducing the probability of those females mating with fertile wild males.

The production phase, including the separation of sexes to ensure males-only releases and the sterilization of males before field release, determines the quality of the sterile males. The mass rearing, handling and release processes consist of a complex series of highly standardized steps (Figure 4.1) organized to yield the most efficient and optimal production and successful release of the target species.

Figure 4.1. Main steps in the mass rearing of *Aedes* mosquitoes.
4.2 Strain selection and colonization

It is advisable to start colonies with genetically diverse “local material”. The minimum recommended to start a colony is 500 pairs, but the greater the number and genetic diversity, the better. To produce high-quality males, it is best to avoid starting the colony with material obtained from an old established laboratory colony. If foreign strains are being considered, it is important to pay attention to national regulatory requirements (cf. Chapter 3).

Aedes mosquitoes can be collected easily from the field with simple entomological tools such as ovitraps or ovicups to collect eggs; dippers or water nets to collect larvae and pupae; and aspirators, sweeping nets or adult traps to collect adults.

For all stages, it is essential to verify the species before introducing wild-caught mosquitoes into the insectary. For more specifications, we refer to the Guidelines for Colonization of Aedes Mosquito Species (Version 1.0) produced by the Joint Food and Agriculture Organization/International Atomic Energy Agency (FAO/IAEA) Insect Pest Control Subprogramme (IPCS).

Note: If a genetic sexing strain (GSS) is available, backcrossing with the local strain is recommended (at least 6 generations). A GSS is a strain where a phenotypic trait is associated with only one sex (e.g., temperature sensitive lethal or coloured pupae) and can be used to achieve sex separation, if possible at an early stage (e.g., egg or larvae), such that only male insects are mass reared. Obtainable by classical genetics, as well as transgenic means, GSS mosquitoes are not released into the field. If a GSS is to be used, mass rearing should be supported by a mother colony or filter colony system (Fisher and Caceres 2000; Gilles et al. 2014), in order to eliminate recombinants.

Guidance framework for testing the sterile insect technique as a vector control tool against Aedes-borne diseases
where the phenotypic trait becomes associated with the wrong sex.

Successful mass production depends on optimal management of the mother colony, which, as stated above, ideally should be genetically diverse and also be free of pathogens. Even if the risk of pathogens affecting mosquito colonies is deemed to be low; due to the critical importance of the initial colony being free of infection, a specialized laboratory should be employed to check its health and infection status.

At the same time, the insects produced should maintain the biological and behavioural attributes favourable for their survival, dispersal and sexual competitiveness in the field. Optimal colony management will ensure standardized and cost-effective production of high-quality sterile males with enhanced field performance. For standard operations for mosquito colony management, please refer to the Guidelines for Routine Colony Maintenance of Aedes Mosquito Species produced by the FAO/IAEA IPCS.

4.3 Mass production

When planning the mass rearing facility, the appropriate arthropod containment level requirements (American Committee of Medical Entomology American Society of Tropical Medicine and Hygiene 2019) must be determined in collaboration with the local/regional/national authorities (cf. Chapter 3 on regulations).

The routine introduction of wild mosquitoes to renew the colony should be avoided to prevent the introduction of undesired effects or pathogens. However, a routine refreshment calendar of the colony is sometimes necessary to maintain its competitiveness and wild traits. For example, when the wild populations are insecticide-resistant, the use of local insecticide-resistant strains in mass rearing is preferred (in agreement with the public health authorities) to better match with the wild strains and have the same resilience to other control methods. This characteristic then requires refreshment to be maintained. For outcrossing, wild males should be used (i.e., wild females excluded) and reared apart for at least six generations. This prevents the introduction of diseases or unfavourable traits.

Efficient production, including synchronized pupation, homogeneous size and high quality, is only possible when all the parameters are fully optimized and standardized and kept under strict continuous control, including:

- Air and water temperatures are controlled in the larval rearing section and in the larval trays;
- Larval density is managed to be in the predetermined range (Figure 4.2);
- Larval diet provides well-balanced nutrients to satisfy the species-specific requirements and an appropriate dose is administered regularly;

Guidance framework for testing the sterile insect technique as a vector control tool against Aedes-borne diseases

- Adult cage size and setting follow the species-specific requirements, particularly regarding environmental conditions (temperature and relative hygrometry) (Figure 4.2).

![Image](image.png)

**Figure 4.2. Larval trays piled in racks (l); adult cage (r.)**

Animal blood used to feed the females must be checked for safety to prevent the introduction of any contaminants and/or pathogens. Irradiation of the blood can reduce bacterial load and improve the health of the colony (Improved and Harmonized Quality Control for Expanded Tsetse Production, Sterilization and Field Application, IAEA TECDOC No. 1683⁶).

The male sorting system should guarantee that residual female contamination is held to a minimum, i.e., below the predetermined threshold agreed with the public health authorities (Focks 1980; Zacarés et al. 2018).

Note: Guidelines for Mass Rearing of Aedes Mosquitoes (Version 1.0) are slated for publication on the Insect Pest Control website under Manuals & Protocols.⁹

---


Mass production and release of sterile male Aedes

4.4. Sterilization

Each species and each developmental stage (i.e., pupae or adults) have specific susceptibility to irradiation doses (Yamada et al. 2019). The parameter of desired male sterility level (not necessarily full sterility) must be set in consideration of competitiveness, induced sterility, risk of population transformation and cost.

The reliability of the irradiator in the context of the local operational conditions should be validated by conducting dosimetry studies on pupae or adults, always using untreated males as controls (Balestrino et al. 2010; Bond et al. 2019; Lebon et al. 2018; Machi et al. 2019; Parker and Metha 2007; Yamada et al. 2014).

For more precise technical information on dosimetry, please refer to International Atomic Energy Agency, Gafchromic® Dosimetry System for SIT—Standard Operating Procedure (2004).10

4.5. Transport and release

Whenever possible, the mass rearing facility should be close to the field sites. If the release area is far from the mass rearing facility, the sterile adult males can be packaged and transported by air or ground.

In case of a transnational sterile male shipment, all the necessary administrative steps should be clarified with the authorities and the transport company. To ensure that the sterile males suffer the least amount of stress, transportation should be organized to guarantee the best possible conditions for the packaged sterile males and the shortest time en route (Chung et al. 2018; Culbert et al. 2018).

The release strategy must specify the numbers (e.g., number of sterile males per hectare) and periodicity (e.g., once a week or more often) of sterile males to be released based on the wild population density and the target objectives. The wild population density must be estimated in different seasonal periods by mark–release–recapture trials (Bellini et al. 2010; IAEA Guidelines).

Homogeneous distribution of sterile males is particularly important in urban settings, where numerous obstacles may hamper dispersal, and must be achieved regardless of the release method (i.e., aerial or ground). Figure 4.3 summarizes the steps in the SIT process from breeding to release.

Figure 4.3. The steps of the SIT process

*SIT Guidelines for the export, shipment, import and release of biological control agents and other beneficial organisms. p.10, Section 3.1.8 “In the case of sterile insect technique (SIT), the sterile insect may be marked to differentiate it from the wild insect.”*
The distribution of the sterile males can be monitored by marking the sterile males as suggested by the ISPM 3 (cf. Footnote 11), however this might negatively affect the sterile males by making them more susceptible to predation or by affecting their quality due to the technique used to mark them. One option is intermittent marking to monitor survival and the ratio compared to wild males.

### 4.6. Quality control

Quality control (QC) measures are essential for optimizing mass rearing and the production of sterile males with good performance. It is essential for mass rearing facilities to keep records and databases of their production and the quality of their sterile mosquitoes. This will facilitate diagnosis of problems and identification of measures to solve them (Caceres et al. 2007; FAO/IAEA/USDA 2014; Mumford et al. 2018) (cf. Chapters 2 and 5).

The QC checks that might be adopted in the mass rearing facility include:

- Female fecundity of the strain (e.g., once every ten generations) (Bond et al. 2019);
- Egg fertility, expressed as egg hatch (e.g., once every ten generations);
- Female and male longevity of the strain (e.g., once every 20 generations) (Bond et al. 2019);
- Male wing length (e.g., once every ten generations);
- Male mating competitiveness (e.g., once every ten generations);
- Male flight ability (e.g., every generation via reference flight test) (Culbert et al. 2018);
- Percentage of residual females (e.g., every batch with declaration).

The QC checks that might be applied at the release site include:

- Male mating competitiveness (e.g., at least once every three months);
- Male flight ability (e.g., every release) (Culbert et al. 2018);
- Male longevity (e.g., at least once every five releases) (Bond et al. 2019);
- Percentage of residual females (e.g., every release batch).
4.7 Guidelines and SOPs

Guidelines or standard operating procedures have been developed for the different stages of the SIT process.

Processes

1. Colonization
   
   Guidelines for Colonization of Aedes Mosquito Species (Version 1.0)\(^2\)

2. Colony management
   
   Guidelines for Routine Colony Maintenance of Aedes Mosquito Species (Version 1.0)\(^3\)

3. Mass rearing
   
   Guidelines for Mass Rearing of Aedes Mosquitoes (Version 1.0)\(^4\)

4. Sterilization
   
   Guidelines for Small Scale Irradiation of Mosquito Pupae in SIT Programmes (Version 1.0)\(^4\)

5. Mark-Release-Recapture
   
   Guidelines for Mark-Release-Recapture procedures of Aedes mosquitoes (Version 1.0)\(^4\)

Guidelines or SOPs for transportation and quality control are in preparation at the Insect Pest Control Laboratory of the FAO-IAEA Joint Division. They will be available online at http://www-naweb.iaea.org/nafa/ipc/public/manuals-ipc.html

---


\(^3\) [Link](http://www-naweb.iaea.org/nafa/ipc/public/guidelines-for-routine-colony-maintenance-of-Aedes-mosquito-species-v1.0.pdf)

\(^4\) Slated for publication at [Link](http://www-naweb.iaea.org/nafa/ipc/public/manuals-ipc.html)
4.8 Ongoing SIT projects

Table 4.1 shows a list of ongoing SIT pilot projects against *Aedes* species.

<table>
<thead>
<tr>
<th>Country</th>
<th>City</th>
<th>Size of release area</th>
<th>Inhabitants in the release area</th>
<th>Avg release density (males/ha/week)</th>
<th>Avg production</th>
<th>Current status</th>
<th>Species</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brazil</td>
<td>Recife (PE)</td>
<td>56 ha</td>
<td>18,300 residents</td>
<td>5-10k</td>
<td>BLDC, mass rearing and irradiation capacity, suppression prior release</td>
<td>Bt treatment of larval breeding sites</td>
<td><em>Ae. aegypti</em></td>
</tr>
<tr>
<td></td>
<td>Camaba (BA)</td>
<td>25 ha</td>
<td>50-100k males/ha/week</td>
<td>100k males/week</td>
<td>BLDC</td>
<td>to be defined</td>
<td><em>Ae. aegypti</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cuba</td>
<td>La Habana</td>
<td>15 ha</td>
<td>697 residents</td>
<td>6k males/ha/week</td>
<td>BLDC</td>
<td>to be defined</td>
<td><em>Ae. aegypti</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malaysia</td>
<td>Melaka state</td>
<td>4 ha</td>
<td>16,000 residents</td>
<td>191k males/week</td>
<td>BLDC</td>
<td>to be defined</td>
<td><em>Ae. aegypti</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mexico</td>
<td>Tapachula</td>
<td>24 ha</td>
<td>697 residents</td>
<td>6k males/ha/week</td>
<td>BLDC, sustained releases in 2018-2019</td>
<td>Bt treatment of larval breeding sites</td>
<td><em>Ae. aegypti</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>US</td>
<td>Captiva Island (Lee County, FL)</td>
<td>230 ha</td>
<td>379 residents</td>
<td>30k males/week</td>
<td>BLDC, operational research, insectary with irradiation capacity, communication campaign, MR</td>
<td>Bt treatment of larval breeding sites</td>
<td><em>Ae. albopictus</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>France</td>
<td>Reunion Island</td>
<td>32 ha</td>
<td>3k males/ha/week</td>
<td>100k males/week</td>
<td>BLDC, operational research, communication, MR</td>
<td>Bt treatment of larval breeding sites</td>
<td><em>Ae. albopictus</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Germany</td>
<td>Heidelberg</td>
<td>4 ha (2016)</td>
<td>3k males/ha/week</td>
<td>30k males/week</td>
<td>BLDC, sustained releases in 2016-2019</td>
<td>Insecticide (adult and larvae), entomological surveillance, arbovirus sentinel stations</td>
<td><em>Ae. albopictus</em></td>
</tr>
<tr>
<td></td>
<td>Freiburg</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greece</td>
<td>Vavrona (Athens)</td>
<td>5+5 ha</td>
<td>3k males/ha/week</td>
<td>30k males/week</td>
<td>BLDC, communication campaign, sustained releases in 2018 and 2019</td>
<td>door to door</td>
<td><em>Ae. albopictus</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Italy</td>
<td>Casalzone, Buschi, Bologna</td>
<td>6-45 ha</td>
<td>59-1,3k males/ha/week</td>
<td>100k males/week</td>
<td>BLDC</td>
<td>to be defined</td>
<td><em>Ae. albopictus</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mauritius</td>
<td>Panchvati</td>
<td>3 ha</td>
<td>20k males/ha/week</td>
<td>60k males/week</td>
<td>BLDC, sustained releases in 2018 and 2019</td>
<td>door to door</td>
<td><em>Ae. albopictus</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spain</td>
<td>Valencia</td>
<td>4 ha (Poleyni)</td>
<td>2,500 residents</td>
<td>2k males/ha/week (2018)</td>
<td>BLDC, sustained releases in 2018 and 2019</td>
<td>Insecticide (adult and larvae), entomological surveillance, arbovirus sentinel stations</td>
<td><em>Ae. albopictus</em></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4.1. List of ongoing SIT pilot projects against *Aedes* species at the time of this writing. (Source: derived from IAEA thematic plan 2020–2025.)
Chapter 05

Evaluation of entomological efficacy
Chapter 05  Evaluation of entomological efficacy

Evaluation of entomological efficacy is key to understand the impact of SIT. This chapter provides broad guidelines for generating entomological evidence to enable decision makers to advance an Aedes SIT programme from the initial stages to operational use. A phased conditional approach is proposed in Chapter 1 to guide the SIT testing programme through a series of evaluation steps of increasing complexity, with “go/no-go” decisions made at each phase. Established methods are available to provide robust entomological evaluation at each testing phase. Illustrative “go/no-go” criteria are presented for the key entomological performance indicators.
5.1 Introduction

Unlike short-term vector control interventions, e.g., spraying with ultra-low-volume (ULV) adulticides, SIT acts over the medium to long term to drive down vector density across multiple generations. The SIT offers no personal protection and requires large-scale implementation to deliver community-wide benefits. Thus, the quantification of entomological impact is a central component in the development and evaluation of an SIT programme. While the ultimate impact is measured in terms of epidemiological outcomes (with studies necessarily conducted on large scales), the initial development and evaluation steps focus on entomological outcomes in laboratory, semi-field and field settings.

The suggested strategy follows a phased conditional approach, where the SIT programme progresses through a series of evaluation steps of increasing complexity (and cost) with go/no-go decisions made at each step (Figure 1.5). This strategy emphasizes evidence-based decision making designed to reduce risk and increase decision makers’ confidence and willingness to support continued investment in SIT technology through a multi-stage process towards the ultimate goal of deployment.

The phased development progresses through the following stages:

- Phase I: Laboratory assays to confirm mode of action;
- Phase II: Semi-field and small-scale field trials;
- Phase III: Studies (large-scale field trials) to assess the efficacy of the intervention;
- Phase IV: Pilot implementation studies.

Phase IV studies monitor the effectiveness of the vector control tool when it is used under real-world conditions and collect information on entomological and epidemiological impacts and operational feasibility, including data on acceptability, cost-effectiveness, long-term production, safety and other relevant data.

Table 5.1 summarizes the key endpoints and evaluation criteria for each of these phases. Sections 5.2 through 5.5 expand on the information presented in the table. The specific methods and protocols on how to conduct the entomological assessments are beyond the scope of this document; however, for more detailed information, readers are referred to various resource texts (with examples given below). The aim of this chapter is to provide a roadmap of which entomological work needs to be done and which factors ought to be considered to answer the question “Does SIT work in my particular context?” The focus of this chapter is on entomological efficacy and effectiveness of SIT. Nevertheless, SIT efficiency is also based on epidemiological effectiveness (cf. Chapter 6) and cost-effectiveness, which is an operational decision (cf. Chapter 8).
Table 5.1. Range of studies and key endpoints for evaluating the entomological efficacy of SIT through the phased conditional testing process. Since there are no hard and fast rules for whether SIT is performing sufficiently well, especially in later phases of evaluation, the go/no-go criteria will be established for a specific context, i.e., the criteria included in the table are only illustrative examples.

<table>
<thead>
<tr>
<th>Phase of Testing Stage</th>
<th>Outcome or Endpoint</th>
<th>Indicator</th>
<th>Go/No-Go Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phase I: Laboratory studies</td>
<td>Performance of irradiated males</td>
<td>Pupal mortality during radiation process</td>
<td>&lt;10% instantaneous mortality at target radiation doses</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Survival/longevity</td>
<td>Sterile irradiated male adults suffer &lt;10% reduction in median survival times compared with equivalent non-irradiated males</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flight ability</td>
<td>&lt;10% reduction in flight activity compared to non-irradiated males</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sterility level</td>
<td>Asymptotic dosimetry curve calculated to deliver &gt;99% sterility with minimal impact on other performance traits</td>
</tr>
<tr>
<td></td>
<td>Population suppression potential</td>
<td>Mating competitiveness in cage (1:1:1 ratio)</td>
<td>Fried C Index ≥ 0.7</td>
</tr>
<tr>
<td>Phase II: Contained and small-scale field trials</td>
<td>Performance of irradiated males</td>
<td>Rate of induced sterility in females</td>
<td>&gt;90% reduction in viable egg production in lab-cage populations for an over-flooding ratio of 10:1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rate of induced sterility in females</td>
<td>Fried C Index &gt; 0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Longevity in large cages</td>
<td>Sterile irradiated males suffer &lt;10% reduction in average survival times compared with non-irradiated males</td>
</tr>
<tr>
<td></td>
<td>Entomological efficacy in the field</td>
<td>Survival rate</td>
<td>Strongly system dependent, but should be measured to guide subsequent release frequency required to achieve a homogeneous ratio of sterile:wildtype males</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dispersal rate</td>
<td>Strongly system dependent, but should be measured to guide subsequent spatial distribution of release to achieve a homogeneous ratio of sterile:wildtype males</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mating competitiveness in the field</td>
<td>Fried C Index &gt; 0.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Induced sterility rate in the local population</td>
<td>Statistically significant induced sterility (absolute value is difficult to define a priori)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vector density in treated and control areas</td>
<td>Statistically significant suppression of local vector population (measured as eggs or adults)</td>
</tr>
</tbody>
</table>

\(^{15}\) Fried’s Competitiveness Index (cf. Glossary).
5.2 Outline of phase I studies

**Phase I** laboratory tests examine the intrinsic biological activity of the vector control tool. In the case of SIT, the aim is to characterize the negative consequences of mass rearing in artificial conditions and irradiation on the performance of male mosquitoes and the positive consequences of irradiation on reducing the reproductive output of a natural population of female mosquitoes (i.e., the control potential). If, in controlled laboratory settings, irradiated male mosquitoes have limited capacity to fly and mate or fail to induce marked reductions in female fecundity, there is little point in scaling up to subsequent evaluation phases, and this will result in a no-go decision in terms of advancing to the next stage.

Note: These evaluation phases assume that mosquito production and irradiation processes have been developed to produce a suitable SIT product for testing (cf. Chapter 4).

<table>
<thead>
<tr>
<th>Phase III: Large-scale field trials to determine entomological (and epidemiological) efficacy</th>
<th>Entomological efficacy in the field</th>
<th>Vector density in treated and control areas</th>
<th>Statistically significant reduction in vector density between treated and control areas (a threshold may be needed or not, and, if needed, it is determined by local/site-specific transmission ecology).</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Transmission potential</td>
</tr>
<tr>
<td></td>
<td>Epidemiological efficacy</td>
<td>cf. Chapter 6</td>
<td>cf. Chapter 6</td>
</tr>
<tr>
<td>Phase IV: Large-scale trials to evaluate effectiveness under operational conditions</td>
<td>Entomological effectiveness in the field</td>
<td>Vector density in treated and control areas</td>
<td>Significant reduction in vector density between treated and control areas</td>
</tr>
<tr>
<td></td>
<td>Epidemiological effectiveness in the field</td>
<td>cf. Chapter 6</td>
<td>cf. Chapter 6</td>
</tr>
</tbody>
</table>

**Notes**

- **Sterility level:**
  - Rate of induced sterility in females
  - Mating competitiveness in the field
  - Entomological efficacy in the field
  - Epidemiological efficacy

- **Induced sterility rate:**
  - Rate of induced sterility in females
  - Performance of irradiated males
  - Induced sterility rate in the local population
  - Statistically significant induced sterility (absolute value is difficult to define a priori)

- **Vector density in treated and control areas:**
  - Statistical significance in the local vector population (measured as eggs or adults)
  - Significant reduction in vector density between treated and control areas

- **Entomological and epidemiological effectiveness in the field:**
  - Evaluation criteria could include declines in the number of blood-fed females collected in the treated area, proportion of infected vectors and bites per person per day.
5.2.1 Survival and longevity

Survival and longevity of the released sterile male mosquitoes are important parameters that may affect the success of an SIT programme. The aim is to use a radiation dose sufficient to generate high levels of male sterility (assessed based on a dose response curve), but with minimal impact on other traits (Yamada et al. 2014). Survival in controlled laboratory settings in small cages likely will be high, making it difficult to observe subtle differences compared with non-irradiated males and females. Nonetheless, the longer the sterile males can survive, the higher the probability of mating with a wild female (assuming they remain sexually active as they age). A typical method of comparison would involve simultaneously recording daily mortality of irradiated and non-irradiated adult male mosquitoes in laboratory cages, with all mosquitoes having constant access to sugar water (Bellini et al. 2013a; Bond et al. 2019).

**Indicative go/no-go criteria:**

1. <10% instantaneous male mortality at target radiation doses;
2. <10% reduction in average survival times of sterile irradiated males compared with equivalent non-irradiated males;
3. >99% sterility of irradiated males.

5.2.2 Mating competition and impact on female fecundity

Another go/no-go decision point is whether the irradiated sterile males are sufficiently competitive with the non-irradiated males, such that they reduce the reproductive output of females when released at appropriate ratios. The fertility of the males can be assessed by measuring the hatching rate of eggs produced in controlled conditions by a known number of virgin females after mating with an equivalent number of males over one gonotrophic cycle (Bellini et al. 2013a; Bond et al. 2019).

Mating capacity of irradiated males can be measured by determining the number of females a single male can successfully inseminate over a pre-determined number of days (Bellini et al. 2013a). Overall competitiveness can be assessed through the calculation of the Fried Competitiveness Index (Fried 1971; Pagendam et al. 2018). Typically, the male mating competitiveness index (Fried’s C Index) would be estimated by comparing the percentage of hatched eggs from cage experiments combining non-irradiated females and males, a mixture of non-irradiated females and irradiated males, and a mixture of non-irradiated females and both irradiated and non-irradiated males. However, recent research indicates that Fried’s C Index can be estimated effectively using experiments from mixed
mating cages alone (Pagendam et al. 2018). By using different ratios of non-irradiated and irradiated males to mate with fertile females, the experiments can help to determine the release ratio of sterile males during field trials in phases III and IV.

Indicative go/no-go criteria:

(1) >0.7 for the competitiveness of irradiated males relative to non-irradiated males.

5.2.3 Flight ability

High radiation doses can reduce flight ability and mating performance of males. Estimating flight ability in the laboratory is challenging, but a flight cylinder assay previously used for other insects recently has been adapted to mosquitoes and proven to be not only a robust tool for evaluating flight ability, but also a rapid assay method that correlates well with multiple measures of male mosquito quality (Balestrino et al. 2017; Culbert et al. 2018; Bond et al. 2019).

Indicative go/no-go criteria:

(1) <10% reduction in flight ability of irradiated males relative to non-irradiated males.

5.3 Outline of phase II studies

5.3.1 Semi-field evaluations

Phase II semi-field studies add more ecological realism than can be achieved within simple laboratory environments, while still retaining a relative high level of experimental control. This research can generate valuable insights in situations where there is no prior experience with SIT. Studies could include experiments in large field cages to measure female fecundity, percent egg hatching, and capacity to induce sterility, calculated by placing different combinations of non-irradiated (fertile) and irradiated (sterile) males into semi-field enclosures with fertile female mosquitoes and comparing them with an analogous combination of non-irradiated males and females in control enclosures (for illustrative examples of semi-field studies, cf. Chambers et al. 2011, Olivia et al. 2012 and Bellini et al. 2013a). Survival can be measured either
by recovering mosquitoes at the end of the observation period or by counting daily survival of males housed in individual cages within the semi-field setup.

Indicative go/no-go criteria:

(1) >90% reduction in viable egg production in mosquito populations in semi-field studies for an over-flooding ratio of 10:1;
(2) Fried C Index >0.5;
(3) <10% reduction in average survival times of sterile irradiated males compared with non irradiated males.

5.3.2 Small-scale pilot field trials

Release strategies for SIT aim for a homogeneous ratio of sterile to wild males over time and space. The dispersal distance of the released males determines the optimal density of release sites, with the optimal frequency of release determined by survival rate. The greater the dispersal distance and the greater the survival rate, the less intensive the required release rates. Dispersal rate and survival rate can be estimated using mark-release-recapture of sterile males (Bellini et al. 2010). In addition, as a tool for estimating egg density or calculating the egg hatch rate or percentage of sterile eggs collected, ovitraps placed in treated versus control areas can be used to determine the capacity of irradiated males to induce sterility in the local population (Bellini et al. 2013b). Adult mosquitoes also can be sampled to provide direct measures of density and the egg hatch rate of gravid females (O’Connor et al. 2012).

Indicative go/no-go criteria:

(1) Survival rate (will be system dependent, but should be measured);
(2) Dispersal rate (will be system dependent, but should be measured);
(3) Male competitiveness (Fried C) index >0.2;
(4) Statistically significant induced sterility (measured as reduced egg hatch rate);
(5) Significant suppression of local vector population (measured as reduced egg or adult density), although this will likely depend on the scale of releases, as small-scale studies will be more affected by immigration of mosquitoes from adjacent populations.
5.4 Outline of phase III studies

Phase III evaluations involve large-scale field trials that aim to achieve sustainable suppression of the target vector population over a large area. Such studies must include epidemiological evaluations (cf. Chapter 6), when SIT is tested in areas with disease transmission, and be combined with measurement of entomological indicators such as mark-release-recapture measures of adult population density, sterility rate (egg hatch rate), ratio of sterile to wild males, egg density and competitiveness index. In cases where SIT is being considered as a preventive tool to reduce the risk of disease establishment or outbreak (i.e., the disease is not necessarily present in the area at the time of implementation), the focus will be on entomological indicators. Phase III should provide solid evidence for decision makers as to whether the SIT programme should be integrated into a national vector control operation.

Indicative go/no-go criteria:

(1) The primary evaluation criterion for efficacy in large-scale entomological trials is a significant reduction in mosquito population density in the treatment areas relative to the control areas;
(2) Secondary entomological criteria could include declines in measures such as oviposition rate, number of blood-fed females collected in the treated area and proportion of infected vectors.

5.5 Outline of phase IV studies

Phase IV studies evaluate effectiveness as the experimental scale expands from trial to operational implementation. Effectiveness studies aim to evaluate an intervention under realistic operational conditions and, in so doing, provide additional insights for policy and practice. Typically, the entomological measures would be similar to those of phase III but might become less intensive as phase IV moves closer to routine monitoring and evaluation. National vector and disease surveillance programmes could provide routine monitoring and evaluation once the SIT programme is considered for integration into the national vector control operation (cf. Chapter 9).
objectives

A key starting point in the evaluation process is to clearly define the goals of the SIT programme overall (i.e., what control objective SIT is meant to deliver), as well as the objectives for each phase of testing. The primary objective is to produce irradiated mosquitoes that are sterile, competitive with wild males and able to suppress wild populations. The SIT works by reducing vector density, which, in turn, can reduce disease transmission. However, because the relationship between vector density and human disease can be complex, the epidemiological consequences need not be straightforward, even if SIT delivers measurable reductions in vector density. Moreover, different disease outcomes and targets potentially cover a range of objectives, such as reduction in disease incidence, reduction in disease prevalence, reduction in frequency and/or size of epidemics, local eradication and prevention or reducing risk of disease where the diseases are not yet present. Having clearly defined targets from the outset is important for framing and gauging the success of the control programme and for comparing the results of each phase against appropriate go/no-go criteria to progress through the phased conditional approach.

5.6 General considerations and guiding principles

5.6.1 Defining objectives

A key starting point in the evaluation process is to clearly define the goals of the SIT programme overall (i.e., what control objective SIT is meant to deliver), as well as the objectives for each phase of testing. The primary objective is to produce irradiated mosquitoes that are sterile, competitive with wild males and able to suppress wild populations. The SIT works by reducing vector density, which, in turn, can reduce disease transmission. However, because the relationship between vector density and human disease can be complex, the epidemiological consequences need not be straightforward, even if SIT delivers measurable reductions in vector density. Moreover, different disease outcomes and targets potentially cover a range of objectives, such as reduction in disease incidence, reduction in disease prevalence, reduction in frequency and/or size of epidemics, local eradication and prevention or reducing risk of disease where the diseases are not yet present. Having clearly defined targets from the outset is important for framing and gauging the success of the control programme and for comparing the results of each phase against appropriate go/no-go criteria to progress through the phased conditional approach.

5.6.2 Selection of study site

Appropriate study sites must be selected for each of the phases of evaluation. As every study site will have unique features, general guidelines are difficult to convey. Nonetheless,
achieving and demonstrating impact will tend to be easier if:

- There is some level of geographic or ecological isolation for studies in phases II and III;
- The target mosquito species is the main vector in the selected site;
- Sites are of manageable size for surveillance and monitoring;
- There is good cooperation of the local government and local communities.

Consideration should be given to the location of treatment and control areas in order to minimize contamination or spillover effects due to the movements of mosquitoes or humans.

5.6.3 Baseline interventions as comparators

The SIT is not generally considered to be a stand-alone intervention. It is more cost-effective and easier to implement effectively if the density of the local vector population is low. Due to its mechanism of action, SIT acts too slowly to be an effective response tool for epidemics or outbreaks. Accordingly, SIT should be viewed as part of an integrated vector management strategy and its impact should be considered over the medium to long term and measured against a baseline of existing control tools.

5.6.4 Outcome (endpoints and effect size)

The SIT works by reducing vector density, but reductions in density alone do not necessarily lead to significant epidemiological impacts. This disconnect can make it difficult to interpret effect sizes, as there is no clear threshold that relates to transmission, which can be very heterogeneous in time and space for diseases such as dengue, as well as strongly influenced by the susceptibility of the human population.

Moreover, many indices are available to estimate vector abundance, including:

- Percent premises/houses positive for adults;
- Percent premises/houses positive for females;
- Percent houses positive for blood-fed females;
- Percent houses positive for males;
- Mean number of females per house;
- Mean number of blood-fed females per positive house;
- Mean number of males per positive house;
- Percent houses positive for immatures (pupae);
- Number of immatures (pupae) per house;
- Number of immatures (pupae) per number of household inhabitants;
- Container index (CI) = \[\text{number of containers with immatures/wet containers inspected}\] x 100;
- House index (HI) = \[\text{number of houses with immatures/houses inspected}\] x 100;
- Breteau index (BI) = number of positive containers per 100 houses inspected;
- Pupae per person index (PPPI) = ratio of pupae to persons living in each experimental cluster computed at cluster level.
Some of these measures are not necessarily good indicators of the mosquito population characteristics that are the most important for transmission, namely female mosquito density and longevity. Ovitrap data, for example, do not always correlate with adult density in most situations (Focks 2004). Similarly, indices such as the container index, house index and the Breteau index fail to take into account variations in container productivity and provide little information on transmission risk (Focks 2004). At least during efficacy testing, the emphasis should be on measures such as pupae per person, density of parous females, adult vector density or number of bites per person (pursuant to the ethical regulations for human landing catches).

### 5.6.5 Trial design

The quality of evidence for evaluating efficacy depends to a large extent on trial design. Details of methods for planning and conducting entomological trials are beyond the scope of this document, but readers are directed to the WHO manual on study design of field trials for vector control interventions (WHO 2017) and other resources (Wilson et al. 2015; WHO 2018).

In Figure 5.1, we present a hierarchy of study designs utilized by WHO for evaluating the efficacy and methodological quality of vector control interventions (Wilson et al. 2015; WHO 2017). Studies with limited replication, poor randomization and inappropriate control treatments will tend to provide poor-quality evidence, and thus risk failing to show an impact where there should be one, or, alternatively, suggest an impact when in fact there isn’t one. One of the challenges is that well-replicated studies with good controls and appropriate statistical power tend to be large in scale (certainly for phase III) and take a lot of resources to implement. The quality of evidence required ultimately is a programmatic decision, but it is important to appreciate the possible trade-off between cost and quality. Further discussions of trial design in the context of epidemiological outcomes are included in Chapter 6.
Randomized controlled trials: cluster or individually randomized controlled trials as well as randomized crossover, randomized step-wedge, randomized controlled before-and-after, randomized controlled time series, and randomized controlled interrupted time series studies.

Non-randomized trials: including non-randomized crossover, non-randomized step-wedge, non-randomized controlled before-and-after, and non-randomized controlled interrupted time series studies.

Observational studies: such as case-control, cohort, and cross-sectional studies.

Not recommended: non-randomized controlled trials, non-randomized controlled time series designs, studies without a control group or using a non-contemporaneous control group.

**Figure 5.1.** Hierarchy of study designs for evaluating the entomological and epidemiological impact of a vector control intervention (in this case, SIT) implemented at large scale (phase III). The study designs vary in terms of the methodological quality of evidence they provide (modified from Wilson et al. 2015).
5.6.6 Understanding of confounders

The SIT is species-specific. If there is more than one species responsible for transmission of the target vector-borne disease (e.g., *Ae. albopictus* is a competent vector of many of the same arboviruses as *Ae. aegypti*), the epidemiological impact of SIT could be diluted, even if the entomological impact is strong. This issue underscores the need to characterize study sites prior to intervention. Baseline data on mosquito species, seasonal density, dispersal of females and egg hatch rates, measures of disease transmission (incidence, prevalence, dispersal of females and possibly seroconversion rate), habitat features including density and distribution of households and potential mosquito breeding sites, existing control operations etc. should be collected for both treatment and control sites. These data can help guide study design (e.g., restricted randomization of treatment and control clusters) and inform the interpretation of results.

5.6.7 Quality control

For the efficacy studies for phases I to III, quality control checks should be in place to ensure that the SIT intervention, along with any control arm interventions, is being implemented in an optimal manner. The aim of these initial phases is to evaluate the intervention under optimal conditions. Without good quality control, it is difficult to determine whether, for example, poor results stem from SIT having limited impact in a particular location or because it wasn’t implemented rigorously. Phase IV studies provide information on how robust the effects are under realistic operational conditions (i.e., field setting).

A key element in quality control is to ensure the quality of the SIT mosquitoes themselves. Regular checks should be conducted to assess and quantify flight ability and longevity and to demonstrate the capacity of the irradiated sterile males to induce sterility in the females (Balestrino et al. 2017; Culbert et al. 2018) (cf. Chapter 4).
Chapter 06

Epidemiological efficacy and effectiveness trials to evaluate SIT against Aedes-borne diseases
For any new vector control tools in new product classes, two control trials are the minimum number needed to assess their generalizability in a region (WHO 2017). Selection of appropriate intervention and control sites is a crucial step that impacts the success of any SIT programme. Besides addressing epidemiological and entomological aspects, trials must reflect practical considerations around, but not limited to, funding, infrastructure and ethical and socio-economic factors. Epidemiological and entomological indicators and endpoints also need to be determined/assessed before trial initiation, at baseline and again post-intervention. Establishing an independent expert group to validate the interpretation of the results is recommended.

This chapter highlights various steps to be undertaken while planning and conducting epidemiological trials—in due consideration of the available funding, existing infrastructure, feasibility, acceptability, as well as ethical, social, legal and other considerations—to determine the efficacy and effectiveness of the intervention.
6.1 Introduction

The SIT is aimed at suppressing the mosquito vector population to an extent that will significantly reduce infection and/or disease from *Aedes*-borne viruses, i.e., dengue, chikungunya, yellow fever, Zika and any other arboviruses transmitted by this mosquito genus (Almeida et al. 2019; Jansen & Beebe 2010; Lees et al. 2015). The SIT’s efficacy and effectiveness will be a critical determinant for decision making about deployment (Almeida et al. 2019; Alphey et al. 2010; Benelli et al. 2016; Bonizzoni et al. 2013). In addition, if it is to be used as a public health intervention tool, SIT must be shown not to be detrimental to human health or the environment.

Epidemiological efficacy trials test the efficacy of SIT against the diseases in selected geographical sites by comparing intervention sites with control sites under stringent study conditions. In phase IV, effectiveness trials test the operational effectiveness of SIT over larger geographical areas under local programmatic, i.e., real-world, conditions and assess its capacity to reduce infection and/or disease burden (which are the epidemiological endpoints).

In addition to assessing operational feasibility, effectiveness trials collect information on the release mechanisms, acceptability and economics (including a cost effectiveness analysis). The entomological outcomes and a subset of the epidemiological outcomes assessed during the efficacy trial should be continuously monitored to ascertain whether the positive effects on human populations are being sustained. Plans should include scale-up of disease surveillance and monitoring systems to assess SIT impact at a population level.

The process of carrying out an efficacy study on epidemiological outcomes for SIT targeted at *Aedes* mosquitoes includes several steps (WHO 2017), which are described below.
6.2 Step 1: Develop the PICO question

PICO (Population Intervention Comparator Outcome) is the standard epidemiological question (Huang et al. 2006), which, applied in the SIT context, will answer the following clinical question: Is SIT efficient and effective in reducing the incidence of Aedes-borne infection and/or diseases in human populations, including, but not limited to, dengue, chikungunya, yellow fever and Zika?

\[ \text{Efficacy} \] will be a critical determinant for decision-making about deployment.

Without a well-focused PICO question to define the population, the intervention, the comparator and the outcome (Box 6.1), it can be very difficult and time-consuming to identify appropriate resources and search for relevant evidence. Practitioners of evidence-based practice (EBP) use the specialized PICO framework to formulate the question, facilitate the literature search and provide the relevant answer.

**Box 6.1. Defining PICO: Population, Intervention, Comparator and Outcome for SIT against Aedes-borne diseases**

- **Population**: Any community affected by Aedes-borne infection(s) with documented reporting of cases for at least a few years, and not in an epidemic situation or moving out of an epidemic. Stable populations with minimum mobility are preferable. Due to the importance of accurate disease surveillance, the health agencies of the country must have a surveillance system in place to capture all information related to cases occurring in that population.
- **Intervention**: Releases of sterile Aedes mosquitoes (via SIT). This intervention can be in the context of prevalent routine vector control measures in a particular area.
- **Comparator**: Comparison with stand-alone prevalent routine vector control measures.
- **Outcome**: Reduction in infection and/or disease caused by Aedes mosquitoes, i.e., dengue, chikungunya and/or others.
6.3 Step 2: Design of the study

Depending on disease pattern, variability, temporal trends, country infrastructure, available funding, personnel and logistics, intervention trials can have varied study designs like randomized control trial (RCT), cluster-randomized trial (CRT), stepped wedge randomized trial or the rolling-carpet principle or wave principle methods (Grayling et al. 2017; Hemming et al. 2015; Heintze et al. 2007; Kroeger et al. 2006; Vanlerberghe et al. 2009; WHO 2017). Randomized controlled trials (individual or cluster) and follow-up over at least two transmission seasons are WHO-recommended trial designs to demonstrate the public health value of new tools that do not fall within an already existing class; these are followed by stepped wedge and non-randomized control trials on a case-by-case basis (Figure 6.1) (WHO 2017).

Figure 6.1. Hierarchy of trial designs recommended by WHO and which type of design WHO considers sufficiently robust to generate evidence on the efficacy and public health value of vector control products (extracted from WHO 2017).
6.3.1 Randomized controlled trials and cluster-randomized controlled trials

The term randomized controlled trials (RCT) refers to interventions implemented in villages or any other units of population in which the intervention (programme of releases of sterile male mosquitoes) and the control units are randomly allocated, whereas the term cluster-randomized controlled trials (CRT) refers to interventions implemented in village, ward or urban administrative units called clusters (WHO 2017), which are randomly allocated to intervention arms or control arms. CRT is a commonly used study design for measuring the efficacy of vector control.

6.3.2 Stepped wedge cluster-randomized trial

In stepped wedge cluster-randomized trial (SW-CRT), the intervention is rolled out to clusters in a stepwise fashion, whereby the order in which clusters receive the intervention is determined by randomization (Grayling et al. 2017; Hemming et al. 2015; WHO 2017). An SW-CRT may be used when logistical, practical or financial constraints make the staged roll-out of an intervention desirable. SW-CRT should be performed only if a standard CRT cannot be carried out and good evidence already exists indicating that the intervention is effective and should be rolled out to the entire population.

6.3.3 Rolling-carpet and wave principle methods

If baseline entomological studies have found that the target Aedes populations are distributed continuously, the rolling-carpet principle (Box 6.2) or the wave principle (Box 6.3) methods can be used to test SIT against Aedes-borne disease (Hendrichs et al. 2005). The rolling carpet principle entails a unidirectional front in interventions, whereas the wave principle employs a bidirectional or multidirectional front (Multerer et al. 2019).
Box 6.2. Rolling carpet method

This method is more dynamic than CRT. In the rolling carpet method, the intervention area is divided into blocks (Figure 6.2). The estimation of baseline entomological and epidemiological indicators, vector control measures to bring down Aedes density, release of SIT against Aedes and post-release determination of entomological and epidemiological indicators are carried out simultaneously in a sequential manner in different blocks. This approach can be more cost-efficient than a static CRT approach, in which each of the four different phases would be implemented in a given block, before proceeding to the next block (Hendrichs et al. 2005).
Temporal (upper, with or without overlap of releases in adjacent blocks) and spatial (lower) diagrams of the rolling carpet principle applied in four intervention blocks using eradication and suppression against a pest population distributed continuously (adapted from Hendrichs et al. 2005).

**Figure 6.2.** Temporal (upper, with or without overlap of releases in adjacent blocks) and spatial (lower) diagrams of the rolling carpet principle applied in four intervention blocks using eradication and suppression against a pest population distributed continuously (adapted from Hendrichs et al. 2005).
Box 6.3. Wave principle

One type of area-wide integrated pest management (AW-IPM) is tested/deployed according to the wave principle, whereby the intervention moves in expanding operational block sizes at each stage. The intervention develops along a multidirectional front beginning from Stage 1 (collection of baseline data) and continuing to Stage 2 (reductions in vector population), Stage 3 (releases of SIT Aedes) and Stage 4 (areas with population suppression) (Figure 6.3). Since each successive phase requires increasing amounts of sterile males and abundant resources are needed to sustain the expansion, the wave principle method is more resource-intensive than rolling-carpet (Hendrichs et al. 2005). Mobile insectaries may be needed to overcome the logistical hindrances.

Figure 6.3. Diagram with the different stages of an AW-IPM programme using SIT according to the wave principle against a pest population with a continuous distribution. In this theoretical example, the intervention develops along a multidirectional front in the first stages until full production capacity of sterile males is reached. Beginning in Stage 1, the intervention continues along a circle front and requires the establishment of temporary buffer zones (Hendrichs et al. 2005).
Because the results are available more quickly and accrue over time, the planners and implementers of an SIT programme may find it advantageous to deploy the rolling-carpet or wave methods. The sequential nature of these approaches means the requirements for personnel, logistics and sterile mosquitoes are staggered, thus implementation becomes less challenging in comparison to a CRT approach of one phase across all blocks simultaneously (Heintze et al. 2007; Vanlerberghe et al. 2009). Moreover, the indicators estimated at different time points in different blocks through these approaches may give a better picture of variation in entomological and epidemiological parameters.

Important note: Before selecting any of the aforementioned study designs, a country’s resources (e.g., public health surveillance system, trained workforce, sterile mosquito production capacities, funding and infrastructure) must be evaluated. The selected epidemiological trial must be statistically robust and designed to measure reductions in an endpoint such as seroconversion/seroprevalence.

6.4 Step 3: Determine the sample size

The RCT or CRT are recommended as the best methods to assess the comparative clinical efficacy and effectiveness of SIT; they can also provide data for estimating cost effectiveness. The optimal design of an RCT is dependent on the sample size calculation, which must ensure that the study not only has a high probability of producing significant results, but also is based on the ethical recruitment of study participants, to avoid imposing clinical trials on more patients than necessary. One recently adopted approach specified a target difference between treatments that was considered realistic or important by one or more key stakeholder groups. Called DELTA (Cook et al. 2018), this approach allows a sample size calculation which ensures that the trial will have the required statistical power to identify the existence of a difference of a particular magnitude.

Another element to take into account in a CRT sample size calculation is the variation between clusters. Outcomes measured in individuals or sampling sites within the same cluster are likely to be more similar than if they are measured between clusters; therefore, the sample size calculation needs to account for the additional variation in outcomes between clusters (WHO 2017). The degree of variation in the outcomes between clusters is measured by the coefficient of variation, which is defined as the ratio of between-cluster standard deviation to the mean:

\[ k = \frac{\text{standard deviation}}{\text{mean}} \times 100 \]
The sample size is thus estimated as a function of the coefficient of variation within an interval of confidence (Kristunas et al. 2017). The number of clusters should be sufficient to allow differences between the test and control arms to be detected statistically.

### 6.5 Step 4: Site selection for intervention and control

Selecting appropriate intervention and control sites is a crucial step that will influence the success of the SIT release programme. Hence, the choice of the site should be based on the criteria described below and in consideration of the local situation (Benedict et al. 2008; Hendrichs et al. 2005; Iyaloo et al. 2014).

The three primary epidemiological criteria upon which to base the choice of sites for SIT testing are: (1) an isolated transmission situation, (2) a single vector species and (3) significant disease transmission at more or less periodic intervals (Malcolm et al. 2009). It may not be possible to meet all of the above criteria in communities where arboviral diseases are circulating, i.e., mostly urban and peri-urban areas. Multiple vectors with different ecologies (inter alia Ae. aegypti, Ae. albopictus, Aedes polynesiensis) may be involved in transmission (Eder et al. 2018; Telle et al. 2016) across local, focal and heterogeneous sites. Although they vary in space and time, transmission foci are connected at short distances by a combination of human and mosquito movement patterns (WHO 2017). The human populations of both the intervention and control sites need to be fully characterized with regard to various parameters, such as:

- Socio-demographic (population characteristics, age and socio-economic structures, health-seeking behaviour);
- Epidemiological (disease pattern, number of reported cases, dengue and severe dengue cases, age distribution);
- Environmental (meteorological conditions, housing type, housing conditions, water storing habits, presence of potential breeding sites, general layout of the houses).

**Note:** It is recommended that the intervention and control sites have similar availability, accessibility and level of healthcare.

A small-scale pilot trial allows assessment of the practical and technical challenges associated with i) initiating and sustaining a more extensive suppression programme, ii)
measuring the effect of the intervention and iii) controlling for any natural fluctuation in target populations unrelated to the trial (Wilson et al. 2015).

**Allocation:** Since SIT against *Aedes* is also a community-based intervention, allocation of selected sites to intervention or control arms needs to be at the cluster/village level (Iyaloo et al. 2014).

Practical considerations around epidemiological indicators:

- Functioning infrastructure for disease surveillance and reporting: Costs can be saved if facilities which can be used for the project are already in place;
- Study sites of manageable size and favourable topography, with regard to disease transmission: The strength and validity of the study must be balanced with the available resources and workforce;
- Ethical, social, legal and other considerations (cf. Chapter 7): Criteria for selecting a field location may include a previous record of authorization to work in a particular area. This approval may be granted by local communities, local authorities and appropriate regulatory and government agencies (cf. Chapters 1 and 7).
6.6 Step 5: Baseline parameters

Epidemiological data must be generated for both the intervention and control sites before initiating the intervention. Depending on the type and number of vector species present, the difference in the ecology of transmission across the sites needs to be taken into account.

6.6.1 Epidemiological endpoints

The major epidemiological indicators are detected through active or passive surveillance and include incidence, prevalence and the number of cases, seroconversion rates, serotypes, size and speed of outbreaks. The indicators best adapted to the situation must be chosen to assess the impact of SIT as an intervention strategy. Once endpoints have been decided upon, baseline parameters must be assessed for both intervention and control sites with equal uniformity, robustness and rigour.

6.6.2 Contamination effect

The movement of vectors and humans between clusters can cause contamination effects between study arms. Major interference would be a direct contamination of the control group, while partial interference is spillover effects within the same treatment group. However, when spillover occurs, participants (or units) in the control group may experience a direct or indirect treatment effect from the programme that can make it difficult to accurately interpret study findings (Wilson et al. 2015).

Movement of mosquitoes, specifically the immigration of wild infected female mosquitoes into the release clusters and the emigration of sterile male mosquitoes and sterile females inseminated by sterile males, can confound the interpretation of releases with regard to disease transmission and prevent a positive trial outcome (Kittayapong et al. 2019). Measurements of dispersal (mark-release-recapture) can guide the selection of conditions that provide sufficient isolation or the implementation of appropriate buffers to prevent such immigration (cf. Chapter 5).

Since the SIT intervention discussed in this guidance document targets Aedes mosquitoes, confounding factors have to take Aedes mosquito behaviour into account. Since Aedes mosquito females bite during the day when people are active, the movements of people...
(daily or occasional) can influence the impact and assessment of the intervention. For this reason, it is important to capture data about not only the number of people who live in the experimental cluster, but also their activities and displacement in and out of the cluster.

The above problem can be mitigated by selecting a large enough study area to include large numbers of individuals, which dilutes the risk of infection outside their respective area. Further trial planning includes social surveys to identify individuals who may become infected outside of the trial area. Collecting participants’ travel histories allows statistical analysis of the number of people exposed to the risk of infection and the number of people less exposed because they have travelled for significant periods of time and spent a relatively brief period of time being exposed.

Monitoring epidemiological outcomes in a less mobile sentinel cohort (women, children) within a larger cluster area is one of the strategies for improving the reliability of the data.

6.7 Step 6: Blinding

Studies are single blind when the participants do not know which treatment group they have been assigned to, double blind when study participants and investigators are unaware of which group is control vs. intervention, or triple blind when study participants, investigators, laboratory staff and those analysing the data are all blinded (Wilson et al. 2015). Blinding the participants, healthcare providers (or outcome assessors) and researchers to the intervention received by participants can reduce two important forms of bias: performance bias and detection bias.

Performance bias occurs when there are systematic differences in the diagnosis/care received by participants in the intervention and control arms. This can be due to differences between the study arms in terms of participants’ willingness to seek diagnosis/treatment or use personal protective measures or the level of diagnosis/care provided by healthcare staff.

Detection bias occurs when there are systematic differences in how outcomes are assessed between participants in the intervention and control arms.

In SIT trials, blinding of study participants is not possible, since community engagement programmes must be in place and communities informed about the intervention proposed. At the same time, due to a sense of security/protection from the intervention, the population living in intervention cluster may reduce its use of routine protective measures against vectors, such as taking personal protective measures against mosquito bites during the day. This type of behavioural difference may have an impact on the
transmission force of the diseases and must be acknowledged via studies to detect any difference between the personal protection behaviour in both intervention and control arms.

However, even if performance bias cannot be avoided, to prevent/mitigate detection bias, it is still important to maintain the blinding of those assessing the outcome as much as possible.

6.8 Step 7: Implementation of the intervention and partnerships to be established for field testing

Since the trial is to be undertaken at multiple sites, related partner organizations should be identified to be involved in the trial at the various geographical points. Engaging a trial design specialist is helpful in planning and conducting the trial. Various approvals and clearances must be in place before embarking on implementation of the intervention in a community.

Institutional ethical review committee clearances are needed from all participating centres.

Trial planning should take into consideration the ethical issues covered in Chapter 7. Intervention trials must be registered in the country’s clinical trial registry and results presented to the local authorities at regular intervals (Weijer et al. 2012; Taljaard et al. 2013).

The following partnerships are requested before the implementation is started and at all phases of testing:

- Regulatory approval. The identity of this authority may differ from country to country. In view of the novelty of the technology, national legislation may entrust this responsibility to a board/commission representing several ministries like health, environment and vector control (cf. Chapter 3);
- In-depth interactions with all relevant stakeholders, including media. (cf. Chapter 7);
- Community engagement exercises to cultivate understanding and acceptance by communities;
- Meticulous planning for releases and subsequent fieldwork as well as collection of data on epidemiological parameters.
6.9 Step 8: Measuring the outcome and effectiveness of the technology

6.9.1 The epidemiological outcome indicators

The endpoint is a reduction of disease. Reduction of disease can be measured by various means, including infection incidence, clinical disease incidence or prevalence of infection in at-risk populations and seroprevalence in a surveyed population (Cromwell et al. 2017).

At least two years of data (exclusive of baseline data) are required to effectively demonstrate abatement in areas where disease transmission is highly variable from year to year, with epidemic waves alternating with low prevalence periods. However, even two years may not be enough, with supplementary data from additional years of study needed.

The epidemiological parameters used as outcome indicators are decided upon at the beginning of the trial (Box 6.4) and assessed at periodic intervals, with the frequency of assessment depending on the parameters and other factors. The epidemiological endpoints could be the number of cases detected through active or passive surveillance, seroconversion rates, circulating serotypes and outbreaks. It is essential for data to be collected with equal rigor in both the intervention and control sites.
Guidance framework for testing the sterile insect technique as a vector control tool against Aedes-borne diseases

Box 6.4. Examples of outcome indicators

At locations with historically high levels of dengue infection, where the population is exposed to dengue virus (DENV), the population develops homotypic protection against the infecting serotype and temporary cross-protection (heterotypic protection) to other serotypes lasting up to two years (WHO 2018). In this previously exposed population, the transient rise in IgM and a 4-fold rise of IgG, which are the indicators required for confirming a recent dengue infection, would be difficult to capture and equally difficult to interpret. Moreover, in locations where more than one flavivirus is transmitted (inter alia, yellow fever, Japanese encephalitis, West Nile virus, Zika) or where people have been vaccinated against other flaviviruses (e.g., yellow fever, Japanese encephalitis), interpretation of DENV seroconversions needs to account for cross-immunity to closely related viruses.

Therefore, in endemic countries where a large portion of the population is affected by high levels of infection acquired during regular outbreaks, it would be more efficient to assess the impact of the intervention (in terms of a reduction in dengue infection) in a dengue-naïve population which has not been exposed to dengue infection, typically children of less than a determined age. This dengue-naïve population (age cut-off depending on endemicity level) can be monitored by any of the different tests available for dengue diagnosis over different time points to assess for seroconversion, reflecting the exposure to dengue viral infection.

The baseline data must be collected in both the intervention and control arms before the start of the intervention. The same indicators must be followed during and after the intervention, at an adequately chosen time interval, such as one-year interval (primarily to cover the dengue transmission season). It is important that the same individual children, in both the intervention and control sites, are tested at the defined regular intervals always with the same methodology as was done at baseline. The results will provide the proportion of dengue-naïve population (children) who have seroconverted within a pre-defined time period, such as at one-year intervals, for example. Repeating this procedure at regular time intervals enables following the seroconversion dynamic in both the intervention and control sites, comparing the impact of the intervention (SIT) on disease infection into a naïve population.
To complement the more classical epidemiological indicators, other indicators can be collected, with the caveat that such indicators require additional resources in terms of funding, materials and personnel. Performing a cost-effectiveness analysis will assist in choosing the best indicator to follow. Other indicators include:

– Routine febrile surveillance consisting of one to three visits per week per household of people living near cohort participants to enable longitudinal comparisons of people with documented arboviral illness (Reiner et al. 2016);
– Geographical cluster studies that screen people living within a designated radius (ca. 100 m) of a person with a laboratory-diagnosed dengue virus infection (the index case) to measure variation in fine-scale spatial patterns of DENV transmission (Reiner et al. 2016);
– Serological plaque reduction and neutralization assays for virus detection, along with active surveillance, performed on a subgroup of people with clinically apparent infection may yield more accurate information on dengue risk. However, in areas which are endemic for other flaviviruses, cross-reactivity with dengue virus is a common occurrence, making it difficult to evaluate impact on the four different dengue virus serotypes (Yung et al. 2016; Jewell et al. 2018);
– The epidemiological impact of SIT also is assessed by test-negative design where dengue cases and arbovirus-negative controls are sampled concurrently from within the population of patients presenting with undifferentiated febrile illness, with case or control status classified retroactively based on the results of laboratory diagnostic testing.

Efficacy can be estimated by comparing the exposure distribution (the probability of living in an SIT-treated area among virologically confirmed dengue cases versus the exposure distribution in test-negative controls) (Anders et al. 2018; WHO TDR 2014).

An independent expert group should be established to validate the interpretation of the results and conduct technical reviews and assessments of epidemiological outcomes, as per standard procedures for all research activities.

When the intervention is moving from experimental to programmatic, its ongoing effectiveness in a public health programme must be determined. In this phase, the effectiveness of the vector control tool in operational use under real-world conditions is measured, as well as information collected on the feasibility, release mechanisms, acceptability, economics and safety of the tool (WHO 2017).

If the coverage area is wide, it may be necessary to conduct longitudinal bolstered case surveillance, managed by the public programme with/without support of research organizations.

The entomological and epidemiological indicators that were assessed during the efficacy trials must be monitored continually to determine whether the positive effects on human populations are being sustained (WHO TDR 2014). Epidemiological indicators can be followed in a subset/representative group of the exposed population (cf. Chapter 9).
Chapter 07

Ethics and community/stakeholder engagement
This chapter highlights the topics of ethics and community and/or stakeholder participation in the process of testing the SIT intervention to control Aedes-borne diseases. While interlinked, the two topics have different purposes and objectives. When doing any research that involves human subjects, researchers must follow the highest possible ethical principles and standards stipulated in international research ethics guidelines. An essential component of these ethical principles is to inform communities and stakeholders and involve them in any research or intervention that will affect their health, life and wellbeing. Meanwhile, communities’ and stakeholders’ understanding of, support for and collaboration with the research and intervention is crucial for the successful implementation of any research activity, including SIT testing, and for sustaining the effect of the interventions. Therefore, the SIT testing team must take the subjects of ethics and community/stakeholder engagement into account from the very beginning of an SIT testing project.
7.1 Introduction

Testing SIT to control *Aedes*-borne diseases is, by nature, research on an intervention that may involve multiple stakeholders and communities. Based on international ethics guidelines for health-related research involving humans (CIOMS 2016); researchers, sponsors and health authorities have the moral obligation to ensure that all research is carried out in ways that uphold human rights, and that study participants and the communities in which the research is conducted are treated respectfully, protectively and fairly. Thus, the SIT testing team needs to follow research ethics guidelines and to consider, plan, prepare and execute various community and stakeholder engagement activities.

It is essential to comply with research ethics guidelines along every step of the SIT testing process, because the production and deployment of SIT may bring potential health and other risks to communities, depending on where the SIT mosquito factory is located or where the sterilized male mosquitoes will be released to control diseases. To be successful, the SIT intervention—as a new mosquito control tool—needs the understanding, support and collaboration of involved stakeholders and communities (WHO 2017; Bartumeuse et al. 2018). The SIT testing team needs to be aware that the diverse communities living where SIT testing is to be conducted are embedded within different socioeconomic, political, cultural, environmental and ecosystem contexts. This understanding will allow the team to fulfil its ethical responsibilities and plan and adapt its community participation strategies and actions based on locally prevailing conditions.

Using a life cycle approach, this chapter first highlights ethics challenges that may arise for the teams testing SIT interventions, then focus on community/stakeholder engagement and participation, which is indispensable for the implementation and long-term success of any SIT intervention.
7.2 Ethical issues

In any research project involving human subjects, researchers have an ethical responsibility and a moral obligation to protect the rights, dignity and welfare of the research participants. Any research involving human subjects or animals needs to adhere to international, national and institutional standards, principles and regulatory requirements for research ethics. The WHO Manual (Section XV.2) defines research with human subjects as:

“Any social science, biomedical, behavioural, or epidemiological activity that entails systematic collection or analysis of data with the intent to generate new knowledge, in which human beings:

i) are exposed to manipulation, intervention, observation, or other interaction with investigators either directly or through alteration of their environment; or

ii) become individually identifiable through investigator’s collection, preparation, or use of biological material or medical or other records.”

Based on the above definition, the testing of SIT to control Aedes-borne diseases with epidemiological outcomes falls into the category of research with human subjects, therefore SIT testing teams need to follow research ethics principles and conduct the SIT intervention and research in an ethical manner. Institutions and organizations with strict research ethics requirements include, but are not limited to, international organizations such as the World Health Organization (WHO); national organizations such as the National Institutes of Health (NIH), the National Science Foundation (NSF), the Food and Drug Administration (FDA), the Environmental Protection Agency (EPA), and the US Department of Agriculture (USDA) in United States, and similar bodies in other countries. Examples of research ethics guideline documents and policies, inter alia, include the International Ethical Guidelines for Health-related Research Involving Humans (CIOMS 2016), the Singapore Statement on Research Integrity, the Code of Ethics of the American Society for Clinical Laboratory Science, the American Psychological Association’s Ethical Principles of Psychologists and Code of Conduct, the American Anthropological Association’s Statement on Ethics and Principles of Professional Responsibility, the Nuremberg Code and the World Medical Association’s Declaration of Helsinki.

Among others, the International Ethical Guidelines for Health–related Research Involving Humans sets out 25 ethics guidelines for research and covers a broad range of ethical issues, including scientific and social value and respect for rights; research conducted in low-resource settings; equitable distribution of benefits and burdens in the selection of individuals and groups of participants in research; potential individual benefits and risks of research; caring for participants’ health needs; community engagement; collaborative partnership and capacity-building for research and research review; informed consent; requirements for establishing research ethics committees and for conducting ethics reviews of protocols; public accountability for health-related research; and conflicts of interest.

---

16 The International Ethical Guidelines for Health-related Research Involving Humans was written by the Council for International Organizations of Medical Sciences (CIOMS) in collaboration with WHO.
Although these ethical codes, guidelines, policies and principles are important and useful, like any set of rules, they do not cover every situation and sometimes conflict and require considerable interpretation. Therefore, it is important for SIT testing teams to learn how to interpret, assess and apply diverse ethics rules for research and to make decisions and act ethically in various situations.

All research involving human beings should be reviewed by one or more independent ethics review committee(s) to ensure that the appropriate ethical standards are being upheld. Informed consent must be obtained from research participants, either as individuals or groups, as applicable (Creswell and John 2014). Since SIT testing contains many research components involving human subjects, SIT testing teams need to consider applying for an ethics review or clearance from one or several relevant ethics committee(s) for research and obtain ethics approval before beginning any research operation. The information submitted to the ethics committee for research includes, but is not limited to, the research protocol and disclosure of any conflicting interests (CIOMS 2016). However, different countries have different approaches to ethics reviews for research. In some countries, reviews occur only at an institutional level, in others at both a national and institutional level, in still others at a regional level (WHO 2011), therefore the SIT testing team needs to figure out the applicable requirements and act accordingly.

Currently, the process of testing SIT to control Aedes-borne diseases is divided into four phases (cf. Figure 1.5), with the SIT testing team potentially facing different ethical issues in each phase that need to be considered, planned for and acted upon.

**Phase I** (cf. Chapter 4) includes laboratory studies and laboratory mosquito populations in cages. No human subjects from the community population are involved during this phase. The laboratory staff members are subject to the obligations and rules of their working contracts, which in most countries include all required ethical considerations. Nonetheless, SIT testing teams must carefully assess and minimize risks to researchers and technical staff by specifying and explaining the risks; they also must be prepared to provide adequate compensation in case of an injury as a result of the research (CIOMS 2016). Ethical requirements, such as informed consent, are usually not needed in phase I. By contrast, communication strategies targeting different stakeholders and communities must be developed during this phase or even earlier.

**Phase II** is implemented in confined field trials and/or ecologically confined field trials and involves the communities situated where the trials are to be conducted. Consequently, it is necessary to obtain informed consent from community populations as a group or as individuals, unless a waiver can be obtained from an ethics committee. The SIT testing may require both individual and community consent. Individual informed consent refers to the voluntary and informed consent of individual research participants. Community/group consent is delivered to the SIT testing team by the leaders of the communities to authorize the trials with irradiated sterile male Aedes mosquito releases. On the other hand, the establishment of a mass-rearing facility typically requires an industrial permit from the relevant regulatory institution either at the local or national level (Box 7.1).
Community/group consent can serve several purposes. It can be used as a form of consultation with the community before individuals are approached, as a method of obtaining permission from leaders, or as an additional means of providing information. Community consent may be crucial in certain cases, but this must be in addition to, not instead of, properly informed individual consent. Most research ethics guidelines agree that informed consent must be obtained from research participants and that community consent does not replace informed individual consent (Nuffield Council on Bioethics 2004).

In phase II, communication activities need to be undertaken to inform the communities about the nature, objectives, significance and implications of the trial, the possible risks and benefits that this trial will bring to them, and their rights to refuse or withdraw from the trial. The SIT testing team needs to answer questions and respond to concerns raised by the community.

Informed consent—at both the community/group and individual levels—does not simply mean obtaining the signed informed consent form from the community or individuals, but signifies a process for providing adequate information about SIT testing to the community and individuals in an appropriate manner by the appropriate persons to allow the community and individual participants to understand the nature, potential benefits and risks of the SIT intervention, and, based on this understanding, to freely decide on participation or refusal.

The key success element for obtaining informed consent is effective communication between the research team and the community/participants. Researchers need to do their best to communicate balanced, understandable and objective information about the research activities and operations accurately, intelligibly and appropriately, taking into account local knowledge and beliefs.

Most research ethics guidelines recommend written informed consent, but thumbprint or verbal consent with a witness is acceptable in situations where participants are illiterate. Further, for research involving human subjects not capable of deciding because of their youth or disabilities, informed consent must be given by the responsible person. Even after informed consent is obtained, information about SIT testing must continue to be provided throughout the entire process.

In phase III, larger open field releases of irradiated sterile male mosquitoes in natural conditions will involve broader communities and more stakeholders. The SIT testing team will face increasing ethical obligations, potentially requiring informed consent from more stakeholders and intensified communication activities. To give just one example, if sterilized male mosquitoes need to be transported via a vehicle from the SIT factory to the sites where they will be released into the environment, the relevant authorities, such as administrators and traffic police, will need to be informed about this intervention.

In phase IV, a plethora of entomological, epidemiological and other disciplinary
Research activities may involve many human subjects during implementation and post-implementation. People in the community may be surveyed to get their perception of the effects of the SIT intervention or asked to provide biological samples to determine its epidemiological impact, thus the SIT testing team must ensure that it is fulfilling its ethical obligations. In this phase, as in all others, the SIT testing team is responsible for keeping the research participants and their communities informed of the research progress via appropriate means, at suitable timeframes, in a language that people can understand (WHO 2011).

Throughout the entire SIT testing process, the SIT team needs to not only fulfil its ethical obligations, but also proactively inform communities about SIT monitoring, engage them into complementary control activities and encourage their acceptance of the technology. Fulfilling SIT programme staffing requirements by hiring from local communities (in conjunction with adequate training) is another effective way of fostering participation.

Ethics principles must include honesty, objectivity, integrity, carefulness, openness, respect for intellectual property, confidentiality, responsible publication, responsible mentoring, respect for colleagues, social responsibility, non-discrimination, competence, legality, animal care and the protection of human subjects; the International Ethical Guidelines for Health-related Research Involving Humans requires researchers to be sensitive to and respect communities’ culture, traditions and religious practices (WHO 2011). For any research conducted on human subjects, researchers must take care to minimize harms and risks and maximize benefits; to respect human dignity, privacy and autonomy; to take special precautions with vulnerable populations; and to strive to distribute the benefits and burdens of the research fairly (Shamoo and Resnik 2015).

In order to conduct SIT testing in an ethical manner, the SIT testing team needs to take the actions outlined in Box 7.2.

**Box 7.2. Minimum package of requirements to conduct ethical SIT testing**

- Submit all required materials, including the research protocol, to the appropriate ethical review committee(s) (ERC) for review and approval before the starting the SIT testing.
- Plan communication strategies and prepare communication materials to inform communities and relevant stakeholders where the SIT testing will be implemented, on the nature of the testing, the potential benefits and risks associated with the testing.
- Obtain informed consent from the research participants and communities/groups (leaders), whenever necessary.
- Report to the ERC whenever there is any significant change in the research protocol and seek renewal of the ERC approval as needed.
- Regularly undertake structured ethics reflection within the SIT testing team; conduct research and the intervention ethically and responsibly.
7.3 Communities and stakeholder engagement or participation

The process of testing SIT to control Aedes-borne diseases will involve different communities and many different stakeholders. Communities are living near the sites where mosquito factories will be located, and in the villages, towns or parts of cities where the sterile male mosquitoes will be released. Stakeholders are defined as the individuals, groups, institutions, organizations, government bodies or other entities who have some decision-making power and can influence or are affected by the execution or results of SIT testing. Involving communities and stakeholders in SIT testing is not only an ethical requirement, but also imperative for the smooth implementation of SIT testing. Thus, stakeholder and community engagement are critically important for the success of an SIT programme (Box 7.3).

Box 7.3. Example of vector control intervention failure caused by a lack of stakeholder and community engagement

In Kenya, an initial distribution of insecticide-treated bed nets to protect people from malaria-infected mosquitoes faced challenges, not because the technology and distribution plan were not sound, but because the engagement of the community members was overlooked in the initial development of the technology (Chuma 2010). Further investigations performed after the initial distribution discovered that people had rejected the white-coloured bed nets because they mimicked the burial shrouds used by the local population. When new bed nets were manufactured in a different colour, adoption rates—and thus the impact of the technology on protecting people—increased dramatically (Gore-Langton et al. 2015). This exemplifies the importance of ongoing and iterative engagement with communities, particularly the value of creating partnerships with communities at an early phase of project/technology design and implementation to get their input and buy in (National Academies of Sciences, Engineering, and Medicine 2016).
The fourth edition of the International Ethical Guidelines for Health-related Research Involving Humans states that “from the inception of research planning, it is important to ensure full participation of communities in all steps of the project, including discussion of the relevance of the research for the community, its risks and potential individual benefits, and how any successful product and possible financial gain will be distributed, for example through a benefit-sharing agreement” and its Guideline 7 states: “Researchers, sponsors, health authorities and relevant institutions should engage potential participants and communities in a meaningful participatory process that involves them in an early and sustained manner in the design, development, implementation, design of the informed consent process and monitoring of research, and in the dissemination of its results”.

Stakeholder and community participation must continue throughout the entire process of SIT testing as shown in Figure 7.1. However, the diversity of communities in different settings—in terms of socioeconomic development level, political system, culture and social norms, environmental conditions and ecosystem—affects and determines community members’ values, beliefs, attitudes, knowledge, perceptions and behaviour towards diseases and diseases control. The SIT testing teams need to be aware of this and, before designing community engagement strategies, must conduct research using methods such as a situational analysis (UNICEF and WHO 2012) to understand the communities involved in SIT testing.

Figure 7.1. The SIT process and involved stakeholders and communities

27 Stakeholder and/or community participation are used interchangeably with stakeholder and/or community engagement.
7.3.1 Definition of community and/or stakeholder participation

In its broad sense, community participation can be defined as “the process by which individuals, families or communities assume responsibility for their own welfare and develop the capacity to contribute to their own and the community’s development” (Oakley 1987). In the context of development, community participation also refers to an active process whereby the beneficiaries influence the direction and execution of development projects, rather than merely receive a share of the benefits (Samuel 1987). In the context of SIT testing, community participation and stakeholder engagement can be understood as community and/or stakeholders being accepting of and/or actively involved in the development, trials and release/deployment of sterile male SIT Aedes mosquitoes. Community, here defined as a broad term, includes not only the rural or urban communities where the SIT mosquitoes are to be released, but also the scientific community, the health practitioner community, the mass media and any other group of people to be considered in the context. The SIT testing team must engage as early as possible with the different community/stakeholder categories (maybe at different phases of the project) and find out how best to communicate and engage with and tailor messages to each.

7.3.2 The purpose of community and/or stakeholder participation

There are at least two reasons for involving community and/or stakeholders in research. First, communities have the right to be provided with adequate information about research that may affect their health, environment and ecosystem and to freely decide whether to participate in the research or not. This ethical obligation is well stipulated by many international, national and institutional research ethics guidelines and principles, which state that for research involving humans, researchers have ethical responsibilities to inform the communities which will be affected either beneficially or negatively by the research and to obtain their informed consent for participation in the research. Second, real operational experience has demonstrated that community engagement and stakeholder acceptance and/or participation are essential for realizing project goals and objectives.

Community participation can build and maintain trust between researchers and communities, help researchers adapt research design to the local context, facilitate the communication of information to participants and discourage inappropriate inducements (Nuffield Council on Bioethics 2004). Therefore, acceptance and/or active community and/or
Guidance framework for testing the sterile insect technique as a vector control tool against Aedes-borne diseases

Stakeholder involvement in SIT testing helps to ensure its ethical and scientific quality and to bring about the successful completion of the proposed research and/or intervention (Box 7.4). It also helps the SIT testing team understand and appreciate the community context, promotes smooth study deployment, contributes to a community’s capacity to understand the research process, enables members to raise questions or concerns and builds credibility between the community and the researchers, which is a critical success factor for any SIT intervention.

Box 7.4 Objectives of community and/or stakeholder engagement

- To fulfill researchers’ ethical obligations, obtaining the consent, understanding, collaboration and trust of communities and stakeholders
- To improve the project and ensure the achievement of objectives

7.3.3 How to foster community and/or stakeholder participation

Testing SIT to control Aedes-borne diseases is a process that will involve different communities and stakeholders at the different phases of implementation. Thus, community and/or stakeholder acceptance, engagement and/or participation need to be ongoing processes rather than a one-off action. Effective communication between the SIT testing team and community members is the foundation for community/stakeholder participation; hence, a forum/platform or other appropriate mechanism, such as a community advisory group, needs to be established to foster ongoing communication between the SIT testing team and the communities/stakeholders. Community members should be encouraged to raise any concerns that they have from the outset of the project and as the research proceeds (Box 7.5).
There are a number of principles the SIT testing team can take into consideration to foster community acceptance/participation activities when planning and implementing the projects, among them:

- Sensitivity to local social norms and culture, including gender and other social strata;
- Striving to understand the community via situational analysis;
- Early engagement with the community;
- Clear and complete information/transparency;
- Respect for the community;
- Responsiveness to the community’s concerns;
- Involvement of social scientists and communication experts, whenever possible;
- Consideration of the characteristics of communities, e.g., whether rural or urban;
- Allocating resources for community engagement activities.

The life cycle of implementing SIT provides many opportunities (cf. Figure 1.5) for pursuing active community and stakeholder participation to ensure better outcomes.

Opportunities for fostering community and stakeholder participation are listed below:

- Development of a communications strategy;
- Communication with community leaders or representatives to gain access to the community;
- Preparation of Information Education Communication (IEC) materials for stakeholders and community members, since social mobilization strategies designed in collaboration with the target audience will be more effective than those imposed without consultation or opportunities for meaningful dialogue (WHO 2012);
- Solicitation of individual informed consent for epidemiological surveys (cf. Chapter 6);
- Communication on risks and risks management (cf. Chapter 2);
- Dissemination of SIT intervention testing results.

The SIT testing team should select communication activities appropriate for the local conditions and within available resources. Activities that the SIT testing team can undertake to facilitate active community and

---

**Box 7.5. Example of community engagement in a malaria project**

“As co-development is one of our core values, we decided that the community itself should design its own acceptance model. Early on, a dialogue was established to agree on a set of principles—transparency, inclusiveness, openness to different perspectives—and the community of Bana elaborated its own acceptance model. They chose to establish a reference community group, representing the whole community and communicating the community’s decision to the project, after their consultation. The acceptance to participate to the small-scale release of sterile mosquitoes was given by this reference group in May 2018”. Extracted from a target malaria project in Bana, Burkina Faso (Diabate 2019)
Guidance framework for testing the sterile insect technique as a vector control tool against Aedes-borne diseases

stakeholder participation include, but are not limited to, the following:

- Conduct stakeholder analysis to identify who will be affected, in what way and to what extent;
- Encourage stakeholder consultation and public dialogue;
- Set up a community advisory board to facilitate community participation;
- Develop communication strategies and plans that include, inter alia, target audience, purpose and frequency of the communication; what information via what channels and techniques; when and where, by whom;
- Design and select the channels of communication: Mass media (radio, television, newspaper); mobile phone; Internet-based communication tools; community outreach activities such as individual interviews, focus group discussions, community meetings, street theatre and performance, awareness raising campaigns, talk shows; and other means can be employed, as appropriate, to communicate information to stakeholders and communities;
- Invite community members to report and share their observations and perceptions of the SIT intervention with the SIT testing team (i.e., participatory monitoring and evaluation);
- Listen and respond to community concerns.

“You would never produce communication materials and products without getting to know the people affected”. – WHO 2012

28 Communication strategies will be highly dependent on the socioeconomic and cultural conditions of the communities.
Chapter 08

Cost-effectiveness assessment
To successfully and sustainably scale up interventions, decision makers require evidence not only of an intervention’s impact on health outcomes, but also of its cost and cost-effectiveness. From a policy perspective, **cost analysis** provides information relevant for the financial planning, implementation and affordability of evidence-based interventions, whereas **cost-effectiveness analysis** indicates the relative efficiency or the relative value for money of interventions (IAEA 2008).

The SIT is envisioned to be deployed as an intervention complementary to other mosquito vector control methods in the context of integrated programmes, in order to increase the effectiveness of current vector control efforts against *Aedes*-borne diseases (Flores and O’Neill 2018). With pilot releases of sterile mosquitoes occurring at multiple sites in different countries across the world, much progress has been made in scaling SIT to phases II and III field trials for evaluation (Lees 2015; Bellini 2013; Bond 2019; Boyer 2012). In the coming years, SIT will be subject to extensive testing in phase III and IV studies targeting *Ae. aegypti* and *Ae. albopictus*, the most important vectors within the genus *Aedes*, in a range of contexts and settings. In this chapter, we introduce and review the methods for conducting cost and cost-effectiveness analyses to inform future programming and deployment of SIT as a new vector control intervention for the control of arboviral diseases transmitted by *Aedes* mosquitoes.
8.1 The use of cost-effectiveness analysis for priority-setting in health

Policy makers in all healthcare systems face difficult decisions about which interventions to fund, because available resources will never be sufficient to deliver all possible means of improving health to all people who might benefit from them. Cost-effectiveness analysis is a method widely used in the public health sector to evaluate the economic efficiency of a new intervention relative to current practice or alternative interventions. The primary objective of cost-effectiveness analysis is to compare the costs and the health benefits of interventions to guide the allocation of limited healthcare resources by prioritizing those that offer the largest health benefit for the least amount of money (Jamison 2006; Musgrove 2006). To achieve this, the estimated cost-effectiveness of a new intervention is compared either with the cost-effectiveness of a set of existing interventions or with a fixed, context-specific benchmark representing the maximum willingness to pay for an additional unit of health benefit (Musgrove 2006; Woods 2016). Prioritizing interventions that are more cost-effective over those that are less allows the highest possible overall level of health to be generated for the population served (Drummond 2005). Although it is just one of the many decision-making criteria in a complex policy-making process, cost-effectiveness is an important consideration for priority-setting in health policy, whose objective is to decide how to spend public funds to improve population health (Jamison 2006; Musgrove 2006).
8.2 The use of cost-effectiveness analysis in economic evaluation of SIT

Cost-effectiveness analysis applies strictly to interventions. An intervention is broadly defined as a deliberate action to improve health by reducing the risk, duration or severity of a health problem (Jamison 2006). The SIT has a number of unique characteristics not usually found in other vector control interventions:

1) It provides area-wide vector control without requiring access to households or other private property (Flores 2018);
2) It operates in an inverse density-dependent manner, i.e., as the size of the target vector population becomes smaller and smaller, the effectiveness of a constant rate of sterile insect release increases (Feldmann 2001);
3) It requires important capital investment for infrastructure and capacity building (IAEA 2008); Further and as for other vector control interventions, it necessitates a high degree of multisectoral organization and management at the level of large-scale vector or disease control programmes to maintain community protection from Aedes-borne diseases (Flores 2018).

Although SIT is often perceived as a stand-alone intervention method, past and current practice from agricultural pest management shows that SIT rarely has been used that way (Alphey 2010). Particularly, the inverse density-dependence of the method suggests that SIT would work synergistically with other vector control methods, particularly those targeting the adult females or immature stages of Aedes vectors (Feldmann 2001). Therefore, rather than analysing the costs and the effects of SIT individually, we can use cost-effectiveness analysis to estimate the additional cost of incorporating SIT into an integrated vector control programme as a principal component and quantify the additional health benefit that is expected to result. In this case, a package of interventions, including an SIT component, is subject to economic evaluation. Adding a new intervention to an existing package of interventions to address the same health problem can be considered a change in the integrated vector control strategy. It is possible to evaluate various combinations of interventions to determine which combination is the most cost-effective and how the cost-effectiveness of the new intervention depends on the other intervention(s) with which it is combined. An example would be combining
SIT (or any other vector control measure) with other interventions aimed at controlling the Aedes-borne diseases such as vaccination (Fitzpatrick 2017).

The outcome of a cost-effectiveness analysis depends on the comparator chosen. If there is no reference to a comparator (i.e., the null value being the natural course of disease without intervention), the main outcome of the analysis would be an average cost-effectiveness ratio, evaluating the total costs of an intervention relative to its total health benefits (Drummond 2005). Promoted at one point by the World Health Organization, this type of generalized cost-effectiveness analysis can be used to select a mix of interventions to maximize health within a fixed health budget (WHO 2003). However, the dearth in most countries of reliable information on intervention coverage, costs and benefits (Murray 2000) makes it difficult to obtain accurate cost-effectiveness results from such analyses.

In many cases, the main outcome of a cost-effectiveness analysis is an incremental cost-effectiveness ratio comparing the costs and the health benefits of at least two competing interventions or packages of interventions, one of which typically reflects current practice (Drummond 2005), whereby a lower ratio indicates more health benefits per incremental dollar spent (Box 8.1). If the incremental cost-effectiveness ratio falls into an acceptable range, the intervention or package of interventions is determined to be more economically efficient than current practice, thus warranting consideration for adoption from a policy perspective (Musgrove 2006). The development of this evidence base is important, as it has significant implications for the affordability, scalability and sustainability of effective interventions, particularly in low resource settings with several competing health priorities where Aedes-borne diseases are endemic (Liyanage 2019).

**Box 8.1. Definition of an incremental cost-effectiveness ratio (ICER)**

- The ICER is the ratio of the change in costs to incremental benefits of an intervention:

\[
\text{ICER} = \frac{\text{Cost}_{\text{intervention}} - \text{Cost}_{\text{current practice}}}{\text{Effect}_{\text{intervention}} - \text{Effect}_{\text{current practice}}}
\]

- Costs are usually described in monetary units, while effects are measured in terms of cases, fatalities or disability-adjusted life years (DALYS) averted.
- If the intervention is more effective and less expensive than current practice, the ratio is positive, i.e., the intervention is preferred over current practice.
8.3 The estimation of cost-effectiveness

Using cost-effectiveness analysis for resource allocation requires the health benefits of interventions to be measured in common units in order to facilitate comparisons across interventions or diseases. Most analyses typically start with some natural health unit such as cases of disease or deaths (Drummond 2005). Evaluation of vector control interventions may also focus on intermediate outcomes such as entomological endpoints—for example, vector density. When the cost-effectiveness analysis focuses on the effects of disease, the common unit of health loss or gain resulting from an intervention should also consider the duration and the severity of disease and the preference for timing of health benefits (Fox-Rushby 2001).

To that end, disability-adjusted life years (DALYs) is the health gap metric most commonly used as a quantitative measure of health benefits (Box 8.2). The DALYs metric incorporates assumptions and measurements about the severity of non-fatal conditions, the age at the time of disease or death, the duration of disease sequelae with or without intervention, and the remaining life expectancy at that age (Fox-Rushby 2001). DALYs are calculated as the sum of the present value of future years of healthy life lost through illness/disability (years of life lived with a disability or YLDs, weighted by the severity of disability) and the future years of life lost through premature mortality (years of life lost, YLLs) as a result of a disease or a condition (Murray 1996). Health interventions aim to reduce DALYs.

**Box 8.2. Disability-adjusted life years (DALYs)**

- One DALY represents the loss of the equivalent of one year of full health.
- DALYs for a disease are the sum of the years of life lost as a result of premature mortality in the population and the years lost as a result of disability for incident cases of the health condition:

\[
\text{DALYs} = \text{YLL} + \text{YLD}_{\text{weighted}}
\]

- DALYs is a health gap measure that extends the concept of potential years of life lost as a result of premature death to include equivalent years of “healthy” life lost to states of less than full health, broadly termed disability.
Developed for the Global Burden of Disease (GBD) study by the World Health Organization (Murray 1996), the DALYs approach was introduced in the World Development Report in 1993 (World Bank 1993). Although the primary application of DALYs is in estimating trends in the global and regional burden of disease, the metric has also been widely used as an outcome measure for cost-effectiveness analysis over the past twenty-plus years. Nevertheless, the DALYs approach has received considerable criticism because of the value choices built into the metric through the disability weights, the age weighting and discounting (Mont 2007).

The disability weights range from zero (perfect health) to one (death) and measure the limitations from a disease or a condition in the absence of intervention (World Bank 1993). The GBD study recently has re-estimated the disability weights for 220 different health states to address the long-standing criticisms over their validity (Salomon 2010). The age weighting, another controversial value choice that gives less weight to years of healthy life lost at young and older ages, are no longer applied in cost-effectiveness analyses (Murray 2010). Discounting reflects inherent uncertainty about the future (Drummond et al. 2005). However, it has been argued that there is no intrinsic reason to assign less value to a year of health because it is anticipated in the future (Tsuchiya 1999). In 2012, WHO also dropped the use of discount rates to further simplify the calculation method for DALYs in the global burden of disease calculations (Murray 2010). Yet, discounting is still applied to future health benefits at a rate of 3-6%, and most cost-effectiveness guidelines recommend discounting future costs and benefits at the same discount rate (Attema 2018).

Another controversy in DALYs calculations is the choice of a life table, because life tables with high life expectancies yield more life years than life tables with shorter life expectancies and may overstate the health benefits of interventions (Musgrove 2006). In practice, life expectancies may be taken from life tables that are country-specific or standardized across larger regions; these are published by WHO in the Global Health Observatory data repository. 19

DALYs averted during the intervention period can be computed using the standard methods and formulations (Murray 2010) or recently developed, easy-to-use tools aimed at public health professionals interested in quantifying disease burden (Devleesschauwer 2014; Center for the Evaluation of Value and Risk in Health 2018).

To demonstrate the full potential of SIT as a complementary intervention, pilot projects theoretically should be located in areas with high disease burden and be of sufficient scale and duration to allow reasonable projections of the intervention costs and effects on disease, ideally using epidemiological endpoints such as disease incidence.

19 https://www.who.int/gho/en/
The analysis of the comparative costs of alternative interventions is common to all forms of economic evaluation, including cost-effectiveness analysis. The primary purpose of the cost analysis is to compile information on the costs of introducing a new intervention singly or in combination with other interventions. While the identification, measurement and valuation of costs often occur simultaneously in practice, it is best to view each as a separate step in a cost analysis. The choice of the study perspective affects the costing method (Drummond 2005). For example, if a payer perspective is adopted, the most relevant costs are the expenditures in the payer’s budget.

There are typically four main cost categories (Drummond 2005; Johns 2003) which would also apply to a mosquito-SIT intervention:

1. Personnel costs are calculated for staff involved with laboratory colonization, mass rearing, production and release of sterile mosquitoes and for supervision, monitoring and evaluation of the intervention;
2. Consumable costs include costs of all consumable items, such as rearing diet, general supplies, transport, quality control, as well as small equipment that has no resale value after one year;
3. Overhead costs include utilities (e.g., water, electricity, communications), rent and maintenance costs of production facilities and equipment;
4. Capital items include rearing and irradiation equipment, sex sorting machinery, vehicles for transportation and release, buildings for mass production and storage, and other relevant capital items with an expected useful life of more than one year.

The first three categories (personnel, consumables, overhead costs) are typically referred to as recurrent costs, while the fourth category (capital items) falls under capital costs (Johns 2003). Sterile insect mass rearing, irradiation and release is a continuous process, hence associated recurrent costs should be tracked and quantified over time. Once the important and relevant costs in each of the four categories have been identified, resource usage must be measured in appropriate physical units over time (Drummond 2005), bearing in mind that resources are divisible and can be shared across interventions. To address the measurement challenge posed when resources are shared by different interventions, an appropriate basis of allocation related to the joint use of shared resources should be chosen and applied to apportion the costs associated with such resources (Drummond 2005). For example, the percentage of time devoted to the activities for different vector control interventions can be used to allocate personnel and equipment costs.
The capital costs of an SIT production facility include land, building materials, construction labour and equipment costs. Some of these costs are locally determined, whereas the price of building materials may be set internationally (IAEA 2008). Some highly specialized equipment, such as oviposition cages, racks and trays for mass rearing, may or may not be produced locally. Encouragingly, the cost of adult mosquito cages has fallen significantly from over US $2,220 to US $220 per cage (Zheng et al. 2019). Annual depreciation costs should be calculated for each capital item, assuming an appropriate useful life for each item, and apportioned according to the estimated share of its use if the production facility is shared for other purposes (Drummond 2005). To estimate the total cost of SIT over the intervention period, the last step in the costing analysis is to add recurrent costs and annualized capital costs (Drummond 2005; Johns 2003).

There may be considerable variation in such costs in different locations (Johns 2003). In the long run, it may be informative to generate general guidelines based on an analysis of SIT facilities built at a range of production capacities. A financial model was previously developed by the IAEA to examine the relationship between the costs, level of production and sale price of sterile insects, using information from sterile medfly production facilities in operation (IAEA 2008). However, the most common arrangement so far has been government-sponsored production, whereby costs have been absorbed into insect management budgets (IAEA 2008), which likely will be the case for countries affected by Aedes-borne diseases.

Clearly, there may be significant cost savings associated with large-scale production facilities. Recurrent costs not directly related to the level of production, such as administrative and other full-time personnel, may provide some economies of scale. Further, reductions in other types of recurrent costs are expected to occur over time. For instance, the cost of larval diets has decreased by about 90%, with further reductions in operational costs expected due to aerial release of mosquitoes by drones and monitoring via ovitraps at a lower density (Zheng et al. 2019). Second, major reductions in mass rearing costs are anticipated through the application of emergent and novel technologies, such as the development of automated pupae sex sorter machines, which would facilitate separation of male from female mosquitoes on an industrial scale (Zheng et al. 2019).

The objective in valuing costs is to estimate the value of resources used by an intervention (Drummond 2005). Costs are typically assessed in the local currency and can be extracted from intervention or programme budgets. All costs can be converted to US dollars (US $) to facilitate international comparisons and must be expressed in constant dollars of some base year, usually the present year, to remove the effects of inflation from the analysis (Drummond 2005; Johns 2003).

In a cost analysis, costs incurred during the start-up period, which typically include the costs of activities conducted before the deployment of SIT (e.g., planning, recruitment and training of staff) should be identified and quantified separately (Drummond 2005). As discussed above, the capital costs of a mass
rearing facility for SIT are likely to fall under the start-up costs and include the costs of land, building materials, construction labour and equipment. To estimate the cost of intervention scale-up necessitates distinguishing between start-up costs and post-start-up costs. A distinction also should be made between research costs and routine monitoring and evaluation costs in phase IV trials. Ideally, all research costs in phase III and IV studies should be excluded from the cost analysis; however, routine monitoring and evaluation costs can be included, as it is expected that these costs would also be incurred in intervention replication and scale-up (Johns 2003). Staff time spent on research (e.g., data collection) should be recorded separately from time spent on intervention delivery.

The costs of pilot-scale SIT programmes can facilitate an estimation of costs at larger implementation scales. Given the potential economies of scale, pilot-scale costs are expected to be higher than post-pilot-scale costs; both should be estimated to inform SIT planning and implementation, as was done in Zheng et al. (2019) for a combined Incompatible Insect Technique (ITT)/SIT programme for *Ae. albopictus* control in China (Box 8.3).
Box 8.3. Actual and predicted future costs (in US $) of pilot and operational trials for a combined IIT/SIT Ae. albopictus control programme in China (Zheng et al. 2019).

<table>
<thead>
<tr>
<th>Pilot trial, based on combined IIT/SIT release in Sites 1 and 2 in 2016 and 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Production cost / million males,</td>
</tr>
<tr>
<td>including quality control in laboratory and field</td>
</tr>
<tr>
<td>Release cost / ha / week</td>
</tr>
<tr>
<td>Monitoring cost / ha / week</td>
</tr>
<tr>
<td>Number of HC males released / ha / week (Minimum, Maximum)</td>
</tr>
<tr>
<td>Totals cost / ha / week (Minimum, Maximum)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Operational trial: initial suppression for first two years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predicted reduction of production cost, %</td>
</tr>
<tr>
<td>Predicted improvement of competitiveness</td>
</tr>
<tr>
<td>Predicted reduction of release rate, %</td>
</tr>
<tr>
<td>Release cost / ha / week</td>
</tr>
<tr>
<td>Monitoring cost / ha / week</td>
</tr>
<tr>
<td>Totals cost / ha / week (Minimum, Maximum)</td>
</tr>
<tr>
<td>Totals cost / ha / year (Minimum, Maximum)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Operational trial: continued suppression for next eight years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Predicted reduction of release density, %</td>
</tr>
<tr>
<td>Totals cost / ha / year (Minimum, Maximum)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Operational trial: overall cost for all ten years</th>
</tr>
</thead>
<tbody>
<tr>
<td>Totals cost / ha / year (Minimum, Maximum)</td>
</tr>
</tbody>
</table>
8.5 Computing incremental cost-effectiveness ratios

For a meaningful comparison, it is necessary to examine the additional costs that a new intervention imposes on another, compared with the additional benefits it delivers. The cost effectiveness analysis of SIT will rely on the cost and health outcome data from phase IV trials conducted in different contexts and settings. The analysis will centre on incremental cost-effectiveness ratios (cf. Box 8.1), where the numerator represents the incremental costs of SIT relative to the existing vector control strategy, and the denominator represents its incremental benefits expressed in DALYs averted due to the reduced incidence of an Aedes-borne disease of interest. To that end, a cost-effectiveness analysis of SIT examines the extra amount to be paid to avert an extra DALYs by strengthening the existing vector control strategy with SIT.

Determining whether a given intervention will be cost-effective in a specific implementation setting normally rests on a local standard or a cost-effectiveness threshold that reflects the opportunity cost of resources in terms of the health benefits forgone if SIT is adopted as an additional measure of vector control (Woods 2016). As discussed previously, in cases where evidence about an intervention’s epidemiological effectiveness is lacking, entomological endpoints can be used to compute incremental effects in a cost-effectiveness analysis.

However, it must be emphasized that a decision to use one technology vs. another against Aedes-borne diseases will be based primarily on its impact on disease transmission. Box 8.4 provides an example of such an analysis from a provider perspective, focusing on the effectiveness and incremental costs of an SIT-supported strategy relative to the conventional strategy for the control of Aedes mosquitoes in urban areas in Italy (Canali 2019).
Guidance framework for testing the sterile insect technique as a vector control tool against Aedes-borne diseases

Box 8.4. Comparative cost-effectiveness analysis of SIT in Italy

A recent cost-effectiveness analysis focused on the integration of SIT into the conventional vector control strategy against Ae. albopictus in Italy. The analysis examined the incremental cost per resident of achieving a 1% reduction in the mean annual egg density in ovitraps, which is an entomological endpoint. Three strategies were compared:

- Strategy A: Conventional control (e.g., spraying)
- Strategy B: Door-to-door (mainly source reduction, but also anti-larval treatment of large containers)
- Strategy C: SIT supplemental to Strategy A

**Incremental costs:** Based on expert opinion, it was estimated that an SIT facility working 25 weeks per year with a production capacity of 10 million sterile Ae. albopictus males per week would allow the integration of SIT into the conventional vector control strategy at €3.80 per 1,000 sterile males. The incremental cost per resident was calculated for three different sterile/wild male ratios (20:1, 10:1 and 5:1), which determine the number of sterile males per hectare that need to be released weekly in the treated urban area, given its population density.

**Incremental effects:** Based on the results of recent trials conducted in the intervention area, mathematical models were used to define the relationship between the sterile/wild male ratios and the expected reduction in vector density in ovitraps, considering the reduction in mosquito egg fertility, seasonal mosquito population dynamics and net mosquito immigration from bordering areas under conventional control. These models allowed the estimation of the number of sterile mosquitoes to be released weekly each year to maintain the desired sterile/wild ratio based on the daily death rate of sterile males.

**Incremental cost-effectiveness ratios:** ICERs compared the incremental cost per resident of achieving a 1% reduction in the mean annual egg density in ovitraps with an SIT-augmented strategy relative to the conventional strategy. ICERs were computed for the three different sterile/wild male ratios, using a discount rate of 2.85% and 3%. The results indicated that the SIT-supported vector control strategy was more effective in reducing vector density in ovitraps than the conventional strategy alone (which did not achieve a satisfactory reduction), but at a higher cost per resident. However, this increased cost was still lower than that of the alternative new technology tested in Strategy B.

**Conclusion:** For all the considered scenarios, even for extreme worst vs. best case evaluations, Strategy C (SIT+conventional) was more cost-effective than either Strategies A or B.
There are various types and sources of uncertainties relating to the effectiveness and cost data used in cost-effectiveness analyses. In its Model Business Plan for a Sterile Insect Production Facility, the IAEA estimated the initial capital costs and the recurrent costs for a sterile insect production facility under a range of scenarios, which could be incorporated into a cost-effectiveness analysis (IAEA 2008). An important feature of economic evaluation studies, sensitivity analysis is used to handle parameter uncertainty and assess the robustness of the cost-effectiveness results. There are a number of forms of sensitivity analysis, namely, one way and multi-way sensitivity analysis and scenario analysis (Drummond 2005). Cost effectiveness analyses increasingly incorporate probabilistic sensitivity analysis, where probability distributions are applied to the specified ranges for the key parameters, and samples are randomly drawn from these distributions to generate the empirical distributions of the costs and health benefits (Drummond 2005). The main advantage of this approach is that it allows the combined effect of all parameter uncertainties in the cost-effectiveness analysis to be characterized and the implications for a decision based on mean costs and benefits of an intervention to be reported. However, it should be noted that sufficient data for estimating probability distributions around mean parameter estimates are rarely available, particularly in low- and middle-income countries (Jamison 2006; Musgrove 2006).

As mentioned in the introductory remarks for this chapter, decision makers require evidence on the effectiveness of interventions on health outcomes, such as disease incidence. However, before scaling up and deploying an intervention, decision makers must also know if the intervention is affordable. The cost analysis provides information relevant for the financial planning, implementation and affordability of evidence-based interventions, whereas the cost effectiveness analysis indicates their relative efficiency or their relative value for money. While the burden that disease places on populations can be expressed by health gap measures such as DALYs, the true health impact is presumed to be considerably higher due to the broader societal impacts that are not directly related to health and remain uncaptured by these summary measures.
Chapter 09

Programme monitoring and evaluation
This chapter discusses the general concept of monitoring and evaluation for the SIT testing framework, highlights the relationship between monitoring and evaluation (M&E) and outlines the requirements for a functioning M&E system based on an input-process-output-outcome-impact pattern. M&E indicators for the planning and implementation stages and for long-term impact are provided as entomological and epidemiological evaluation components.

### 9.1 General concept

Similar to other vector control strategies, SIT requires monitoring and evaluation to guide the planning and implementation of the system, measure its effectiveness, seek improvement and evaluate the integrated resources (WHO 2012). M&E enables responding to deficiencies or failure by replacing them with more functional efforts, methods and/or techniques. The implementation of SIT as a vector control strategy follows a stepwise phased conditional approach (Figure 1.5), in which each phase needs to be successfully completed and embedded into decision-making and operational processes before proceeding to the next one (Figure 9.1). The validity and progress of each element will be assessed by the monitoring and evaluation process.

*Figure 9.1. General framework for M&E of testing SIT.*
9.2 Specificities of monitoring and evaluation

The components of an SIT programme interlock with and depend on one another (Figure 1.3). Together, monitoring and evaluation elucidate the cause-and-effect relationships between activities and impact. While interrelated, monitoring and evaluation differ in their approaches. Monitoring is used at the programmatic level to identify weaknesses in implementation, while evaluation is more at a global level and indicates whether the programme shows success or failure. The differences between monitoring and evaluation are shown in Table 9.1.

Table 9.1. Specificity of monitoring and evaluation for the following elements: frequency, function, purpose, focus, methods, information source and cost (adapted from the Global Fund Report, 2011).

<table>
<thead>
<tr>
<th>Element</th>
<th>Monitoring</th>
<th>Evaluation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frequency</td>
<td>Periodic, occurs regularly</td>
<td>Intermittent</td>
</tr>
<tr>
<td>Function</td>
<td>Tracking/oversight</td>
<td>Assessment</td>
</tr>
<tr>
<td>Purpose</td>
<td>Improve efficiency, provide information for reprogramming to improve outcomes</td>
<td>Improve effectiveness, impact, value for money, future programming, strategy and policymaking</td>
</tr>
<tr>
<td>Focus</td>
<td>Inputs, outputs, processes, work plans (operational implementation)</td>
<td>Effectiveness, relevance, impact, cost-effectiveness (population effects)</td>
</tr>
<tr>
<td>Methods</td>
<td>Routine review of reports, registers, administrative databases, field observations</td>
<td>Scientific, rigorous research design, complex and intensive</td>
</tr>
<tr>
<td>Information source</td>
<td>Routine or surveillance system, field observation reports, progress reports, rapid assessment, programme review meetings</td>
<td>Same sources used for monitoring + population-based surveys, special studies</td>
</tr>
<tr>
<td>Cost</td>
<td>Steady and regular</td>
<td>Occasional</td>
</tr>
</tbody>
</table>
9.3 Requirements for a functioning M&E system

The key to success for SIT testing is objectively and systematically assigning measurable indicators, which can be either quantitative (numbers) or descriptive (e.g., absent or present). The best scenario uses a balanced combination of both categories. However, the analysis of quantitative data is more immediate, and more easily provides results that can be statistically significant. By contrast, descriptive/qualitative data may need to be transformed before being analysed, and statistical significance is not always achieved.

9.3.1. Organization in charge of M&E

The organization(s) responsible for the SIT testing programme and M&E must be clearly defined at the different phases and globally for the full process. It is recommended that the organization responsible for M&E is not the same as the one in charge of SIT testing, to avoid conflict of interest. In some cases, the authorities provide the oversight and coordination and assign technical bodies to draft the standard operating procedures (SOPs), mechanisms of data collection and the M&E plan, which will describe stakeholders, address responsibilities and define indicators and data collection methods.

9.3.2. Operational steps for M&E of a vector control programme

Monitoring and evaluation of control programmes should start with the planning of the programme and continue through the implementation and operational stages to validate the stepwise progress of the operation using process indicators (Figure 9.2). Monitoring identifies hindrances to further actions and indicates modifications. The evaluation of both outcome and impact indicators points out whether programme goals are being achieved.
9.3.3. Collection and dissemination of data

Data collection mainly involves official maps, reports and documents from the corresponding national authorities. Via regularly collection of data from sentinel sites, epidemiological surveillance systems are essential for monitoring the impact of the control measures on vectors, disease, cost and the environment.

To determine weaknesses or areas of improvement, data must be interpreted and disseminated to help in programme planning and policy formulation. In addition, data analyses help to evaluate the status of implementation and to validate outcomes/impacts. Data dissemination not only involves the policymakers responsible for planning, but also considers feedback from the public. To achieve goals efficiently, data must be communicated in a timely manner and in the proper form (WHO 2012).
9.4 M&E of outcomes and expected impact of the success of SIT

The components of an M&E programme for SIT include input indicators, process indicators, output indicators, outcome indicators and impact indicators. The progress of all the components of the SIT testing programme should be monitored by regular data collection, reporting and analysis. The M&E plan can be developed based on the WHO framework (WHO 2016). Figure 9.3 provides examples of indicators for each component.

By adding extra indicators to the existing ones, integrating SIT within other vector management strategies increases the complexity of monitoring and evaluation.

**Table: Examples of indicators for each component**

<table>
<thead>
<tr>
<th>Input Indicators (strategies, funds, approvals, and others)</th>
<th>Process Indicators (manpower, techniques and others)</th>
<th>Output Indicators (delivery, practices and others)</th>
<th>Outcome Indicators (coverage, use, vector reduction)</th>
<th>Impact Indicators (disease burden)</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Approve SIT by decision committee</td>
<td>- Number of sentinel sites with functional surveillance</td>
<td>- Number of SIT covered sites/villages or other communities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Mass rearing facilities</td>
<td>- Developed SIT research and techniques</td>
<td>- Number of ovitraps/sites</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Training courses and SoPs for SIT</td>
<td>- Number of ovitraps/site</td>
<td>- Number of eggs/ovitrap and percentages of egg hatch/ovitrap</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Number of SIT campaigns</td>
<td>- Ratio of Sterile male/wild males after releases</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Number of operational research outcomes used in implementation of SIT</td>
<td>- Rate of suppression of wild population</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Developed SIT SoPs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Number of sites where SIT is applied compared to conventional only applications</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Reduction in density of Aedes eggs, larvae and adults</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Induction of sterility in the population</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Number of dengue (Aedes-borne disease) confirmed cases</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Effectiveness of SIT programs in reducing dengue burden vs. conventional only control measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Cost-effectiveness</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Ecological soundness</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Sustainability</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Figure 9.3.** Examples of the relationship between inputs, process, outcomes and impacts of SIT to control *Aedes* (adapted from WHO 2012, 2016).
According to WHO (2016), the definitions of indicators and processes are listed below:

1) **Input indicators** reflect resources mobilized to support the process and include strategies, policies, funds, guidelines, authoritative bodies;
2) **Process** is the transformation of all resources to output efforts include manpower, training, techniques;
3) **Output indicators** are higher level resources using the inputs such as knowledge, delivery, practice;
4) **Outcome indicators** are the tangible direct results such as coverage, use, vector reduction;
5) **Impact indicators** are the final objectives of the programme: disease burden.

The performance framework of the programme should be based on an input-process-output-outcome-impact pattern (Figure 9.3). Inputs and processes will result in outputs; well designed outputs achieve short-term effects (outcomes), which in turn lead to long term effects (impact) (Global Fund Report 2011).

Based on data collected by national M&E systems, indicators should align with national plans for disease control (intervention- and disease-specific indicators) and include programme coverage and effect of the intervention on vector population and disease control (WHO 2012, 2016). Indicators should align with targets and programme outcomes.

**9.4.2. Targets for indicators**

Setting representative targets for indicators is a key factor of the planning process. Proper targets should rely on a recent inclusive analysis of the epidemiological situation, including defining target and at-risk populations. Targets should be set according to the national disease strategy framework.

Factors to be considered when setting targets include, but are not limited to, at risk population, type of epidemic, main transmission factor, number of people at risk, mapping, appropriate intervention method and coverage and gaps (Global Fund Report 2011).
9.5 Data sources to support M&E

9.5.1. Surveillance indicators in SIT testing for Aedes-borne diseases

Surveillance data is the baseline source of information in control programme evaluation. Vector surveillance based on routine monitoring is set to assess certain risks and provide a description of spatial and temporal risk. In addition, it is the method for capturing inconsistencies that arise in the course of evaluation (Tabbabi and Daaboub 2017). Table 9.2 shows dengue surveillance indicators, which could be used as outcome indicators for SIT.

Table 9.2. Example of indicators and what they are representing for the evaluation of the effectiveness of dengue prevention and control programmes (cf. Chapters 5 and 6) (adapted from WHO 2009).

<table>
<thead>
<tr>
<th>Data Source</th>
<th>Purpose</th>
<th>Surveillance Indicator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epidemiological data</td>
<td>Determine effectiveness of the programme</td>
<td>No. of suspected cases</td>
</tr>
<tr>
<td></td>
<td>Identify areas in need of resource allocation</td>
<td>No. of laboratory-confirmed cases</td>
</tr>
<tr>
<td></td>
<td>Determine coverage of the programme</td>
<td>No. of hospitalized cases</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No. of at-risk health centres reporting</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No. of cases per health centre</td>
</tr>
<tr>
<td>Alternative indicators</td>
<td>Ensure accuracy of dengue classification: dengue fever (DF), dengue haemorrhagic fever (DHF), dengue shock syndrome (DSS)</td>
<td>Clinical syndromic case definition as fever</td>
</tr>
<tr>
<td></td>
<td>Determine the public’s understanding of disease and areas of concern</td>
<td>Surveillance of community awareness and/or participation, through Focus Group Discussion on other methods based on epidemiological data</td>
</tr>
<tr>
<td></td>
<td>Identify problem areas</td>
<td></td>
</tr>
<tr>
<td>Entomological data</td>
<td>Determine changes in vector abundance and distribution; obtain vector population trends</td>
<td>Adult indices, Pupal indices, Larval indices (HI, BI, CI)*</td>
</tr>
</tbody>
</table>

*HI : House Index, BI : Breteau Index, CI : Container Index
9.6 M&E of an SIT operational plan

The success of SIT relies on introducing enough sterility into the wild population to bring about a strong decrease in the vector population, resulting in a decrease in the transmission of pathogens. Standardized quality control methods are used to monitor the quality and effectiveness of the technique and assess its suitability for applications (Balestrino et al. 2017). As one of the most accepted and successfully used techniques for decades, radiation (together with the usual mass rearing adaptation, handling and transportation of mosquitoes that constitute SIT programmes) may negatively affect male mating capacity and competitiveness (Bakri et al. 2005; Bull 2015; Proverbs 1969; Helinski et al. 2009). Therefore, careful quality monitoring must be done on each of these SIT components.

Surveillance methods are required to assess programme progress and determine the effectiveness of the releases of sterile mosquitoes. Table 9.3 shows epidemiological and entomological as well as more general evaluation components for SIT, along with examples of evaluation values (Bond et al. 2019).
**Table 9.3. Entomological and epidemiological indicators and examples of target values for the evaluation of the different components for SIT mosquito programmes.**

<table>
<thead>
<tr>
<th>Type of Components</th>
<th>Outcome or Endpoint</th>
<th>Indicator</th>
<th>Example of target values for indicators defined in Chapters 4, 5 and 6</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Entomological components</strong></td>
<td>Phase I to all phases and Laboratory quality control</td>
<td>Pupal survival</td>
<td>Depending on the species and sex, 90 to 98%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Flight ability</td>
<td>Escape rate, 0.7 to 0.9</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fecundity</td>
<td>90 – 100 eggs/ females over a single gonotrophic cycle.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Adult survival</td>
<td>Median survival time 46 to 73 days depending on species and sex</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Pupa or adult size</td>
<td>Based on cephalothorax width. Base line data are necessary.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mating competitiveness</td>
<td>Fried C index &gt; 0.7</td>
</tr>
<tr>
<td></td>
<td>Phase II and Field cage</td>
<td>Mating competitiveness</td>
<td>Fried C index &gt;0.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sterile/wild ratio</td>
<td>&gt; 10:1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Survival and dispersal</td>
<td>Recapture of released males should be &gt;1% and mean dispersal distance from release point 70 m.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Sterility induction</td>
<td>Decrease in egg hatch should be progressive. To achieve less than 20% egg hatch (&gt;80% induced sterility) is desirable. When population is low, hatch rate is not meaningful, also the results may be delayed and have erratic values.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Suppression</td>
<td>Should be progressive. Based on systematically collected data from ovitraps (eggs and hatched larvae) and adult traps. Data should be compared with historical data from the site and data from control sites. Should be &gt;80%.</td>
</tr>
<tr>
<td><strong>Epidemiological components</strong></td>
<td>all phases</td>
<td>Disease incidence/prevalence studies before, during and after intervention trials</td>
<td>Disease incidence/prevalence studies during intervention trials.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Longitudinal passive case detection of targeted disease and other mosquito-borne diseases.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Post-treatment active and/or passive disease incidence/prevalence</td>
<td></td>
</tr>
<tr>
<td><strong>General</strong></td>
<td>all phases</td>
<td>Cost-effectiveness and monitoring and evaluation of the programme</td>
<td>Cost effectiveness analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Multi-year trials evaluation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Effectiveness of SIT when combined with other control measures in IVM</td>
<td></td>
</tr>
</tbody>
</table>
For vector-borne disease prevention and control, the implementation of the different activities through a pre-determined plan that has been previously tested under real-world conditions, must include M&E at all stages. Both internal and external evaluation processes and indicators will measure how the plan is being implemented (with realistic and adapted timelines) and how effective the activities are (alone and/or combined into the plan) and allow adaptation and improvement. The M&E process also will be used to better understand whether the human and technical resources are adequate, to identify where the weaknesses, deficiencies or failures are, and (potentially) to modify the plan accordingly.

In the specific case of SIT as a vector control strategy following a stepwise phased conditional approach, M&E must be done for each of the different phases, but also more globally for the full process, to look at how the testing is moving from one phase to the next according to the best decision-making options. The complexity of layering an M&E process into a phased approach increases the necessity of building up the approach as early as possible and testing it as many times as required.
Prior to being used on mosquitoes, the sterile insect technique has been used successfully to suppress numerous insects, including the crop pest *C. capitata*, the Mediterranean fruit fly, which was prevented from invading North America at the Guatemala-Mexico border. This agricultural success yielded huge benefits, with the cost ratio of control estimated to be US $150 of benefit for every US $1 spent on control. A veterinary pest, the New World screwworm fly, *Cochliomyia hominivorax*, was eradicated from both North and Central America and North Africa, where it was accidentally introduced. The screwworm fly is responsible for deadly injuries to cattle. And the latest and more recent SIT success was achieved against the tsetse fly, *Glossina austeni*, vector of animal and human trypanosomoses, which was eradicated from one island of Zanzibar.

The SIT is applicable against: i) insects reproducing through sexual mating, since only sterile individuals are released to mate with wild ones; ii) insects that can reproduce in confined and industrial conditions; iii) insects for which sexing of a large number of individuals is available (when only males are released); and finally, iv) insects where male mating competitiveness is similar in artificially bred vs. natural males. Moreover, methods for mass rearing, irradiation, sex separation, handling and release must be cost-effective. Until very recently, the cost of all these requirements were prohibitive for making this technology feasible for mosquitoes.

However, the lack of proven efficient vector control tools against some types of vectors, such as the mosquitoes *Ae. aegypti* and *Ae. albopictus*, has spurred the International Atomic Energy Agency, through its Joint FAO/IAEA Division of Nuclear Techniques in Food and Agriculture (NAFA), to put consistent efforts towards overcoming the technological issues impeding the deployment of this technology against mosquitoes. Once the technology was found to be mature enough, a collaboration was initiated with the Special Programme for Research on Tropical Diseases (TDR) at WHO and the Department of Neglected Tropical Diseases of WHO (NTD/WHO) to test SIT against *Aedes*-borne diseases, major vectors of arboviruses worldwide.

The first step of the collaboration is the development of this guidance document to inform the Member States, research institutions and interested stakeholders about the basics of the how, why and when of testing SIT against *Aedes* mosquitoes. The challenge of this guidance is to translate the findings and methods developed for agriculture into the health field. Further, injuries caused by crop and herd pests are mostly related to density, which is not the case for the transmission of diseases. The vectorial capacity of an insect species, i.e., the capacity of the vector population to propagate a disease, is linked not only to the density of the vector, but to its longevity (survival), infection rate, attraction to the host
(human beings) and competency to amplify the pathogen. Consequently, the evaluation of the impact of SIT on the vector population must take into account all of these parameters. Further, the evaluation of SIT on disease impact will also consider the incidence of the relevant disease(s) and the level of immunity in the human population.

The epidemiological and entomological indicators used to estimate the impact of SIT on a specific disease are variable within a human population exhibiting specific behaviours and living in specific socio-economic environments, both of which are of primary importance in the testing the sterile insect technology. The social/environmental factors encompass the risk assessment and regulatory and/or authorization pathways which must be included in the test planning.

This Guidance Framework for Testing the Sterile Insect Technique as a Vector Control Tool against Aedes-Borne Diseases was developed with the objective of considering all of the specificities of SIT in relation to human disease transmission, so that this technology could be tested in suitable environments and conditions, under the application of the most adequate processes and options. While its target audience is decision makers and the stakeholders’ technical experts, we hope that this document will be useful for a larger population of users as well, including, but not limited to, researchers, vector control agencies and technical staff.
Aerial release: Release of insects, e.g. sterile insects, from the air using aircraft or drones.

Area-wide control: A synonym for area-wide integrated pest management adapted from plant pest control. Control measures applied against a given plant pest over a geographically defined area that includes all known or potential 5 hosts with the objective of preventing pest build-up while minimizing damage to commercial host. Control actions are conducted whenever and wherever the target pest exists regardless of host seasonality (Enkerlin 2007).

Autodissemination: Sterile insects are inoculated with electrostatically charged powder formulated with entomopathogens or slow-acting insecticides, which would be spread throughout the pest population through intraspecific interactions (Robinson and Hendrichs, SIT Glossary 200521).

Colony: Individuals of one species living in close association in space and time (Gordh and Headrick 2001). For insect mass-rearing, a colony of a species consists of all stages of the insect kept in a rearing facility.

Competitiveness: Ability of an organism to compete with conspecific (i.e., belonging to the same species) organisms for a limited environmental resource (FAO/IAEA/USDA 2003).

Cost-effective: An activity that generates sufficient value to offset its cost (Friedman 2007).

Density: The number of individuals of a species per unit of habitat (Resh and Cardé 2003, Pedigo 2002).

Disability-adjusted life year index (DALY): An index that measures the burden of a disease in life years lost due to the disease (Murray 1994).

Dispersal: A non-directional movement of insects within or between habitats (Gordh and Headrick 2001).

Disease transmission: In medical and veterinary entomology, transmitting or passing on a disease, e.g. malaria, nagana, sleeping sickness. Transmission may be biological or mechanical. The passage of an infective parasite from an intermediate host (insect vector) to a definitive host (e.g. human), or vice versa (Gordh and Headrick 2001, Torre-Bueno 1978).

Efficacy: an intervention measured when it is implemented under ideal, highly controlled circumstances; efficacy is typically measured in phase III studies.

---

20 Most definitions were drawn from the SIT Glossary (https://nucleus.iaea.org/sites/naipc/dirsit/Documents/sit-glossary-updated-9-6-10.pdf). Please refer to the full SIT Glossary for additional terms and definitions.
**Effectiveness:** the degree of benefit of an intervention measured when it is delivered and used operationally under routine, “real-world” conditions; effectiveness is typically measured in phase IV studies.

**Elimination:** see ‘Population elimination’.

**Eradication:** A type of regulatory-control programme in which a target pest is eliminated from a geographical region (Gordh and Headrick 2001).

**Evaluation** is a periodic “rigorous assessment of the impacts that can be attributed to a programme or strategy, to demonstrate its value” (WHO, 2012).

**Filter colony:** From the filter rearing system (FRS) concept, which involves maintaining a small colony at a low density, or even under semi-natural conditions, and therefore assumedly a low-selection pressure. Surplus insects from this low-density mother stock or clean stream are fed into a high-density amplification chain, leading up to the final insects to be released. The important feature is that no individuals are ever fed from the amplification stages back to the mother stock.

**Fried C Index:** Fried’s Competitiveness Index is a simple measure for quantifying the mating competitiveness of sterilized males compared to wildtype males (Fried 1971).

**Genetic sexing:** Also ‘genetic sexing system’ (GSS). Genetic method to produce unisexual progeny.

**Genetically modified organism (GMO):** Food or plants with a genetic composition that has been altered in purpose (that is not accidentally) through genetic engineering (Collin 2001).

**Ground release:** Release of sterile insects from the ground.

**Impacts:** Long-term effects

**Implementation:** An act or instance of implementing something; the process of making something active or effective (Merriam-Webster).

**Infective:** Capable of producing infection, a term commonly applied to pathogens or to the vector (mosquito) (adapted from WHO 2016).

**Intervention:** A deliberate action to improve health by reducing the risk, duration or severity of a health problem (Jamison et al. 2006).

**Inundative release:** The release of large numbers of mass-produced biological control agents or
beneficial organisms with the expectation of achieving a rapid effect (FAO 2006).

**Life cycle:** The sequence of stages in the growth and development of an organism, eventually resulting in the reappearance of the first stage (Whiteside et al. 1988; Hill 1997).

**Living modified organism:** Any living organism that possesses a novel combination of genetic material obtained through the use of modern biotechnology (Secretariat of the Convention on Biological Diversity 2000).

**Living organism:** Any biological entity capable of transferring or replicating genetic material, including sterile organisms, viruses and viroids (Secretariat of the Convention on Biological Diversity 2000).

**Local strain/local material:** Colonized mosquitoes which originated from specimens collected in the “general” area targeted for release of sterile males in the SIT programme. The term “general” is subject to interpretation by regulatory bodies.

**Longevity:** Also ‘lifespan’. The length of life of an individual or a population (Hill 1997).

**Mark-release-recapture:** A technique of estimating insect population size by marking, releasing and recapturing of individuals and counting their proportional abundance (Daly et al. 1998).

**Mass rearing:** Mass rearing is a systematic enterprise accomplished with machinery in integrated facilities for the purpose of producing a relatively large number of insects for releases (Leppla et al. 1982). In mass-rearing the objective is to produce large numbers of ‘acceptable’ insects at the lowest possible cost (Singh 1977).

**Migration:** Long-range dispersal, either away from a declining resource or as part of a seasonal cycle (Gordh and Headrick 2001, Auburn 2008).

**Modern biotechnology:** The application of: a) in vitro nucleic acid techniques, including recombinant deoxyribonucleic acid (DNA) and direct injection of nucleic acid into cells or organelles, or b) fusion of cells beyond the taxonomic family, that overcome natural physiological reproductive or recombination barriers and that are not techniques used in traditional breeding and selection (Secretariat of the Convention on Biological Diversity 2000).

**Monitoring** is continuous tracking of programme performance and involves checking progress against pre-determined objectives and targets (WHO, 2016). It involves routine collection and reporting of data on programme implementation to understand how programme implementation is going.
**Mosquito genetically modified (MGM):** Mosquito in which specific genetic material has been altered in a way that does not occur naturally by mating and/or natural recombination (from the definition in Directive 2001/18/EC). Irradiated mosquitoes are not genetically modified organism (GMO) but randomly mutated. They are excluded from GMO referential.

**Mother colony:** A colony of insects that is the original colony established from field-collected insects. The progeny of a mother colony are used to create other colonies called daughter colonies. The mother colony is usually kept smaller in size, and reared differently, than daughter colonies, i.e. the mother colony is kept under conditions that are as similar as possible to field conditions (Parker 2007; Franz 2005).

**Outcomes:** Short-term effects

**Oviposition:** The act or process of laying eggs, ovipositing, depositing; the passage of an egg from the median oviduct to outside the insect’s body (Resh and Cardé 2003, Gordh and Headrick 2001).


**Population elimination:** One objective of a vector control strategy. Local population elimination means the disappearance, in a given area, of an isolated population of vectors. This concept must be distinguished from eradication of a species. (HCB 2017).

**Population modification:** Vector control strategy intended to reduce the inherent ability of individual vectors in a population to transmit a given pathogen (after WHO 2014, ‘population replacement’). The aim is mainly to reduce a vector population’s vector competence without necessarily altering the size of the population, as opposed to population reduction strategies. (HCB 2017).

**Population reduction:** Vector control strategy intended to reduce the size of a vector population below the threshold required for transmission of a pathogen (after WHO 2014, ‘population suppression’) without affecting the vector competence of the remaining individuals, as opposed to population modification strategies. (WHO 2014; HCB 2017).

**Quality control:** A systematic process whereby management critically evaluates the elements of production, establishes standards and tolerances, obtains, analyses and interprets data on production and product performance, and provides feedback so as to predict and regulate product quality and quantity (FAO/IAEA/USDA 2003).
Release: Intentional liberation of an organism into the environment (FAO 2006).

Rolling carpet principle: The various operational phases of pest management are carried out simultaneously in a phased manner. Intervention entails a unidirectional front (Hendrichs et al. 2007).

Self-limiting: A vector control technique is said to be self-limiting if its effects are limited in space and time unless application of the technique is maintained. For control techniques involving release of modified insects, the modification will disappear from the population unless it is reintroduced by regular releases of modified insects. (HCB 2017).

Stakeholder: Anyone with an interest, concern or ‘stake’ in something, in an entity or in what the entity does (Oxford Dictionary 2008).

Sterile insect: An insect that does not produce viable offspring; an insect that, as a result of a specific treatment, is unable to reproduce (FAO 2017), irrespective of its mate.


Suppression: A type of regulatory control programme in which a target-pest population is decreased within a geographical region (Gordh and Headrick 2001). Reduction of a pest population to below some predetermined economic threshold (USDA 1993).

Surveillance: An official process which collects and records data on pest occurrence or absence by survey, monitoring or other procedures (FAO 2006). The watch kept on a pest for detection of the species’ presence and determination of population density, dispersion, and dynamics (Pedigo 2002, Gordh and Headrick 2001).

Target population: The population of an organism that is the intended target, object or focus of an action or programme. In the context of the SIT, the target population is the wild population that the sterile insects are being released against (FAO/IAEA/USDA 2003).

Vector (insect): An organism capable of transmitting or transporting a micro-organism or pathogen or parasite from one host to another (Pedigo 2002, Resh and Cardé 2003, Gordh and Headrick 2001).

Vector density: see ‘Density’

Vector longevity: see ‘Longevity’
**Vectorial capacity (VC):** A measure of the intensity of the transmission, calculated via the mathematical formula \( VC = m a^2 \times p n / \log(p) \), where \( m \) = mosquito density/person, \( a \) = number of bites, \( p \) = daily survival rate of the mosquito and \( n \) = the duration (in days) needed for amplifying the virus into the mosquito (also called the extrinsic incubation period) (MacDonald 1952).

**Wave principle:** The wave principle entails an expanding operational block size with each phase of an AW-IPM programme using the SIT (Hendrichs et al. 2007).
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABDs</td>
<td>Aedes-borne diseases</td>
</tr>
<tr>
<td>AFB</td>
<td>French Biodiversity Agency</td>
</tr>
<tr>
<td>AW-IPM</td>
<td>Area-wide integrated pest management</td>
</tr>
<tr>
<td>CRT</td>
<td>Cluster randomized trial</td>
</tr>
<tr>
<td>DALY</td>
<td>Disability-adjusted life year</td>
</tr>
<tr>
<td>DENV</td>
<td>Dengue virus</td>
</tr>
<tr>
<td>DtD</td>
<td>Door-to-door</td>
</tr>
<tr>
<td>EBP</td>
<td>Evidence-based practice</td>
</tr>
<tr>
<td>EFSA</td>
<td>European Food Safety Authority</td>
</tr>
<tr>
<td>EPPO</td>
<td>European and Mediterranean Plant Protection Organization</td>
</tr>
<tr>
<td>ERC</td>
<td>Ethical review committee</td>
</tr>
<tr>
<td>FAO</td>
<td>Food and Agriculture Organization of the United Nations</td>
</tr>
<tr>
<td>GBD</td>
<td>Global Burden of Disease (title of a WHO study)</td>
</tr>
<tr>
<td>GMO</td>
<td>Genetically modified organisms</td>
</tr>
<tr>
<td>GSS</td>
<td>Genetic sexing strain</td>
</tr>
<tr>
<td>GVCR</td>
<td>Global vector control response</td>
</tr>
<tr>
<td>HCSP</td>
<td>Haut Conseil de la Santé Publique [French Public Health Council]</td>
</tr>
<tr>
<td>IAEA</td>
<td>International Atomic Energy Agency</td>
</tr>
<tr>
<td>ICER</td>
<td>Incremental cost-effectiveness ratio</td>
</tr>
<tr>
<td>IRGC</td>
<td>International Risk Governance Council</td>
</tr>
<tr>
<td>IIT</td>
<td>Incompatible insect technique</td>
</tr>
<tr>
<td>IPCS</td>
<td>Insect Pest Control Subprogramme (refers to FAO/IAEA IPCS)</td>
</tr>
<tr>
<td>LMO</td>
<td>Living modified organism</td>
</tr>
<tr>
<td>M&amp;E</td>
<td>Monitoring and evaluation</td>
</tr>
<tr>
<td>NTD</td>
<td>WHO Department of Control of Neglected Tropical Diseases</td>
</tr>
<tr>
<td>pers. comm.</td>
<td>Personal communication</td>
</tr>
<tr>
<td>PICO</td>
<td>Population Intervention Comparator Outcome</td>
</tr>
<tr>
<td>QC</td>
<td>Quality control</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomized control trial</td>
</tr>
<tr>
<td>SIT</td>
<td>Sterile insect technique</td>
</tr>
<tr>
<td>SOPs</td>
<td>Standard operating procedures</td>
</tr>
<tr>
<td>SW-RCT</td>
<td>Stepped wedge cluster-randomized trials</td>
</tr>
<tr>
<td>TDR</td>
<td>WHO Special Programme for Research and Training in Tropical Diseases</td>
</tr>
<tr>
<td>USDA</td>
<td>United States Department of Agriculture</td>
</tr>
<tr>
<td>US EPA</td>
<td>US Environmental Protection Agency</td>
</tr>
<tr>
<td>Acronym</td>
<td>Description</td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
</tr>
<tr>
<td>VBDs</td>
<td>Vector-borne diseases</td>
</tr>
<tr>
<td>WG</td>
<td>Working group</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
<tr>
<td>YLD</td>
<td>Years of life lived with a disability</td>
</tr>
<tr>
<td>YLL</td>
<td>Years of life lost</td>
</tr>
</tbody>
</table>
References


Almeida L, Duprez M, Privat M, Vauchelet N. (2019). Control strategies on mosquitoes population for the fight against arboviruses. hal-01984426.

Anders et al. Trials (2018) 19:302The AWED trial (Applying Wolbachia to Eliminate Dengue) to assess the efficacy of Wolbachia-infected mosquito deployments to reduce dengue incidence in Yogyakarta, Indonesia: study protocol for a cluster randomised controlled trial


Canali, M. 2019. SIT cost effectiveness comparative analysis in Italy. IAEA 35 pages.


Feldmann, U. & Hendrichs, J. (2001) Integrating the Sterile Insect Technique as a Key
Component of Area-wide tsetse and trypanosomiasis intervention. Food and Agriculture Organization of the United Nations.


Franz, G. (2005). Genetic sexing strains in Mediterranean fruit fly, an example for other


Kittayapong P., Ninphanomchai S., Limohpasmanee W., Chansang C., Chansang U., Mongkalangoon P. (2019). Combined sterile insect technique and incompatible insect technique:


National Environment Agency. Wolbachia is SAFE [Internet]. [cited 21 Mar 2019]. Available:


Nuffield council on Bioethics, the ethics of research related to health care in developing countries: a follow up discussion paper based on the workshop held in Cape Town, south Africa 12-14th February 2004


WHO (2011), Standards and operational guidance for ethics review of health –related research with human participants.


## Annex 1. SIT Checklist

### SIT checklist

Country / region:  
SIT approach:  
Planned phase I testing start date:

<table>
<thead>
<tr>
<th>Framework component</th>
<th>Timeline (months before phase I testing commences)</th>
<th>Issue</th>
<th>Lead agency</th>
<th>Action required</th>
<th>Deadline</th>
<th>Status</th>
<th>Is funding required/ available?</th>
<th>Priority (high/medium/low)</th>
</tr>
</thead>
</table>
| Making the decision to implement SIT | 12                                                 | **Examining public health priorities**  
What public health issues do health authorities want to address given limited resources? |             |                |          |       |                                |                             |
|                      | 12                                                 | **Cost-benefit analysis**  
What actions need to be taken to thoroughly understand the costs and benefits associated with the SIT programme? |             |                |          |       |                                |                             |
|                      | 12                                                 | **Risk assessment**  
What actions need to be taken to gather a broad range of perspectives on risk? What is an acceptable level of risk, and what risk mitigation measures can be taken? |             |                |          |       |                                |                             |
|                      | 12                                                 | **Commitment and resources**  
What actions need to be taken to obtain long-term commitment and adequate resources from stakeholders? What is each stakeholder’s level of commitment, roles, and responsibilities? |             |                |          |       |                                |                             |
<table>
<thead>
<tr>
<th>Programme objectives/targets</th>
<th>Action</th>
<th>10</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Situational analysis</strong></td>
<td>What information is needed for a thorough situational analysis of <em>Aedes</em>-borne disease transmission? What actions need to be taken to obtain this information?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Establishing the target vector, geographical region, and population</strong></td>
<td>What information and actions are needed to establish the target vector, geographical region and population?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Short- and long-term objectives</strong></td>
<td>What information and actions are needed to define the SIT programme's short- and long-term objectives?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulation, permits, and authorisation</td>
<td><strong>Identifying and obtaining necessary approvals and permits</strong></td>
<td>What steps need to be taken to identify and fulfil regulatory requirements at various stages of testing and implementation?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Engaging regulators</strong></td>
<td>What steps need to be taken to establish a working relationship with domestic and international regulators?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Module</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------------------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Production capacity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to ensure adequate mass-rearing capacity/implementation?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What technologies need to be adopted to improve scalability?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory support</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What laboratory procedures need to be established to support SIT-related research and testing?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manpower and training</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to ensure adequate, appropriately trained personnel to support the SIT programme?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Release strategies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What information is required to design an optimal release strategy, and what sets are required to obtain this information?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality control mechanisms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to establish feedback mechanisms and communications channels between management, field and laboratory teams?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expert review</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to establish a review committee to assess and provide expert guidance on the SIT programme?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase</td>
<td>Action</td>
<td>Timeline</td>
<td>Issue</td>
<td>Action</td>
<td>Priority</td>
<td>Component</td>
</tr>
<tr>
<td>-------</td>
<td>--------</td>
<td>---------</td>
<td>-------</td>
<td>--------</td>
<td>----------</td>
<td>------------</td>
</tr>
<tr>
<td>Examining public health priorities</td>
<td></td>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What public health issues do health authorities want to address given limited resources?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cost-benefit analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to thoroughly understand the costs and benefits associated with the SIT programme?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Making the decision</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Risk assessment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to gather a broad range of perspectives on risk? What is an acceptable mitigation measures can be taken?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Commitment and resources</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to obtain long-term commitment and adequate resources from stakeholders? What is each stakeholder's level of commitment, roles, and responsibilities?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Situational analysis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What information is needed for a thorough situational analysis of Aedes-borne disease transmission?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to obtain this information?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Establishing the target vector, population programme</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What information and actions are needed to establish the target vector, geographical region and population?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short- and long-term objectives</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What information and actions are needed to define the SIT programme's short- and long-term objectives?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Identifying and obtaining necessary approvals and permits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What steps need to be taken to identify and fulfil regulatory requirements at various stages of testing and implementation?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Regulation, permits, and authorisation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engaging regulators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What steps need to be taken to establish a working relationship with domestic and international regulators?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Production capacity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to ensure adequate mass-rearing capacity for trials and implementation?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>modalities of implementation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Laboratory support</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What laboratory procedures need to be established to support SIT-related research and testing?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manpower and training</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What needs to be done to ensure adequate, appropriately trained personnel to support the SIT programme?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Release strategies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What information is required to design an optimal release strategy, and what steps are required to obtain this information?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quality control mechanisms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What quality control mechanisms need to be established to ensure that mass rearing and releases are performing optimally?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ethics</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What are the ethical obligations of the SIT programme to the host community, and what steps need to be taken to ensure that these obligations are met?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Key messages</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What steps need to be taken to develop key messages for community engagement?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Targeting stakeholders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Which stakeholder groups are to be targeted, and what is the outreach plan for each group?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public feedback</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to establish public feedback mechanisms? How will the SIT programme respond to public feedback and use it to inform implementation strategies?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Establishing surveillance and monitoring frameworks</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In the absence of an existing surveillance programme, what steps need to be taken to establish a robust and comprehensive disease surveillance framework?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Surveillance, monitoring, and evaluation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Data collection and handling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What types of data will be collected, and how will the data be handled and disseminated?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endpoints</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What information and actions are required to establish entomological and epidemiological endpoints for evaluation of efficacy?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Decision criteria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to establish pre-defined decision criteria for progress to a more advanced phase? Which stakeholders will have oversight of the evaluation and decision-making process?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long-term monitoring</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What steps need to be taken to establish a system for long-term monitoring and assessment of the SIT approach?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feedback mechanisms</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to establish feedback mechanisms and communications channels between management, field and laboratory teams?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expert review</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>What actions need to be taken to establish a review committee to assess and provide expert guidance on the SIT programme?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phased implementation</td>
<td>6</td>
<td>Endpoints</td>
<td>What information and actions are required to establish entomological and epidemiological endpoints for evaluation of efficacy?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>---</td>
<td>-----------</td>
<td>-------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Decision criteria</td>
<td>What actions need to be taken to establish pre-defined decision criteria for progress to a more advanced phase? Which stakeholders will have oversight of the evaluation and decision-making process?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Long-term monitoring</td>
<td>What steps need to be taken to establish a system for long-term monitoring and assessment of the SIT approach?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Feedback mechanisms</td>
<td>What actions need to be taken to establish feedback mechanisms and communications channels between management, field and laboratory teams?</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td>Expert review</td>
<td>What actions need to be taken to establish a review committee to assess and provide expert guidance on the SIT programme?</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>